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While chemotherapy has rendered excellent prognosis in the treatment of 
early-stage (Stages I to IIIA) breast cancer, it can also elicit harmful adverse 
effects. Chemotherapy-associated cognitive impairment, also termed as 
“chemobrain” or “chemofog” in the literature, refers to subtle cognitive changes 
that breast cancer patients experience after the receipt of chemotherapy. The 
reported prevalence of “chemobrain” has been inconsistent in the literature, with 
a range from 16% to 75% of cancer patients experiencing mild to moderate 
cognitive impairment across the studies. Notably, there is a paucity of cognitive 
research performed on Asian breast cancer patients. The determinants of these 
observed cognitive changes are also not well ascertained. Conflicting evidence 
suggests that psychosocial determinants (such as anxiety, quality of life and 
fatigue), pharmacological and biological determinants may be associated with 
cognitive changes in breast cancer patients.   
With the aid of both objective and subjective self-reported 
neuropsychological tools, this thesis aimed to evaluate the prevalence and 
severity of chemotherapy-associated cognitive changes in Asian early-stage 
breast cancer patients, and to identify the clinical, psychosocial, pharmacological 
and biological determinants for this neuro-cognitive adverse effect of 
chemotherapy. 
Through the use of a cross-sectional survey and a qualitative focus group 





existence of the “chemobrain” problem in two groups of important stakeholders, 
the oncology practitioners and Asian breast cancer patients.  
The main thrust of this project revolved around a large-scale prospective 
cohort study that involved the assessment of Asian breast cancer patients’ 
cognitive changes during the course of their chemotherapy treatment. Based on 
the objective computerised neuropsychological tool (Headminder™), it was found 
that approximately one-third of Asian breast cancer patients suffered from 
impairments in the memory and attention upon the completion of 12 weeks of 
chemotherapy. Cognitive deterioration was the most evident at the midpoint of 
chemotherapy treatment, especially in recipients of anthracycline-based 
chemotherapy. Biological markers, interleukin-(IL-)1β, IL-4, IL-8 and tumour 
necrosis factor-α were associated with post-chemotherapy memory, response 
speed and attention changes. On the other hand, patients’ perceived cognitive 
disturbances, as detected by the FACT-Cog, shared a strong relationship with 
patients’ psychosocial distress and health-related quality of life. In particular, 
patients who were both fatigued and anxious reported more severe perceived 
cognitive disturbances.   
This thesis has demonstrated that chemotherapy-associated cognitive 
changes are prevalent and relevant in Asian early-stage breast cancer patients. The 
interplay among demographical, clinical, pharmacological, psychosocial and 
biological determinants contributes to varying severities of cognitive changes in 
Asian early-stage breast cancer patients. The findings presented in this thesis 





oncology practitioners to provide an informed pre-chemotherapy counselling to 
patients, and to identify at-risk patients who may potentially benefit from future 
interventional strategies. 
 
Keywords: Breast cancer, chemotherapy, chemobrain, chemofog, cognitive 
function, neurotoxicity, psychooncology 
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Chapter 1: Introduction and literature review 
1.1 Overview of early-stage breast cancer and treatment modalities 
Breast cancer is the most prevalent cancer among women worldwide. In 
Singapore, breast cancer is the most commonly diagnosed cancer among women. 
It accounts for approximately 30% of all cancer occurrences among females.
1,2
  It 
has been reported that a total of 7781 breast cancer cases were diagnosed between 
2006 and 2010.
1
 The highest incidence of breast cancer is observed in Chinese 
women, followed by Malays and Indians, with age-standardised rates of 60.8, 
58.7 and 53.8 per 100,000 per year, respectively.
1,2
  
The incidence of breast cancer in Singapore has risen rapidly due to 
changing lifestyle and reproduction patterns. The age-standardised incidence rate 
of newly diagnosed breast cancers in females increased three-fold from 21.5 per 
100,000 in 1971-1975 to 60.7 per 100,000 in 2006-2010.
2
  In particular, the 
nationwide breast screening programme in Singapore has led to the detection of 
the disease at an earlier stage; more Singaporean women are diagnosed with 
breast cancer at the early stages (Stages I to IIIA) as opposed to the later stages 




The prognosis for “early-stage breast cancer”, defined here in this thesis as 
Stages I to IIIA breast cancer, is excellent. The age-standardised 5-year observed 
survival rate for breast cancer has increased from 39.4% in the early 1970s to 67.9% 
in the late 2000s. This improvement in survival from breast cancer may be related 






Various treatment modalities in surgery, chemotherapy 
(adjuvant/neoadjuvant), radiation therapy and anti-hormonal treatment for breast 
cancer have led to the improvement of survival rate. Table 1.1 shows a list of 
common treatments that early-stage breast cancer patients in Asia commonly 
receive.   
Surgery is an important modality for treatment of early-stage breast cancer. 
The main rationale of surgical treatment is to remove the tumour within the 
mammary glands. A wide excision involves the removal of the tumour with the 
safest minimal amount of surrounding tissue while a mastectomy refers to the 
total removal of the affected breast and underlying muscles.  
After surgery, breast cancer patients are often treated with adjuvant 
cytotoxic chemotherapy to prevent cancer recurrence in tissues distant from the 
breast. In some cases, neo-adjuvant chemotherapy may be prescribed to breast 
cancer patients prior to surgery for the purpose of reducing the tumour load before 
it is operable. Chemotherapy is usually administered over a duration of 3 to 6 
months. The commonly prescribed chemotherapy regimens for early-stage breast 
cancer patients are anthracycline-based chemotherapies, such as AC and FEC. 
Patients may also be treated with taxane-based regimens which contain paclitaxel 
or docetaxel. The choice of recommended drugs is highly dependent on the 
patient's general health and concurrent medical problems, stage of cancer, and 














Specific types of treatment (common examples 
listed) 
Remarks 




- Wide excision/lumpectomy with/without 








 - AC: IV doxorubicin (60 mg/m2) and IV 
cyclophosphamide (600 mg/m2) every 3 weeks 
for 4 cycles2 
- FEC: IV epirubicin (75-100 mg/m2), IV 
cyclophosphamide (500 mg/m2) and IV 
fluorouracil (500 mg/m2) every 3 weeks for 4 
cycles 
- FAC: IV doxorubicin (50 mg/m2), IV 
cyclophosphamide (500 mg/m2) and IV 
fluorouracil (500 mg/m2) every 3 weeks for 4 
cycles 
 
with/without a second phase of taxane therapy: 
- AC  T or FEC  T: IV paclitaxcel 
(80mg/m2) weekly for 12 cycles 
- AC  T or FEC  T: IV docetaxel  















- TC: IV docetaxel (75 mg/m2) and IV 
cyclophosphamide (600 mg/m2) every 3 weeks 
for 4 cycles 
- CMF: PO cyclophosphamide (100 mg/m2) 
daily for 2 weeks WITH IV methotrexate 
(40mg/m2) and IV 5-fluorouracil (600mg/m2) 







May be administered together with chemotherapy 
as: 
- TCH: IV docetaxel (75 mg/m2) and IV 
carboplatin (AUC 6) every 3 weeks for 6 
cycles WITH IV trastuzumab (4mg/kg) for 1 
week, then 
IV trastuzumab (2mg/kg) for 17 weeks, then 
IV trastuzumab (6mg/kg) every 3 weeks to 
complete 1 year of trastuzumab therapy 
- AC THT: IV doxorubicin (60 mg/m2) 
and IV cyclophosphamide (600 mg/m2) every 
3 weeks for 4 cycles, then 
IV paclitaxel (80mg/m2) weekly for 12 cycles 
WITH IV trastuzumab (4mg/kg) for 1 week, 
then 
IV trastuzumab (2mg/kg) weekly to complete 
1 year of trastuzumab therapy 
Indicated for 
breast cancer 

















- Tamoxifen (20mg daily) 
- Anastrozole  (1mg daily) 
- Letrozole (2.5mg daily) 




cells that present 






- Total of 45 to 60 Gray at 1.8 - 2 Gray fractions 
per fraction over 5 to 6 weeks (all dose 









IV: intravenous; PO: oral 
 
1.2 Summary of chemotherapy-induced toxicities manifested by early-stage 
breast cancer patients 
Chemotherapy is one of the most common treatment modalities in early-
stage breast cancer patients. Although chemotherapy is effective in improving 
breast cancer treatment prognosis, it is also associated with numerous physical 
adverse effects that have a negative impact on breast cancer patients’ health-
related quality of life (HRQoL).
4-13
 To highlight, one recently published 
longitudinal study explored the burden of treatment-related symptoms over time 
and their relationship with health status and HRQoL in 206 women with breast 
cancer from pre-treatment to 1, 3 and 6 months follow-up assessments. It was 
found that symptom burden cluster in women undergoing chemotherapy, such as 
lack of appetite, nausea, weight loss and tiredness, were associated with poorer 
HRQoL.
14






tolerated, many patients often experience limitations in their usual activities of 
daily living both during and upon the cessation of the anti-cancer treatments.
15-17
  
The following paragraphs highlight briefly various types of toxicity that 
early-stage breast cancer patients commonly experience in the acute and late 
phases of their anti-cancer treatments: 
 
Chemotherapy-induced nausea and vomiting (CINV)
18-21
 
Nausea and vomiting is one of the most common side effects of 
chemotherapy. Most early-stage breast cancer patients receive chemotherapy 
regimens that have low to moderate emetogenic potential. Over the years, 
management strategies for CINV have been well defined and established in the 
literature and international guidelines.
19,22
 The objective of antiemetic prophylaxis 
is the complete prevention of CINV, and this is usually achievable in the majority 
of breast cancer patients receiving standard chemotherapy. The three categories of 
drugs with the highest therapeutic index for the management of CINV include 5-
hydroxytryptamine receptor antagonists (granisetron and ondansetron), 





Myelosuppression and febrile neutropenia
23
 
The other common adverse effect related to the cytotoxic nature of 






and febrile neutropenia. The standard management strategy for febrile neutropenia 
involves risk assessment and identification of patients who possess multiple risk 
factors (such as an age of more than 60 years and having severe burden of illness 
based on physical assessments); the use of broad spectrum antibiotics and 
antifungal may be indicated for this group of patients.
24,25
 To decrease the chances 
of developing febrile neutropenia, recombinant human granulocyte colony-
stimulating factor (G-CSF), such as filgrastim and pegfilgrastim, may be used to 







Delayed cardiotoxicity in the form of dose-dependent cardiomyopathy may 
also persist in breast cancer patients after the administration of anthracycline-
based chemotherapies, leading to chronic heart failure. Prevention and 
management of cardiotoxicity involves monitoring of patients’ cardiac functions 
(such as echocardiogram and multi-gated acquisition scans) at baseline before the 







Specific to taxane-based chemotherapies that contain docetaxel or paclitaxel, 
dose-related myalgias and arthralgias may develop within 72 hours of systematic 
exposure. Studies have shown that cancer patients continue to experience residual 






sensations, long after the termination of anti-cancer treatment.
34-36 
Numbness was 
reported to be one of the most prevalent and most frequently occurring symptoms 
in breast cancer patients due to the well-documented side effect of peripheral 
neuropathy in taxane-based chemotherapy recipients.
31,32
 This numbness or 
tingling in the hands or feet can continue to be a persistent residual symptom 
following the end of treatment. In the literature, there are multiple described 
therapies for treating peripheral neuropathy; pharmacological agents such as 
opioids, tricyclic antidepressants, gabapentinoids and serotonin-norepinephrine 
reuptake inhibitor are some treatment options for peripheral neuropathy.
37-40
 
However, more clinical data is needed to support their efficacy in the treatment 
and prevention of chemotherapy-induced neuropathy.  
 
1.3 Documented prevalence of cognitive changes in breast cancer patients  
The previous section summarises the common toxicities experienced by 
early-stage breast cancer patients (referred to as “breast cancer patients” hereafter) 
during the course of their anti-cancer treatment. Most of the toxicities have well-
established risk factors and treatment strategies. 
Of interest to this thesis is a type of central neurotoxicity that has been the 
least investigated. The problem of chemotherapy-associated cognitive changes is 
commonly termed as “chemobrain” or “chemofog” in the literature.41-49 This is a 
neuro-cognitive toxicity of chemotherapy, which was first recognised when 






change in their cognitive functions after they had completed their chemotherapy 
treatment.
50,51
 These cognitive changes involve a wide range of symptoms such 
as having a poor memory, inability to maintain concentration, difficulty in 
thinking and muddled thought processes.
52-55
 Cognitive impairment is a particular 
issue of concern for early-stage breast cancer patients as majority of them tend to 
return to the workforce after their successful cancer treatments.
53,54
 As cognitive 
functioning can cause a profound impact on one’s HRQoL, there is an increased 
preponderance of research on this subject matter over the recent years. 
Research into the prevalence and severity of chemotherapy-associated 
cognitive changes started only in the late 1990s. To date, there are 58 
observational studies in the literature which aimed to investigate the association 
between chemotherapy and cognitive changes in breast cancer patients since 
1998. A summary of these studies is provided in Appendix 1.  
 
Definition of cognitive impairment 
The cognitive function consists of multiple domains, such as attention, 
processing speed, memory, learning, language, visual perception, motor skills 
and response speed. Therefore, any change in the above cognitive domains might 
constitute a “cognitive change”. From Appendix 1, it was clear that studies of 
this subject matter did not have consistent definitions or statistical approaches to 






Defining cognitive impairment is a challenging issue, even in traditional 
neuropsychology research because a typical neuropsychological battery may 
contain several tests for each individual cognitive domain, and each test can be 
scored differently. There are multiple ways of classifying a patient as 
“cognitively impaired”, in comparison to a general population. Most 
neuropsychological tools report their results in the form of a standardised Z score, 
which represent the number of standard deviations from a reference population. 
To measure a longitudinal change in a patient’s cognitive function, impairment is 
usually defined as a change greater than a pre-defined cut-off point, after 
accounting for practice effects associated with repeated measurements.  
Based on this literature review and recommendations from the International 
Cognition and Cancer Taskforce, it is proposed that in general, any changes on 
the neuropsychological tests in the four main cognitive domains of attention, 
memory, processing speed and response speed, may constitute a “cognitive 
change”. The specific statistical approach in defining “cognitive impairment” 
will be elaborated in the subsequent chapters of this thesis. 
 
Prevalence and severity of cognitive changes in breast cancer patients 
The studies reported that prevalence of such phenomenon occurred among 
16% to 75% of the surviving breast cancer patients who experienced mild to 
moderate cognitive impairment across the studies.
9,50,51,56-88
 Domains that were 
the most frequently assessed in these studies are memory and 






conducted in Western countries, with subjects being the American, German, 
Australian and Spanish population of breast cancer patients.
9,50,51,56-77,79-89
 There 
is a lack of robust studies in the literature to evaluate the prevalence and severity 
of chemotherapy-associated cognitive changes in the Asian population of breast 
cancer patients. The following paragraphs highlight 4 studies which were 
recently published in South Korea, Japan and Taiwan.
57,78,90,91
  
Both Chen et.al. and Moon et.al. utilised the Attentional Function Index 
(AFI) to measure the patients’ perceived cognitive functions in the breast cancer 
patients.
78,90
 The former study reported the existence of mood changes and 
perceived cognitive disturbances among 118 chemotherapy-receiving breast 
cancer patients.
78
 However, the validity of this cross-sectional study was limited 
by the absence of a control population (non-chemotherapy receiving breast 
cancer patients) for comparative purposes.  
Chen et.al. explored the trajectory change in perceived attentional function 
of 200 Chinese breast cancer patients, from baseline to 24 months after surgery.
90
 
After adjusting for covariates, the perceived attentional function was not found to 
be associated with the adjuvant treatments. However, this study was also limited 
by a small sample size for each treatment modality. It is worthwhile to note that 
results from the above-mentioned studies were inconclusive as the AFI was not a 
standard objective neuropsychological tool used in cognitive studies and 
attentional function was the only cognitive domain of interest tested.  
A Japanese study was performed on a sample of 18 chemotherapy-








neuropsychological tests were administered to both groups at baseline and 6 
months after the completion of treatment (for the chemotherapy group), or 8 to 
10 months from baseline (for the control group). Interestingly, there were no 
differences observed in the change scores for all neuropsychological tests. The 
scores, however, were significantly associated with psychological variables such 
as anxiety and depression. It is postulated that the patients’ cognitive functions 
could have possibly recovered within 6 months after the completion of 
chemotherapy. Caution has to be taken in the interpretation of the findings as a 
formal definition of cognitive impairment and accounting for practice effect were 
not adopted in this study. 
Notably, Jung et.al. observed severe cognitive impairment in 32 Korean 
breast cancer patients four months after chemotherapy, in comparison with 
healthy controls within 6 months after a negative mammography.
91
 It was found 
that collectivism-based attitude towards woman’s role performance contributed 
to poorer performance on attention and working memory tests in Korean women. 
It is interesting that this article highlighted the importance of cultural 
characteristics in the assessment of cognitive performances. Cross-cultural 
research in the field of neuropsychology has also demonstrated that one’s 
personal experience, including the culture in which he was raised, would 
influence his attention and thought processes.
92
 Cultural differences can also 
influence episodic memory and cognitive correlations across ethnic groups. 
Therefore, there is evidence to suggest that findings from the Western 






urging need to evaluate the prevalence and severity of cognitive changes in 
Asian breast cancer patients.  
 
1.4 Determinants of chemotherapy-associated cognitive changes  
The exact causes and mechanism of chemotherapy-associated cognitive 
impairment have yet to be determined. Nevertheless, many believed that 
demographic, clinical, psychosocial and pharmacological factors are plausible 
determinants of chemotherapy-associated cognitive changes, and the intermediary 





1.4.1 Demographic and clinical determinants 
Demographical factors, including low baseline intelligence and educational 
level, old age, post-menopausal status and low haemoglobin level (less than 12 
g/dl), were identified as determinants of cognitive changes in cancer patients by 
numerous studies. 
70,97,98
 In the field of neuropsychology research, it is widely 
known that aging is associated with mild cognitive decline, such that pathologic 
aging itself can cause cognitive impairment in cancer patients.
99
 On the other 
hand, individuals who receive higher education showed slower cognitive decline 
than those who had a lower level of education, therefore the latter group is known 








A recent study demonstrated that age and pretreatment cognitive reserve 
were related to post-treatment decline in processing speed in breast cancer women 
exposed to chemotherapy.
97
 In this study, a three-way interaction among the 
receipt of chemotherapy, age, and baseline cognitive reserve was observed in a 
sample of 60 chemotherapy-receiving breast cancer patients, indicating that older 
patients with lower baseline cognitive reserve who were exposed to chemotherapy 




It is also suggested that declines in haemoglobin levels during 
chemotherapy treatment are associated with adverse changes in cognitive function. 
In one study, among 49 patients who demonstrated a decline in haemoglobin to a 
final value of less than 12 g/dL at the third cycle of chemotherapy, greater 
declines in haemoglobin were significantly related to greater increases in fatigue 





1.4.2 Psychosocial determinants 
Besides physical adverse effects, cancer patients receiving chemotherapy 
are often affected by treatment-related psychosocial distress such as anxiety, 
depression and cancer-related fatigue.
9,71,87,102-105
 In a recent comparative analysis 
conducted in Asian Chinese breast cancer patients, it was found that patients who 
were receiving ongoing adjuvant therapy showed higher levels of anxiety and 
depression than the post-therapy group.
6
 One local study has also identified 






particular, anxiety symptoms in the subjective-related domains (such as 
nervousness and fear of losing control) played a role in distinguishing between 
patients with and without CINV, especially among those on AC-based 
chemotherapy regimens.
21
 Cancer-related fatigue, which is known in the literature 
as a distressing persistent, subjective sense of physical, emotional, and/or 
cognitive tiredness or exhaustion related to cancer or cancer treatment, can affect 
cancer patients cognitively and emotionally.
10,106,107
  
There is conflicting evidence on the relationships between chemotherapy-
associated cognitive changes and psychosocial factors such as emotional 
functioning, depression and anxiety; it is currently known that psychosocial 
factors are associated with patients’ self-perceived cognitive changes instead of 
objective neuropsychological assessments.
102,105
 It is unknown whether these 
psychosocial factors share a causative relationship with the cognitive problems or 
the existing cognitive problems have led to psychological distress in cancer 
patients. Notably, there is also a lack of exploration in the psychosocial 
consequences and the emotional, psychological and social impact of cognitive 
changes in the breast cancer patients. 
 
1.4.3 Pharmacological agents as determinants108 
Little is known about the pharmacological effects of chemotherapy agents 
on cognitive changes in cancer patients. Although most agents possess poor 
penetration of the central nervous system, scientists observe that cognitive 








Notably, these sub-therapeutic drug concentrations are insufficient to allow 
effective treatment of malignancies. It is proposed that the mechanisms of 
chemotherapy agents, pharmacodynamics and pharmacokinetics factors may 
influence the degree of cognitive changes in breast cancer patients. Therefore, it is 
probable that pharmacological considerations may influence the incidence and 
severity of cognitive dysfunction. It is proposed that revisiting the characteristics 
of the chemotherapy regimens may shed new insights on the possible 
explanations to the occurrence of chemotherapy-related cognitive impairment in 
cancer patients.  
To evaluate the relationships between the types, the dose intensities and the 
durations of chemotherapy regimens on cognitive impairment in cancer patients, a 
systematic literature review was conducted on 21 selected studies. These studies 
were published before December 2013. They involved: 1) prospective, 
longitudinal, cohort of a defined population, 2) adult breast cancer patients, 3) 
neuropsychological testing which included a baseline pre-chemotherapy 
measurement done before administration of chemotherapy and another time-point 
during or/and after chemotherapy, 4) valid, reliable, and sensitive 
neuropsychological tests with published standardised administration procedures, 
5) sufficient information reported (either by quantitative measurement or 
inferential statistics) on at least one domain of cognitive function, and 6) 







A summary of the 21 selected studies is presented in Table 1.2. For 
comparative purposes, studies that concluded the existence of chemotherapy-
associated cognitive impairment were presented separately from studies that did 
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Table 1.2: Summary of longitudinal cohort studies (with pre-chemotherapy and post-chemotherapy cognitive assessments) conducted on breast cancer 
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Legend and abbreviations: (listed according to alphabetical order) 
 
CT: chemotherapy; H: High dose; HC: healthy; L: Low dose; Lipo AC: nonpegylated liposomal doxorubicin; m: month; MMSE: Mini-Mental State Evaluation; NR: Not reported; RCI: 
Reliable change index; S: Standard dose; SBRs: Standardised regression based score; SD: standard deviation; SS: statistically significant; Var: various; w: week 
 
1
 Classification of chemotherapy regimens into first, second and third generation was based on recommendations from the National Cancer Institute
3,122,123
, which classified first generation 
chemotherapy as 5-fluorouracil (5-FU)- based (such as CMF), anthracycline-based regimens (such as AC and FEC) or other older regimens (such as CTC), second generation chemotherapy 
as the addition of taxanes upon completion of anthracycline-based regimens (such as ACT or FECT), and third generation chemotherapy as intensive anthracycline- and taxane- based 
regimens (such as TAC).  
In studies where various chemotherapy regimens are given to patients, the particular regimen that was received by majority (more than 60%) of the cohort was represented by “√√√”; for 
minority (less than 40%), it was represented by “√”, and moderate proportion (between 40% to 60%), it was represented by “√√”.  
2
 Dose density was reported in accordance to how the authors have reported in their study. If the authors did not specify the intensity but had given the raw values, the dose was checked 
against the National Comprehensive Cancer Network (NCCN) guidelines
3
 to determine the dose intensity. If neither of the above information is found, it is documented as “not reported”. 
3 
Acute and delayed cognitive changes are defined as a change within 3 months, and more than 3 months, after completion of chemotherapy, respectively.  
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First generation chemotherapy regimens 
First generation chemotherapy regimens were administered to patients in all 
21 studies. The combination of 5-FU, cyclophosphamide and anthracycline based 
regimens such as FEC and FAC were the most common regimens received by the 
subjects.  
Anthracycline based regimens, such as AC and EC, are the latest first 
generation chemotherapies and are currently widely used in clinical practice. 
However, most of these studies involved only a small population of patients 
treated with anthracycline based regimens. One study reported significant 
decrease in visuospatial skill and total cognitive scores following administration 
of 4 cycles of AC in 30 women.
72
 Of the 30 women who received AC, 33% of the 
patients experienced a decrease in one or more standard deviation (SD) on two or 
more of the neuropsychological tests 1 week post-chemotherapy.
72
 This was the 
first of the few studies available that recruited a homogeneous pool of patients 
receiving the same anthracycline-based regimen. However, this study was also 
limited by the lack of comparison with a control group. It was proposed that 
administration of doxorubicin increased the susceptibility of brain mitochondria 
to calcium
 
induced permeability transition pore opening and oxidative stress, 
predisposing brain cells to degeneration and death in rats.
124,125
 A review once 
proposed that oxidative stress, induced by these cardiotoxic chemotherapy agents, 
could potentially influence cerebrovascular function.
93
 Future studies could be 
conducted to elucidate the neurotoxic mechanism of anthracyclines and its effects 






Brain et.al. investigated the impact of nonpegylated liposomal doxorubicin 
on patients’ autonomy in their activities of daily living.118 Cognitive function of 
40 elderly breast cancer patients with a median age of 75 years was evaluated 
using the Mini-mental State Evaluation (MMSE) at baseline and immediately 
after the last cycle of chemotherapy treatment. It was found that chemotherapy 
had no significant impact on cognitive function. This finding is in contrast to the 
common belief that old age is an important clinical determinant to cognitive 
impairment,
97
 and as elucidated by Hurria et.al. that more self-reported memory 
problems were found in elderly patients who received chemotherapy than those 
who did not
68,126
. However, the findings from Brain et.al. were inconclusive as 
cognitive function, being a secondary endpoint of the study, was measured by 
MMSE, a brief neuropsychological screening tool that was probably not 
comprehensive enough to detect mild to moderate cognitive changes.   
As CMF and CTC are growing out of favour in the current paradigm of 
breast cancer treatment,
3,122,127
 these regimens usually form the minority in most 
studies and hence, we are unable to give a conclusive assessment of CTC and 
CMF on cognitive impairment based on these studies. In one study by Ruzich 
et.al, 35 patients received oral CMF but an overall decline in cognitive function 
was not detected.
83
 This conclusion is in contrast to findings from a mouse model 
which suggested that the combination of methotrexate and 5-FU caused functional 
changes in the frontal lobes and hippocampus.
93,128
 The low prevalence of 
cognitive impairment in this study might be explained by its small sample size. 






neurotoxic, causing acute encephalopathy which only occurs at very high 
doses.
129
 This is in parallel with findings from Schagen et.al who observed that 
dose intensified CTC was associated with more cognitive side-effects than the 
standard dose FEC (25% and 12.8% respectively).
85
 Notably, in contrast to 
Ruzich et.al, this study had a larger sample size of 67 chemotherapy-receiving 
breast cancer patients and 117 non-chemotherapy-receiving breast cancer patients 
and healthy controls.
83
 Therefore, there is some scarce evidence to suggest that 
high-dose CTC may induce more severe cognitive impairment than anthracycline-
based regimens.    
 
Second generation chemotherapy regimens 
A common second generation chemotherapy regimen is the addition of 
taxanes upon completion of anthracycline-based regimens (commonly 
abbreviated as ACT or FECT). A study was performed on 71 breast cancer 
patients of which majority received ACT.71 A significant acute impairment in 
the cognitive domains (such as visuospatial skill, attention, delayed memory, and 
motor function) over 1 week after the completion of all chemotherapy treatment 
was observed. However, it is important to highlight that the change in motor 
function may be due to the inherent adverse effects of taxanes. Improvement in 
the cognitive function followed 6 months after the completion of chemotherapy.
71
 
Current research had identified several candidate mechanisms to the central 
neurotoxicity of anthracycline-based regimens. Incidentally, paclitaxel and 






as IL6, IL8 and IL10, which reduced cognition.
130,131
 (This will be elaborated over 
the next Section 1.4.4). The addition of taxanes might possibly increase the 
degree and duration of impairment. As regimens such as ACT and ECT are 
gaining favour among high-risk breast cancer patients, future research should be 
conducted to investigate their acute and delayed effects on cognitive function. 
Cognitive assessments in cohort studies should be administered to patients for at 
least up to 6 months after the completion of chemotherapy. Moreover, association 
of cognitive changes with biological determinants could be explored to further 
elucidate the neurotoxic mechanism of specific chemotherapy regimens. 
Multiple drugs that were administered concomitantly might exert 
synergistic effects on the brain and influence the integrity of the blood-brain 
barrier (BBB), possibly allowing the less lipophilic drugs to penetrate the brain.
109
 
One study demonstrated that 65% of the chemotherapy cohort receiving FACT 
exhibited an acute decline after chemotherapy treatment in one or more domains 
of the cognitive functioning, with delayed decline in cognition remaining in 61% 
of the patient seven months post-chemotherapy.
117
 Interestingly, within this group 
of patients, 71% evidenced continuous decline in the acute interval. This 
suggested that a regimen cocktail with 4 cytotoxic drugs (5-FU, anthracycline, 










Third generation chemotherapy regimens 
Sparse amount of information allows us to evaluate the association between 
cognitive impairment and third generation chemotherapy regimens, which refer to 
the newer intensive anthracycline- and taxane- based regimens (such as TAC). 
Only 3 included studies that were performed on a total of 17 patients receiving 
TAC and TC.
97,114,116
 Concurrent treatment with taxane, anthracycline and 
cyclophosphamide is now more commonly received by high risk nodal-positive 
breast cancers.
132,133
 However, this regimen is also profoundly myelosuppressive 
and severe clinical neutropenia and anaemia are commonly observed among 
patients.
133,134
 It has been proposed that chemotherapy-induced anaemia may 
cause cognitive dysfunction, such as decreased mental alertness, poor 
concentration, and memory problem.
135
 Such cognitive dysfunction may be 
related to deprivation of oxygen and can cause damage to the brain both in the 
acute and delayed phases.
93
 Therefore, it is worthwhile to explore the cognitive 
effects of patients on the new generation regimens such as TAC and TC on 
cognitive impairment.  
 
Effect of dose intensities and durations of chemotherapy on cognitive impairment 
A total of 5 studies in the literature review captured information on the 
relationship between the dose intensity of chemotherapy and the degree of 
cognitive impairment among breast cancer patients.
50,67,85,121,136
 One study did not 
conclude an overall cognitive impairment in its study subjects and the authors 






were limited to receive in the study.
121
 It was postulated that treatment doses of 
these regimens might have confounded the results.  
Duration of chemotherapy in relation to cognitive impairment is the least 
addressed in the current pool of evidence. Most trials did not specifically measure 
the association between chemotherapy duration and cognitive impairment. Our 
review did not find any correlation between the number of cycles of 
chemotherapy given and the degree of cognition. Typically, breast cancer patients 
are limited to receive 4 to 8 cycles of chemotherapy regimen due to the amount of 
anthracycline exposure. It is proposed that in future cohort studies, stratified 
analysis could be conducted to investigate the effects of treatment duration on 
patient’s cognitive changes. 
Due to limited evidence in the literature, it is still premature to conclude 
whether dose intensities and durations of cytotoxic drugs correlate with cognitive 
impairment in breast cancer patients. This research gap needs to be addressed as 
dose intensification of regimens is increasingly used on the younger and high risk 
breast cancer patients. Information from animal models and experimental studies 
may suggest that dose intensities play a role in neurotoxicity. For example, 
methotrexate is shown to be associated with a dose-dependent inhibition of 
hippocampal cell proliferation.
109,129,137
 Anthracyclines are known to be 
cardiotoxic after long term exposure; however, there is currently limited 
knowledge as to whether the mechanism of neurotoxicity may similarly follow a 
dose-dependent response. Schedule-dependent transient changes in the levels of 






paclitaxel group, IL-6 and IL-8 increased whereas in the weekly paclitaxel group, 
IL-10 increased significantly compared to baseline.
130
 The dose intensity, 
frequency of administration and duration of taxanes may contribute to different 
degrees of cognitive impairment.  
Current clinical evidence is insufficient to evaluate the relationship between 
the types, dose intensities of chemotherapy regimens and cognitive impairment, 
even though experimental and animal studies do suggest a preliminary trend. 
More investigation is needed to support in-vitro observations that cognitive 
changes are associated with dose intensity and duration of chemotherapy. Well-
designed cohort studies and analysis are needed to delineate pharmacological 
factors as determinants of post-chemotherapy neuro-cognitive changes in cancer 
patients.  
 
1.4.4 Biological determinants138  
Recent experimental studies have suggested that pro-inflammatory 
cytokines may be mediators of chemotherapy-associated cognitive changes.
139-146
 
Cytokine induction in the central nervous system has been suggested to mediate 
"sickness behaviour" in patients with severe infection or cancer, together with the 
adverse neuropsychiatric effects of treatment with interferon and 
interleukins.
141,142,147
 It has been widely acknowledged that cytokines and 
inflammatory markers may give rise to a cluster of cancer-related symptoms 
including fatigue, depression and stress, which are also associated with cognitive 
changes.
148-153






neuroimmunoendocrine processes-induced by cancer cells and cytotoxic 
chemotherapy.  
Chemotherapeutic agents, which are mostly unable to cross the BBB due to 
its molecular size, can cause toxicity to the brain indirectly via the pro-
inflammatory cytokine pathways. Cytokines can then penetrate the BBB readily 
by active transport and through circumventricular regions in the brain.
154,155
 They 
bind to the endothelial receptors in the brain vasculature to stimulate the release 
of other inflammatory mediators, such as cell adhesion molecules, chemokines, 
nitric oxide and prostaglandins, that impede the integrity of the BBB.
156,157
 In the 
brain, cytokines elicit local inflammation through oxidative and nitrosative 
processes, especially in the hippocampus and regions of the brain with abundant 
cytokine receptors.
158-164
 For example, animal studies have suggested that 
doxorubicin could increase the level of circulating TNF-α that penetrates the BBB 
to cause the induction of nitric oxide synthase leading to overproduction of 
reactive nitric species and reactive oxygen species that act on brain mitochondria 
to cause oxidative stress.
139
 These reactions would ultimately lead to the clinical 
presentations of cognitive dysfunction.  
To gain a better understanding of the role that cytokines play in the 
“chemobrain” phenomenon, it is necessary to evaluate the sequence of events 
involving chemotherapy and the cytokine-based immune response that affects 
cognitive functioning in cancer patients. Thus far, there is a paucity of studies 
specifically evaluating the relationship among chemotherapy, cytokine induction 






play in the neurocognitive sequelae of chemotherapy, eight selected articles that 
were published between 2000 and 2012 are presented in Table 1.3.
131,151,165-170
 
These eight studies (six full manuscripts and two abstracts) (1) were clinical 
studies conducted on defined cancer populations; (2) included the administration 
of cytotoxic chemotherapy drugs or regimens; (3) involved the quantitative 
measurement of a specific panel of cytokines, such as interleukins (IL), interferon 
(IFN), tumour necrosis factor (TNF), soluble TNF receptor (sTNF-R), growth 
factors and colony-stimulating factors; and (4) included the objective and/or 
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72 healthy           T2: 6m;     
                  T3: 12m     
Legend and abbreviations: (listed according to alphabetical order within categories) 
 
AC: doxorubicin and cyclophosphamide; FAC: cyclophosphamide, doxorubicin and 5-fluorouracil; CANTAB: Cambridge Neuropsychological Test Automated Battery; CMF: 
cyclophosphamide, methotrexate and 5-fluorouracil; CHOP: cyclophosphamide, doxorubicin, vincristine and prednisolone; CRP: C-reactive protein; Ctx: chemotherapy treatment; ELISA: 
enzyme-linked immunosorbent assay; Endo-tx: endocrine (anti-hormonal) treatment; EORTC: European Organization for Research and Treatment of Cancer; FACT-Cog: Functional 
Assessment of Cancer Therapy – Cognitive Function; GM-CSF: granulocyte macrophage colony-stimulating factor; IFN: interferon; IL-: interleukin-; IL-1RA: interleukin-1 receptor 
antagonist; M: month; MCP-1: monocyte chemotactic protein-1; MTX: methotrexate; NP: traditional neuropsychological batteries; PET: positron emission tomography; sTNF-RII: soluble 
tumour necrosis factor receptor-II; TNF: tumour necrosis factor; 5-FU: 5- Fluorouracil 
 
1 “√” refers to the authors’ observations that cytokine levels were elevated in chemotherapy-receiving study subjects, or the presence of a statistically significant correlation between 
chemotherapy and cognitive impairment; “X” refers to the authors’ observations that cytokine levels were not elevated in chemotherapy-receiving study subjects, or the absence of a 
statistically significant correlation between chemotherapy and cognitive impairment  






It is important to note that limited studies in the literature were fully aligned 
with the purpose of determining the relationship among chemotherapy, cytokine 
levels and cognitive impairment. There was a high level of heterogeneity among 
the above selected studies. These inconsistencies included variations in patient 
characteristics, types of chemotherapy, types of cytokines measured, methods of 
measuring cytokines and types of cognitive assessments. Heterogeneity existed 
because cognitive function was not the primary endpoint in some of the selected 
studies. For example, two studies were designed primarily to investigate the 














 and acute myelogenous leukaemia
151
. Hence, the type, dose 
intensity, route of administration and duration of chemotherapy treatment varied 
across the studies. The common chemotherapy drugs of interest were doxorubicin, 
cyclophosphamide, methotrexate, irinotecan and oxaliplatin. Examples of 










Different cytokines, including pro-inflammatory cytokines, anti-
inflammatory cytokines and cytokine receptors were investigated. Majority of the 
studies in the literature measured the serum levels of IL-1β, IL-6 or/and TNF-. 
These cytokines were the biomarkers of interest in these studies probably because 








 including cognitive impairment in neurological diseases 
such as Alzheimer’s disease and multiple sclerosis.142,154 Baseline assessments of 
cytokine levels and cognitive functioning were performed in majority of the 
included studies. However, subsequent measurements were conducted at different 
time-points, ranging from 24 hours to 3 years after chemotherapy administration. 
 
Relationships among chemotherapy, cytokines and cognition 
Although some studies observed dysregulation of cytokine levels with 
chemotherapy, they reported conflicting evidence with regards to the strength and 
direction of the association between changes in cytokine levels and 
cognition.
131,169,170
 Ganz et.al. concluded that higher levels of sTNF-RII correlated 
with lower levels of baseline metabolism in the left inferior frontal gyrus in 17 
breast cancer patients (r=-0.55; p=0.02).
169
 The same study also found higher 
levels of sTNF-RII were significantly correlated with greater memory complaints 
on the Squire Memory Questionnaire after controlling for age, body mass index, 
radiation and depression, and time since last chemotherapy treatment among the 
43 patients who received chemotherapy (r=-0.34, p=0.04). Kesler et.al. observed 
that lower left hippocampal volume of the brain was associated with poorer verbal 
memory performance, higher levels of TNF-α and lower levels of IL-6 in 20 
chemotherapy-receiving breast cancer patients.
170
 
Meyers et.al. observed that pre-chemotherapy levels of circulating IL-1, IL-






in laboratory normal controls.
151
 However, the same study did not assess the 
association between post-chemotherapy cytokine levels and cognitive changes.  
The other studies did not find a significant correlation between cognitive 
impairment and cytokines.
165-168
 Notably, the conclusions drawn by some studies 
were limited by the small sample size,
167,168
 or the lack of comparison with 
controls or baseline/follow-up assessments.
151,167,170
  
As chemotherapy agents are usually administered in combinations, it is 
more meaningful to evaluate the relationship between cytokine-induced cognitive 
impairment and chemotherapy regimens, rather than individual chemotherapeutic 
drugs. The accumulation of a combination of drugs, rather than individual drugs, 
may enhance neurotoxicity in cancer patients.
108
 One study examined the effects 
of anthracycline-based (AC/FAC) chemotherapy and CMF on cytokine levels and 
cognitive impairment.
131
 Significant increases in IL-6 (p=0.042) and IL-8 
(p=0.060) levels were observed in the AC/FAC treatment group, whereas IL-6 
was lowered in the CMF group (p=0.054). Patients receiving AC/FAC 
experienced more severe symptoms including heavy-headedness, difficulty 
thinking, and problems with concentration. Similar degrees of forgetfulness were 
displayed in both groups of patients. Knobel et.al. stated that poorer cognition was 
observed among lymphoma patients who received a combination of 
cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and 
methotrexate, compared with patients who received only CHOP (data not 
presented).
167
 This study provided preliminary evidence on how different 






differently. It was suggested that methotrexate’s ability to cross the BBB and 
obstruct brain vascularisation might have caused the cognitive impairment.
171-174
  
The time concordance between the onset of cytokine induction and the 
occurrence of cognitive impairment was not clearly elucidated in these studies. 
Notably, the current evidence could not ascertain the exact timing of the onset of 
cognitive impairment.
41,175
 One study reported that the circulating level of sTNF-
RII was elevated at 6 months post-chemotherapy and declined to a level similar to 
that of non-chemotherapy controls at 12 months post-chemotherapy and an 
increase in cognitive complaints from baseline was significantly correlated with 
increases in sTNF-RII levels (p=0.05).
169
 Evidence on the onset and duration of 
cytokine induction thus remains inconclusive. 
 
Confounding factors 
Through this review, we identified a number of confounders that contributed 
to the heterogeneity of the studies which were not sufficiently accounted for. 
These confounders need to be evaluated and accounted for when studying the 
relationship between chemotherapy-associated cytokine induction and cognitive 
impairment. This discussion also forms the basis of our recommendations for 
future research. 
i. Effects of cancer  
The study populations differed among the selected studies; they included patients 






are capable of producing cytokines.
153,176
 For example, it was found that TNF and 
transforming growth factor (TGF) were elevated in patients with early-stage 
cancers, whereas patients with progressive disease had elevated levels of 
angiogenin, granulocyte macrophage colony-stimulating factor and TNF-β.176 
Hence, it is difficult to determine whether an elevated cytokine level is partially or 
entirely caused by chemotherapy, the progression of cancer or a combination of 
both. Non-cancer controls may not fully eliminate the effects of cancer on 
cytokine levels as studies have shown that there may be a potential dysregulation 
of cytokine levels in subclinical cancer states observed in healthy subjects.
177,178
 
Notably, individual variability (such as disease progression) can still exist within 
cancer controls. It is plausible that cytokine induction attributed by the different 
nature of cancers and anti-cancer treatments may cause varying levels of 
cognitive impairment in patients. 
 
ii. Effects of gender  
Two studies evaluated the effects of gender on cognitive changes.
167,179
 Males 
demonstrated more cognitive impairment than females on objective cognitive 
tests, although subjective (self-reported) cognitive complaints were higher among 
females.
167,179
 It is postulated that higher levels of oestrogen can offer neuro-
protection, antioxidant properties and maintenance of telomere lengths to protect 
against atrophic changes in the brain.
180,181
 Although serum sex hormone levels 
had been measured, analysis was not performed to investigate their correlation 
with serum cytokine levels.
166






increase pro-inflammatory IL-6 and TNF- cytokine activity.182 Higher subjective 
cognitive impairment among females may be attributable to neuroendocrine-
related problems arising from chemotherapy-induced or aging-related 
menopause.
183,184
 Studies have also revealed that testosterone replacement, which 
can potentially shift the cytokine balance to a state of reduced inflammation and 
suppress the expression of the pro-inflammatory cytokines TNF-α, IL-1β and IL-6, 
has been shown to improve some aspects of cognitive ability in males.
185-187
 
Therefore, the receipt of anti-hormonal treatment must be taken into account in 
the assessment of cognitive changes in patients, especially in cancers such as 
prostate, testicular and breast cancers. 
 
iii. Effects of aging 
The age of subjects across the selected studies ranged widely, from 18 to 84 years. 
With the exception of one study,
169
 age was not routinely adjusted as a 
confounding factor. It was proposed that cancer treatments can cause cognitive 
impairment through the acceleration of the aging process, and the biologic 
mechanisms underlying cancer, cancer treatments, aging, neurodegeneration, and 
cognitive decline are interconnected.
95
 Aging may be associated with increase in 
IL-6, TNF-α and TNFR, regardless of comorbidities.154,188-191 Age-related 
impairment is also associated with increased hypothalamic IL-1β, which can 
damage the neuronal membrane through lipid peroxidation, leading to memory 
and learning deficits.
141,154
 Therefore, age is an important determinant in the 






iv. Effects of disturbances in the sleep-wake cycle 
Increased serum cytokine levels have been found among cancer patients with 
dampened circadian rhythms.
192
 Disordered sleep induces an inflammatory 
response that leads to an increase in IL-6 and TGF-. These cytokines, termed 
nocturnal cytokines, have been shown to affect the sleep-wake cycle, causing a 
disruption in the neuroendocrine control of cortisol release, resulting in further 
release of pro-inflammatory cytokines.
152
 Moreover, dysregulation in sleep is 





v. Effects of psychosocial characteristics (fatigue, depression, anxiety 
and stress) 
Fatigue, depression, anxiety, distress and mood changes have been found to 
reduce patients’ cognitive functioning and could be mediated by chemotherapy-
induced cytokines. A meta-analysis revealed a correlation between fatigue and 
serum cytokine levels of IL-6 and IL-1 receptor antagonist.
196
 However, none of 
the three selected studies that measured fatigue as one of their endpoints showed a 
correlation between cytokine levels and the occurrence of fatigue.
165-167
 
Depression is found to disrupt the hypothalamic-pituitary-adrenal axis and 
production of cortisol and pro-inflammatory cytokines through a positive 
feedback mechanism.
142,153,154,197,198
 To reinforce this relationship, studies have 








 Note that patients’ reports of cognitive problems during 
chemotherapy treatment were typically not related to objective cognitive test 




Recommended guidelines for future research  
Based on the evidence from the literature, a list of recommendations is 
proposed to improve the investigation of chemotherapy-induced cytokines as a 
biological determinant of cognitive changes in cancer patients (Table 1.4). To 
summarise, in line with the International Cognition and Cancer Task Force 
recommendations, it is suggested that studies of this subject matter should include 
a longitudinal design, appropriate choices of chemotherapy-receiving cancer 
patients, disease specific and healthy controls, inclusion of baseline and post-
chemotherapy standard neuropsychological assessments and robust statistical 












Table 1.4: Recommended methodological guidelines for future cognitive studies involving cytokines measurements 
 




Inclusion of suitable controls (non-
chemotherapy cancer patients with similar 
demographics). 
To account for cytokine levels and 
cognitive impairment in cancer patients 
without chemotherapy. 
Did the study include controls who do not require 
chemotherapy, and who had the identical type of cancer 
and demographics as the sample population? 
 
Account for co-morbidities. 
To account for changes in cytokine levels 
and cognitive impairment as a result of 
chemotherapy, rather than other factors. 
  
Did the study account for non-cancer disease states? 
  
(anaemia, depression, anxiety, Alzheimer’s 
disease, multiple sclerosis, Parkinson’s, 
dementia, traumatic brain injury, etc.). 
 
Account for other forms of treatment other 
than chemotherapy. 
To account for changes in cytokine levels 
and cognitive impairment as a result of 
chemotherapy, rather than other forms of 
treatment. 
Did the study account for patients who were receiving 
other forms of therapy that may affect cytokine levels and 
cognitive impairment?  (anti-hormonal therapy, cytokine therapy, 




Inclusion of specific chemotherapeutic agents 
or regimens for assessment. 
To understand the pharmacological effects 
of cytokine-induced cognitive impairment.  
Did the study provide clear data regarding the type of 
chemotherapeutic drugs/regimen involved, the duration, 
cycles, doses, dose intensity and route of administration 
of the chemotherapy treatment? 
Inclusion of specific dose intensity, route of 
administration and duration of 
chemotherapeutic treatment. 
To understand whether there is a correlation 
between route of administration/strength 
and duration of dosing with cytokine levels 















Inclusion of both pre-chemotherapy baseline 
and post-chemotherapy assessments at 
appropriate intervals. 
To account for changes in cytokine levels as 
a result of chemotherapy by comparing 
baseline measurement with post-
chemotherapy measurement. 
 
Were measurements carried out before and after patients 
received chemotherapy/surgery? There is currently 
limited evidence in the literature to recommend a definite 
time frame for cytokine analysis. To capture the 
trajectory of cytokine level changes over the course of 
surgery and chemotherapy treatments, it is proposed that 
measurements should be conducted at: 
1. Pre-surgery time point  
2. Post-surgery time point 
3. Pre-chemotherapy time point (before the 
initiation of cycle 1 of chemotherapy) 
4. At the mid-point of chemotherapy treatment 
5. Post-chemotherapy time point 1 (immediately 
after the last cycle of chemotherapy) 
6. Post-chemotherapy time point 2 (6 months to 1 
year after the last cycle of chemotherapy)  
  
 If applicable, inclusion of pre-surgical 
baseline and post-surgical assessments at 
appropriate intervals. 
To account for changes in cytokine levels as 
a result of tumour progression/tumour load 
by comparing pre-surgical measurement 
with post-surgical measurement. 
 
Inclusion of specific cytokines involved in the 
study. 
To identify the specific cytokine and its 
effects on cognitive impairment. 
Did the study specify the types of cytokines to be tested 
for? 
 
Accounting for accuracy of testing. 
To minimise discrepancies in results due to 
the handling and processing of samples. 
Did the study utilise published procedures for the testing 
of cytokine levels? 
Inclusion of standardised timing across the 
samples for extraction of blood samples. 
Different timings of extraction may result in 
different levels of cytokines. 
 
Did the study indicate a specific time for the extraction of 






In addition to these recommendations, it is also important to standardise the 
protocol and timing for the blood draw and measurement of cytokine levels, and 
account for the confounding factors mentioned in the previous section. In 
particular, studies should control for anxiety, depressive and fatigue symptoms 




To evaluate the role of cytokines as mediator between chemotherapy and 
cognitive impairment, it is recommended that investigators could provide a 
rationale behind the choice of cytokines or biomarkers tested in the studies. Novel 
technologies such as multiplex immunoassay can be applied to enable the analysis 
of several cytokines of interest simultaneously.
200
 Commercially available bead-
conjugated antibodies permit the measurement of up to 25 different cytokines 
within a sample.
201
 Validation studies have shown that results of multiplex 
immunoassay well correlate with traditional enzyme linked immunosorbent assay 
(ELISA) for a large majority of human cytokines and biomarkers.
202-204
 Multiplex 
immunoassay also requires lower-volume samples to detect cytokines over a 
broad dynamic range of concentrations in a more cost-effective way. This 
advantage is favourable for longitudinal studies that have high attrition rates, as 
there may be a limited number of samples to conduct ELISA.   
Other than clinical studies, animal models also offer several advantages for 
evaluating the effect of chemotherapy on cognitive outcomes.
128,174,205,206
 Animal 
models can eliminate numerous confounders outlined in this review, such as the 






The time of administration of chemotherapeutic drugs, behavioural assessments 
and blood draw can be standardised in animal studies to reduce the variability 
observed in clinical studies. Results from animal models can aid in elucidating the 
biological mechanisms involved in chemotherapy-induced cognitive changes and 
the specific underlying brain regions involved. 
All current studies of this subject matter attempt to measure cytokine 
concentration in patients’ serum/plasma, and not the cerebrospinal fluid (CSF). 
However, it is logistically challenging to obtain CSF from subjects in a research 
setting. It is proposed that for future studies that involve intrathecal administration 
of chemotherapeutic drugs, especially in leukaemia patients, CSF can be collected 
to examine the relationship between the concentration of cytokine in CSF and 
cognitive functioning before and after the cancer treatment.  
Results from recent published imaging studies also support the hypothesis 
that chemotherapy affects the brain structure and provide research directions for 
candidate mechanisms of chemotherapy-associated cognitive change. Two 
included studies examined the relationship among structural changes in the brain, 
cytokine levels and cognitive impairment.
169,170
 One of the studies found that IL-6 
and TNF-α levels and hippocampal volumes were associated with verbal memory 
functioning despite its relatively small sample size.
170
 Imaging studies play an 
important role in complementing and providing support for the role of pro-
inflammatory cytokines in chemotherapy-associated brain injury and subsequent 
cognitive impairment. It allows researchers to identify the specific site of 






In summary, although current literature observed that patients on 
chemotherapy experienced cognitive impairment and dysregulation in pro-
inflammatory cytokines of IL-1, IL-6 and TNF-, there is limited evidence to 
suggest that there is an association between the severity of cognitive impairment 
and cytokine dysregulation. The intermediary role of cytokines in post-
chemotherapy cognitive impairment is still controversial and requires further 
evaluation. Currently, it is difficult to draw conclusive inferences regarding the 




1.5 Choice of appropriate neuropsychological tools207 
It is observed that inconsistencies in the choice of neuropsychological 
assessments have led to difficulties in evaluating the prevalence, severity and 
determinants of cognitive changes in breast cancer patients. Literature review 
(Appendix 1) shows a divergent selection of neuropsychological tools employed 
in the 58 published cognitive studies in breast cancer patients. Both objective and 
subjective neuropsychological assessments are often utilised in studies to evaluate 
the presence of cognitive changes in breast cancer patients. The International 
Cognition and Cancer Task Force recommend the use of both objective and 








1.5.1 Objective neuropsychological assessments  
Objective assessments involve the use of traditional “pencil and paper” 
neuropsychological batteries or computerised batteries to evaluate a patient’s 
objective clinical cognitive performance. Albeit guidance for selection of 
appropriate tools for objective assessment is lacking in the literature, a handful of 
reviews has made some useful recommendations.
96,199,208
 Traditional assessments 
remain as the most widely used method to evaluate objective cognitive changes 
associated with adjuvant chemotherapy in breast cancer patients.  
Although the incorporation of computerised assessments offers a great 
number of advantages over traditional batteries (Table 1.5), computerised 
assessments were only utilised in 28% of the included studies. This is probably 
due to the lack of published validation data to support its use in cancer research. A 
list of computerised neuropsychological tests and their specifications are 
summarised in Table 1.6. It is observed that indeed, there is a lack of 
psychometric data of these computerised assessments and further validation work 








Table 1.5: Advantages of computerised neuropsychological assessments 
 
 Advantages  
1 Requires no extensive training for the tester 
2 Possesses control over the order, number, presentation rate and complexity of test stimuli, 
hence allowing for reproducibility 
3 Can be modified with alternate versions to allow considerable variation in test parameters, 
hence reducing practice effect209,210 
4 Removes subject/examiner interaction which is a potential source of interview bias
211 
5 Can record and analyse responses of the patient automatically, hence reducing error with 
less variance in scores208,212 
6 Saves sixty percent in administration time over traditional assessments
213 
7 Independent of subjects’ language efficiency214,215 
8 Possesses increased security of test data and patient records with computerised storage 
mediums212 
9 Can be portable with the use of notebook computers 









Table 1.6: Specifications of commonly used computerised neuropsychological 
assessments 
 
1.5.2 Subjective/self-reporting neuropsychological assessments 
Subjective assessments involve patient’s self-reporting of their perceived 
cognitive changes. In recent years, subjective neuropsychological assessments are 
routinely incorporated within cognitive studies for breast cancer patients. 
Inconsistency is also found with the choice of subjective assessment tools utilised 
across studies. A summary of the subjective assessments are shown in Table 1.7. 
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assessing cognition, the duration of perceived ability assessed, the domains 
assessed, and the range of abilities assessed.   
Perceived cognitive changes are an important aspect because it is found to 
be associated with psychological distress and poorer HRQoL in breast cancer 
patients.
102
 Subjective assessments reflect the perceived impairment of 
chemotherapy recipients and, indirectly, their psychological distress and quality 
of life. However, objective impairment that is a result of cancer treatment has 
very weak, or even no correlation with perceived impairment.
102,199
 The weak 
correlation between subjective and objective assessments may probably be due to 
the different constructs tested. The questions that are asked within the subjective 
tests and the tasks performed in the objective tests are not assessing the same set 
of cognitive domains. Furthermore, these two methods of cognitive testing take 
place within different environments: subjective assessments relate more to 
patients’ activities of daily life, while objective assessments are often 
administered by trained personnel under very conducive conditions.
218
 Hence, it is 
common to find that impairment is more pronounced from the patients’ 
perceptions than the objective results. Future studies should incorporate subjective 
assessments, in addition to objective assessments, and also report scores 
pertaining to individual domains rather than overall cognition. This is to enhance 
the correlation between assessments and to better understand the functional site 
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Number of items 25 38 
Cognitive subscale: 2 
(Full scale: 30) 
Original version: 16 





Duration of perceived 
ability assessed 
Past 6 months Not applicable Past 7 days 
Time of 
administration 
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1.6 Management of cognitive changes 
To date, a number of pharmacological and cognitive-behavioural 
interventions have been tested to manage cognitive impairment in patients with 
cancer.
225-236
 The results from a recent randomised clinical trial suggested that 
brain cancer patients with the most severe impairment in the cognitive domain of 
executive function at baseline benefited the most from methylphenidate and 
modafinil.
225
 Another double-blinded, placebo controlled trial evaluated the use of 
donepezil with Vitamin E in patients with 9 small cell lung cancer after 
completion of all cancer therapy, including prophylactic cranial irradiation.
236
 
Cognition, adverse events, and quality of life were assessed throughout the study 
period. However, there was no notable improvement in cognitive stability and 
HRQoL. Although Ginkgo biloba has been investigated in the literature to reduce 
the risk of dementia and other age-related neurodegenerative diseases, it does not 
seem efficacious in the limited trials to date.
237,238
 It is important to note that these 
trials are limited in their sample sizes and the population of interest was not 
restricted to breast cancer patients. As the treatment modalities and disease 
presentations are different, the results of these studies cannot be extrapolated to 
the breast cancer population. Hence, it can be concluded that currently, no definite 
pharmacological management of cognitive impairment in cancer patients have 
been found.  
There are also a handful of studies that evaluated the effects of non-
pharmacological intervention on preventing cognitive decline in cancer 
patients.
227,235




practiced medical qigong had statistically significant improvements in self-
reported cognitive functions and HRQoL.
235
 Other studies have documented the 
usefulness of mindfulness therapy for improving mood and psychological 
functioning, decreasing fatigue, and enhancing well-being in cancer patients.
239
 
However, there is a lack of robust evidence to support the implementation of these 







1.7 Research gaps, hypotheses and specific aims 
The previous section summarised the background literature surrounding the 
main topic of this thesis, which is chemotherapy-associated cognitive changes in 
breast cancer patients. Studies that have evaluated the magnitude and impact of 
this problem are limited in number and diverse in quality. The multiple factors 
that have been postulated to contribute to cognitive changes in cancer patients 
have increased the complexity of this research. Evidence of the potential 
pharmacological, psychosocial and biological factors has not been established in 
the current literature.  
Pertaining to methodological design of studies, the differences between and 
within different types of neuropsychological tests have made selection difficult. 
While objective neuropsychological assessments evaluate the neurotoxic effect of 
chemotherapy agents on the clinical presentation of cognitive impairment in 
patients, subjective assessments relate to the effects of chemotherapy on their 
perceived cognitive ability and functionality. Both subjective and objective 
cognitive assessments for attention, memory, executive function and processing 
speed are needed to obtain a comprehensive determination of a patient’s cognitive 
status. Computerised administration of cognitive tests may be more advantageous 
than traditional neuropsychological batteries of evaluation. By using appropriate 
neuropsychological tools to assess cognitive changes, an eventual improved 
understanding of the nature, severity, site, onset and duration of cognitive 





1.7.1 Research gaps and hypotheses 
It can be inferred from the literature review presented in the previous 
sections that there is a paucity of research that evaluates cognitive changes in 
breast cancer patients, particularly in Asian populations. Overall, this thesis 
hypothesised that: 
 Both Asian breast cancer patients and oncology practitioners perceive 
chemotherapy-associated cognitive changes as a prevalent and important 
supportive care problem in oncology.  
 The interplay among demographical, clinical, pharmacological, 
psychosocial and biological determinants contributes to varying severities 
of cognitive changes in Asian breast cancer patients. 
 
1.7.2 Specific aims  
 Using a retrospective study, this thesis aimed to assess the relevance of 
this “chemobrain” phenomenon preliminarily by evaluating the 
prevalence of documented risk factors for chemotherapy-associated 
cognitive changes in Asian breast cancer patients. 
 Through a focus group discussion, this thesis aimed to evaluate 
qualitatively the relevance, experiences and coping mechanisms of 





 By conducting a survey, this thesis aimed to evaluate the perceptions of 
oncology practitioners on the presentations, causes and management 
strategies of chemotherapy-associated cognitive changes in Asian breast 
cancer patients. 
 Through a rigorous methodological and statistical approach, this thesis 
aimed to validate the English and Simplified Chinese versions of the 
Functional Assessment of Cancer Therapy–Cognitive Function (FACT-
Cog) (Appendices 2 and 3) version 3 as a valid and reliable subjective 
neuropsychological tool of choice to detect clinically significant 
deterioration in breast cancer patients. 
 By conducting a longitudinal, cohort study using both objective and 
subjective neuropsychological tools, this thesis aimed to evaluate the 
prevalence and severity of chemotherapy-associated (both objective and 
subjective) cognitive changes in Asian breast cancer patients, and identify 
the clinical, psychosocial and pharmacological factors that are the 
determinants associated with cognitive changes among Asian breast 
cancer patients. 
 Using a translation approach, this thesis aimed to evaluate the potential 
role of inflammatory markers as biological determinants associated with 






1.7.3 Overall approaches 
The work presented in this thesis can be divided into three phases (Table 1.8): 
Phase 1: To establish the relevance and experiences of cognitive changes in 
Asian populations of breast cancer patients through a retrospective study, and to 
gather qualitative/quantitative information on breast cancer patients’ and 
oncology practitioners’ perception of this subject matter. 
Phase 2: To optimise a subjective neuropsychological tool through rigorous 
translation, validation and cultural adaptation processes. 
Phase 3: To evaluate quantitatively the prevalence and severity of objective and 
subjective cognitive changes in a prospective cohort of Asian breast cancer 
patients, and identify the clinical, psychosocial, pharmacological and biological 





Table 1.8: Overall aims, research questions and approaches outlined in this 
thesis 
Aims Research questions Approach 
Phase 1: To assess the relevance of the problem  
 
 
To assess the relevance of the 
problem of chemotherapy-
associated cognitive changes in 
Asian breast cancer patients  
How prevalent are the documented risk 
factors for chemotherapy-associated 






How prevalent is anxiety, an important 
documented risk factor for cognitive 






Do Asian breast cancer patients perceive 
chemotherapy-associated cognitive 
changes as an important and relevant 






Do oncology practitioners perceive 
chemotherapy-associated cognitive 
changes as an important and relevant 






Phase 2: To optimise the cognitive  tools 
 
 
To optimise the subjective 
neuropsychological tools used for 
the assessment of perceived 
cognitive changes in breast 
cancer patients 
 
Is the Functional Assessment of Cancer 
Therapy –Cognitive Function (FACT-
Cog) (Appendices 2 and 3) version 3 a 
valid and reliable subjective 
neuropsychological tool of choice in 





What is the change in score on FACT-
Cog that signifies a clinically significant 





Phase 3: To evaluate the prevalence, severity and determinants of the problem 
 
 
To evaluate quantitatively the 
prevalence and severity of 
chemotherapy-associated (both 
objective and subjective) 
cognitive changes in the Asian 






Do Asian breast cancer patients who had 
received chemotherapy suffer from more 
severe perceived cognitive disturbances 





From the start till the completion of 
chemotherapy, what is the prevalence and 
severity of both objective and subjective 
chemotherapy-associated cognitive 









Aims Research questions Approach 
To identify the demographical, 
psychosocial, pharmacological 
and biological factors as 
determinants associated with 
objective and subjective cognitive 
changes among the Asian 
population of breast cancer 
patients 
 
What is the association among Asian 
breast cancer patients’ levels of anxiety, 
fatigue, health-related quality of life and 
the severity of their cognitive changes? 
How do different chemotherapy regimens 
contribute to different severities of 






 What is the association between patients’ 
levels of biological determinants (pro-
inflammatory cytokines) and cognitive 




1.8 Significance of the work presented in this thesis 
Cancer mortality rates have dropped significantly since the introduction 
and use of effective chemotherapy combinations, especially with regard to 
positive outcomes for early-stage breast cancer which is particularly sensitive to 
treatment. The challenge is now to reduce the morbidity associated with cancer 
further and improve the quality of life of breast cancer patients. Due to the 
relatively young median age of 50 years at the point of diagnosis,
1,2
 survivors of 
early-stage breast cancer are capable of returning to their pre-cancer level of 
functioning and lifestyle upon the completion of their anti-cancer treatment. 
Notably, a substantial proportion of the breast cancer survivors may return to the 
workforce as contributors to society. As such, cognitive ability is an important 
component in their HRQoL. This thesis has intense scientific merit in the fields 
of oncology, psychology and translational research and will have a strong impact 





1.8.1 Impact on clinicians and oncologists 
Delineating the nature, prevalence and severity of this potential neurotoxic 
effect of chemotherapy will contribute to a more comprehensive and holistic 
view on the toxicities associated with anti-cancer treatments. Understanding the 
determinants of cognitive changes in cancer patients will aid clinicians in giving 
informed recommendations for chemotherapy regimens and counselling on 
adverse effects to patients. As ongoing and future research attempts to elucidate 
the underlying mechanisms related to chemotherapy-associated cognitive 
impairment, ultimately clinicians may be able to identify high-risk or vulnerable 
patients and personalize their anti-cancer treatment to avoid undesired toxicities. 
 
1.8.2 Impact on pharmacy and nursing practices 
Findings from this thesis could result in a potentially practice-changing 
outcome in supportive care and psycho-oncology management for cancer 
patients. Specific to allied health professionals, such as oncology pharmacists 
and nurses, knowing the determinants of cognitive decline will pave the way for 
future pharmacological and psychosocial interventions to address the unique 
needs of different groups of cancer patients. 
To date, cognitive studies in Asian cancer patients have been a challenge 
due to the language, cultural and complexity issues of traditional 
neuropsychological assessments. The results of this study may provide insight 




clinical settings where cancer patients are multi-ethnical, multi-cultural and non-
English speaking. The routine tracking of cancer patients’ cognitive function as 
an integral component of supportive care and symptom monitoring may be 
possible in the near future.   
 
1.8.3 Impact on patients 
Establishing the relevance and existence of cognitive changes in Asian 
populations of breast cancer patients will improve their awareness of this 
potential adverse effect associated with chemotherapy. With a more holistic 
supportive care treatment and a quality survivorship care plan, breast cancer 
patients’ psychosocial needs will be better addressed.   On a societal level, future 
interventions in the management of cognitive changes may help cancer survivors 
to contribute to society and the workforce.   
 
1.8.4 Impact on future pharmaceutical research 
Using theoretical data gathered from the study, differences in the 
expression of candidate genes that lead to variations in the severity and type of 
cognitive changes across ethnic groups can be investigated. The results on 
prevalence from this study may pave the way for future genetic research work. 
Understanding the role of biological factors in cognitive changes may 
provide directions for the development of pharmacological agents to manage or 




of pain and affective disorders, several pharmacological agents were tested to 
antagonise cytokine-induced sickness behaviour in animals. It is anticipated that 
neuro-protective agents may eventually be discovered to counter the potential 







Chapter 2: Preliminary evaluation of the prevalence of documented clinical 
determinants for cognitive changes in Asian breast cancer patients 
The literature review from Chapter 1 reveals that there is a lack of 
prevalence data on chemotherapy-associated cognitive changes in Asian breast 
cancer patients. Neuropsychological tests are currently not routinely conducted 
on breast cancer patients in an Asian clinical setting. Existing studies suggest that 
certain clinical factors, such as age and post-menopausal status, and other 
underlying psychological distress symptoms such as anxiety, depression and 
fatigue, may be determinants for cognitive changes in cancer patients.
87,93,103,199
 
These documented risk factors are useful as surrogate markers that may 
potentially help to gauge the relevance of this “chemobrain” phenomenon in 
Asian breast cancer patients. 
 
2.1 Prevalence of documented clinical determinants of cognitive changes in 
Asian breast cancer patients: A retrospective approach
240
 
The objective of this preliminary study was to investigate retrospectively, 
the prevalence of these documented risk factors among breast cancer patients and 
to identify the proportion of patients who possessed these documented risk factors.  
The specific research question that this chapter aims to answer is: 
- How prevalent are the documented risk factors for chemotherapy-





- What is the proportion of patients who possessed multiple risk factors for 
chemotherapy-associated cognitive changes? 
 
2.1.1 Methodology  
Study design and setting 
This was a retrospective study conducted at the National Cancer Centre 
Singapore (NCCS). Approval from the Singhealth Centralised Institutional 
Review Board (CIRB) was obtained and written informed consent was waived 
due to the retrospective nature of this study that did not involve interaction with 
patients.  
Patients 
This retrospective analysis involved 160 breast cancer patients who were 
previously recruited into another local epidemiological study by Yap et.al. on 
CINV between August 2009 and November 2010.
20
 
These 160 breast cancer patients 1) were at least 21 years of age, 2) have 
good performance status which was defined as an Eastern Cooperative Oncology 
Group (ECOG)
241
 score of 0 or 1, 3) received anthracycline-based regimens and 4) 
were willing to provide informed consent. The exclusion criteria for the study 
were patients who were unable to speak, understand and give written consent in 







Patients’ demographic (such as age, race, educational status etc.) and 
medical information (cancer stage, chemotherapy regimens, medication history 
etc.) were obtained from patients’ medical records and electronic databases 
available in NCCS. 
Information pertaining to patients’ psychosocial distresses, such as anxiety 
and fatigue, were obtained from the in-house database owned by the local 
research team. Of interest to this retrospective analysis are the following tools that 
were administered to the patients who participated in the CINV study:
20
 
i. Fatigue interference score 
A single-item fatigue interference score captures the severities of patients’ 
tiredness. Patients were asked to provide a score (Likert scale of 0-10) to describe 
how fatigue had interfered with their abilities to engage in activities of daily 
living since the time of cancer diagnosis, or within the last 6 months of survey 
administration.  
The maximum fatigue interference score is 10 points. A higher score is indicative 
of higher level of fatigue. Patients are classified into experiencing severe fatigue 
(score of 7 and above), moderate fatigue (score of 4 to 6) and mild/no fatigue 
(score of 3 or below). 
ii. Beck Anxiety Inventory (BAI) 
The BAI is a validated questionnaire comprising 21 self-reported anxiety-





scale ranging from 0 (“Not at all”) to 3 (“Severe”).242-244 Each item is descriptive 
of subjective, neuropsychological, somatic, or panic-related symptoms of anxiety. 
The maximum score for BAI is 63 points. A higher BAI score is indicative of 
higher level of anxiety symptoms. A total score can be tabulated and patients are 
classified into experiencing severe anxiety (score of 26-63), moderate anxiety 




BAI is demonstrated to have a high internal consistency with Cronbach’s α 
ranging from 0.92 to 0.94 for adults and test-retest reliability (1-week interval) of 
0.75.
242
 Both the English and Chinese BAI have been used to evaluate the 
presentation of anxiety-related symptoms in local neuropsychiatric patients.
245
 
Definitions of risk factors for chemotherapy-associated cognitive changes 
 Based on the literature review presented in Chapter 1, the 8 documented 
risk factors for chemotherapy-associated cognitive changes in cancer patients 
were old age, post-menopausal status, low cognitive reserve, anaemia, receipt of 
anti-hormonal therapy, concomitant receipt of neurodegenerative medication, 
fatigue and anxiety. The detailed descriptions of these risk factors and 







Table 2.1: Definitions of documented clinical and psychosocial risk factors of 




Definition Justifications for the choice of 
definitions and/or cut-off points 
1 Old age95,97,246,247  Age of more than 65 
years  
Based on current evidence in the 
literature that breast cancer patients 
who were older than 65 years of age 
had poorer cognitive performance than 




Amenorrhea for at least 
12 months 
Based on the definition stipulated by 
the NCCN guidelines for the treatment 
of invasive breast cancer.3 
3 Receipt of anti-
hormonal 
treatment76,80,98,248,249 
Receipt of tamoxifen or 
any aromatase inhibitors 
for more than one month 
Based on the definition stipulated by 
the NCCN guidelines for the treatment 
of invasive breast cancer.3 
4 Severe 
fatigue64,65,104,105,250,251 
A score of more than 6 on 
the 10-point fatigue 
interference scale  
This cut-off point corresponded to a 
severe degree of fatigue on the 10-
point Likert scale.   
5 Moderate to severe 
anxiety69,102,252 
A score of more than 16 
on the Beck Anxiety 
Inventory 
This cut-off point corresponded to a 
moderate to severe degree of anxiety 
based on the Beck Anxiety Inventory 
manual.244 
6 Anaemia135,253 Haemoglobin level of less 
than 12g/dL at the end of 
3rd cycle of chemotherapy 
Based on current evidence in the 
literature that greater declines in 
haemoglobin were significantly related 
to worsening cognitive performances 
in breast cancer patients whose 
haemoglobin levels were less than 12 
g/dL at the third cycle of 
chemotherapy.135,253 








epileptic medications for 
more than 3 months 
Based on the pharmacology of most 
neuropsychiatric medicines that 
require the patient to receive a regular 
dose of 6 to 12 weeks of the drugs to 
experience the full positive and side 
effects of the drugs.  
8 Low cognitive 
reserve97 
Receipt of less than 12 
years of education.  
 
Educational level is used as a 
surrogate marker for cognitive reserve. 
A cut-off point of 12 years 
corresponds to pre-university or 
diploma education within the local 
context. 








Descriptive statistics were used to summarise the prevalence of documented 
risk factors for cognitive changes in cancer patients. All analyses were performed 
using Statistics Package for Social Science (SPSS) version 20. 
 
2.1.2 Baseline characteristics of patients 
Baseline characteristics of the 160 breast cancer patients are presented in 
Table 2.2. In this retrospective analysis, majority of the patients were Chinese 
(76.3%) and had a mean age of 55.5±6.8 years. Most of them had early-stage 








Table 2.2: Baseline characteristics and prevalence of clinical and psychosocial 
risk factors of cognitive changes in breast cancer patients (N=160) 
Baseline characteristics  Frequency  (%) 
Race Chinese 122 (76.3) 
 Indian 7 (4.4) 
 Malay 25 (15.6) 
 Others 6 (3.8) 
Stage Stage I 14 (8.8) 
 Stage II 74 (46.3) 
 Stage III 61 (38.1) 
 Stage IV 11 (6.9) 
Chemotherapy regimen AC-based 125 (78.2) 
 FEC-based 35 (21.9) 
Risk factors  Frequency  (%) 
Age < 65 years old 149 (93.1) 
 > 65 years old 11 (6.9) 
Menopausal status Pre-menopausal 67 (41.9) 
 Post-menopausal 93 (58.1) 
Education level < 12 years of education 111 (69.4) 
 > 12 years of education 49 (30.6) 
Fatigue No/mild fatigue  95 (59.4) 
 Moderate fatigue 42 (26.3) 
 Severe fatigue 23 (14.4) 
Anxiety * Minimal/mild anxiety 112 (70.1) 
 Moderate anxiety 42 (26.3) 
 Severe anxiety 5 (3.1) 
Anaemia Haemoglobin > 12g/dl 50 (31.3) 
 Haemoglobin < 12g/dl 110 (68.8) 
Receipt of anti-hormonal 
treatment 
No anti-hormonal treatment 58 (36.3) 
Received anti-hormonal treatment 102 (63.8) 
    Letrozole   76      (47.5) 
 Anastrozole  6  (3.8) 
 Tamoxifen  12  (7.5) 
Receipt of concomitant 
neurodegenerative medication 
No concomitant medication 103 (64.4) 
Received concomitant medication 57 (35.6) 
  Opioids  15      (9.4) 
 Anti-depressants  2  (1.3) 
 Anti-epileptics  3  (1.9) 
 Hypnotics  30  (18.8) 
 Benzodiazepines  23  (14.4) 
*N=159 (one missing data) 







The overall prevalence of documented risk factors is summarised in Figure 
2.1. Majority (76.3%) of the patients had 2 to 4 risk factors (out of 8) that 
predisposed them to cognitive dysfunction (Figure 2.2). 
 
Figure 2.1: Proportion of patients with documented risk factors for cognitive 





Figure 2.2: Prevalence of individual risk factors for cognitive changes in breast 












Two to four risk factors
























2.1.3 Prevalence of demographic/clinical risk factors 
The most common clinical risk factors observed were low cognitive reserve 
(69.4%), anaemia (68.8%) and the receipt of anti-hormonal treatment (63.8%).  
Low baseline cognitive reserve has been documented as a risk factor for 
post-treatment cognitive changes.97 Cognitive reserve represents innate and 
developed cognitive capacity, which is influenced by various factors, including 
genetics, education, occupational attainment, and lifestyle. Research has 
demonstrated that people with low cognitive reserve are more vulnerable to the 
development of neurocognitive disorders (eg, Alzheimer’s disease) and to 
cognitive decline after a variety of insults to the brain.
250,251
 However, caution has 
to be taken in the interpretation of this result as the number of years of education 
is used as a surrogate marker for cognitive reserve in this retrospective analysis. A 
more accurate measure of cognitive reserve is the use of validated Intelligent 




Results from this retrospective study shows that approximately two-thirds 
of the patients received anti-hormonal treatment. This prevalence rate corresponds 
to the epidemiological data in Singapore, which shows that 51% of pre-
menopausal and 60% of post-menopausal breast cancer patients present with 
oestrogen receptor tumour cells.
259
 Current evidence in the literature revealed that 
the receipt of anti-hormonal therapy is strongly associated with perceived 
cognitive disturbances. 
80,98,248,249
 One study detected more severe perceived 





who had been exposed to tamoxifen or aromatase inhibitors, than those who had 




2.1.4 Prevalence of psychosocial risk factors 
Documented psychosocial risk factors that were associated with cognitive 
changes, such as anxiety, were less common (29.4%). Interestingly, it was 
observed from the literature that the prevalence of anxiety was higher, ranging 
from 30.0 % to 67.6 %, in similar studies conducted in the Western population of 
breast cancer patients.
261-263
 The difference in prevalence might be contributed by 
methodological inconsistencies; it is important to note that different anxiety 
screening tools were utilised across all studies. BAI was utilised to capture 
anxiety characteristics in our study, whereas the Hospital Anxiety and Depression 
Scale (HADS) was used in the other studies.
261-263
 The prevalence and severity of 
anxiety among Asian breast cancer patients will be further explored over the next 
section (Chapter 2.2). 
The proportion of patients who suffered from fatigue is rather low in this 
sample population. This observation may be explained by the large proportion of 
patients who were relatively young, ambulating with good performance status, 
had early-stage disease and did not suffer from clinically-significant anaemia. 
Hence, they were not expected to suffer from significant fatigue. However, it is 
worthwhile to note that the selection of an assessment tool that can appropriately 
capture one’s fatigue symptoms is an inherent issue of this retrospective study. 





difference in fatigue perceptions exist between patients and oncologists.
264
 
Anecdotal evidence suggests that patient-reported toxicity measures are accurate 
reflections of their clinical status.
265
 Currently, there are over 20 tools developed 
to assess patients’ reported level of fatigue.266 However, many of these tools are 
lengthy and patients may experience difficulty understanding the items asked. 
Single-item fatigue scales, such as the visual analogue scale, are common and 
useful tools to evaluate cancer patients’ fatigue intensity and interference.266,267 
Tools with multiple items may be too complex and time-consuming to be 
administered, which may subsequently lead to participant burden and poor 
response rates. It is suggested that the future development of more comprehensive 
fatigue assessment tools should specify how fatigue has interfered with the 
patients’ social, leisure and self-care activities to aid in their understanding of 
fatigue severity as a risk factor for cognitive changes. 
 
2.1.5 Limitations of study 
As this study is retrospective in nature, it is inevitable that the accuracy or 
consistency on how the relevant information was recorded could not be 
ascertained. To overcome this limitation, a rigorous data collection approach that 
utilised both in-house electronic databases and case notes were adopted to ensure 
that the data collected were comprehensive. The tools that were used to evaluate 
the prevalence of fatigue and anxiety may be different from the other studies in 
the literature. Therefore, the prevalence results presented in this study may not be 





identified risk factors and the definitions adopted in this preliminary study were 
based on evidence from the Western breast cancer population. Hence they might 
not be applicable to the Asian breast cancer patients. However, due to the paucity 
of published cognitive studies in the Asian cancer population at the time of 
inception of this thesis, we justify that it might be valid to extrapolate findings 
from other ethnic groups for the purpose of this preliminary study. 
 
2.1.6 Summary of important findings 
This is a preliminary study that serves to identify the prevalence of 
documented risk factors for chemotherapy-associated cognitive changes in local 
breast cancer patients.  
The identified prevalence of the clinical determinants such as post-
menopausal status (58.1%), old age (6.9%), anaemia (68.8%) and the receipt of 
anti-hormonal treatment (63.8%) corresponded with findings from literature. 
However the prevalence of anxiety (29.3%), which had been documented in 
literature as a significant determinant of cognitive changes, was comparatively 
lower than the reported prevalence in the Western cancer population. Majority of 
the patients (76.3%) possessed two to four documented clinical risk factors for 
cognitive dysfunction. Since these risk factors are evident and prevalent in the 
sampled breast cancer patients of this preliminary study, it is worthwhile to 
further evaluate the relevance and occurrence of chemotherapy-associated 









Retrospective data from the previous preliminary study (Chapter 2.1) 
suggested that the prevalence of anxiety in Asian breast cancer patients was 
comparatively lower than the reported prevalence in the Western cancer 
population. Studies in the literature have revealed that among newly diagnosed 
breast cancer patients, almost half of these patients have reported to be afflicted 
with anxiety symptoms.
13,269,270
 Untreated anxiety has been shown to increase the 




As anxiety is documented as a strong determinant of cognitive changes, 
69,102,252 it may be clinically useful to identify the prevalence and severity of anxiety 
in breast cancer patients. However, there is a paucity of published studies that 
evaluate the clinical presentations of anxiety symptoms experienced by Asian 
breast cancer patients across the different stages of chemotherapy treatment. In 
addition, majority of the studies examined prevalence and clinical determinants of 
anxiety among Caucasian breast cancer patients, with limited evidence to 
ascertain the relevance and severity of anxiety-related distress in the Asian breast 
cancer population.
5,270-272
 In view of these research gaps, this study was designed 
to examine the prevalence, severity and presentation of anxiety symptom domains 
among Asian breast cancer patients at different phases of cancer treatment, and to 







Study design and setting 
This was a single-centred, observational study conducted between August 
2009 and January 2012 at the NCCS. This study was approved by the CIRB and 
informed consent was obtained from all patients. 
Patients 
All eligible patients must be (1) diagnosed with early-stage breast cancer 
(defined as breast cancer of stages I, II or IIIA) by a medical oncologist, (2) above 
21 years of age, and (3) able to read and understand either English or Mandarin. 
Patients were excluded if they had underlying medical disorders that limited their 
mental capabilities to provide informed consent. To evaluate the presentation of 
anxiety symptoms at different stages of cancer treatment, eligible patients were 
stratified into three groups based on their chemotherapy treatment status, namely 
pre-chemotherapy (Pre-CT), during-chemotherapy (During-CT), and post-
chemotherapy (Post-CT). The Pre-CT group consisted of newly diagnosed 
chemotherapy-naïve patients who had no prior exposure to cytotoxic 
chemotherapy, the During-CT group consisted of patients who were undergoing 
adjuvant anthracycline-based chemotherapy at the point of data collection and the 
Post-CT group consisted of patients who had completed their adjuvant 







Eligible patients were interviewed during their follow-up consultations at 
NCCS. All interviews and data collection were conducted by trained investigators. 
Patients’ demographical and clinical information, such as education level, marital 
status, employment status, cancer stage and ECOG performance status, were 
collected. The concomitant use of neuropsychiatric medications (such as 
antidepressants, antiepileptics, hypnotics, and anxiolytics) and analgesics (such as 
paracetamol, non-steroidal anti-inflammatory drugs and opioids) were also 
documented. For the Post-CT group, patients who had received adjuvant radiation 
therapy would be documented. 
Study tools 
i. BAI 
The BAI is a 21-item instrument which assesses the severity of anxiety symptoms 
experienced by the patients in the past month. The 21-item instrument can be 
categorised into a 4-factor structure corresponding to the neurophysiological, 
subjective, autonomic and panic components of anxiety (Table 2.3). Details of the 















Anxiety symptom / characteristic 1 
Autonomic Feeling hot, indigestion, flushed face, hot/cold sweats 
Neurophysiological Numbness, wobbliness, dizziness, 
unsteady, hands trembling, shaky, faintness 
Panic Heart pounding, feelings of choking, breathing difficulty, fear 
of dying 
Subjective Unable to relax, terrified, nervousness, scared, fear of the worst 
happening, fear of losing control 
1 Each symptom was rated by patients on a 4-point scale, ranging from “0 to 3” with increasing order of severity, where “0” 
represented “not at all”, “1” represented “mild”, “2” represented “moderate” and “3” represented “severe”. 
 
ii. Fatigue interference score 
A single-item fatigue interference score captures the severities of patients’ 
tiredness. Details of the fatigue interference score are presented in Chapter 2.1.1.  
Statistical analysis 
Descriptive statistics were utilised to summarise patient demographics and 
clinical characteristics. Median and interquartile range (IQR), and mean ± SD, 
were used for reporting non-parametric and parametric data, respectively. Non-
parametric tests such as Mann-Whitney and Kruskal-Wallis tests were used to 
identify differences in continuous variables among groups whereas chi-square and 
Fisher exact tests were used for categorical variables. Two-sided p-values of less 
than 0.05 were considered significant. Follow-up tests were conducted to evaluate 





Anxiety severity, which was represented by BAI raw scores, was classified 
into categorical ratings (“minimal”, “mild”, “moderate” and “severe”) for the ease 
of clinical interpretability. Patient characteristics that were associated with anxiety, 
as depicted by the raw BAI scores, were evaluated using linear regression analysis. 
A best-fitted model was created by the inclusion of both documented clinically-
relevant factors and exploratory variables using the forward-stepwise model 
selection approach. Documented clinically relevant factors referred to age, 
education level, marital status, employment status, time from diagnosis and the 
receipt of concomitant analgesics, mastectomy, chemotherapy and adjuvant 
radiation treatment.
4-6,10,13,106,263,269,270,272-282
 In order for other exploratory 
variables to be included in the linear regression model, it must be statistically 
significant at a cut-off p-value of 0.1 in the univariate analysis (through the use of 
simple inferential statistics and hypothesis testing) and considered clinically-
relevant, based on consensus among clinicians in the research team. This 
approach was adopted to prevent detraction from the statistical power by 
including clinically-irrelevant variables in the model. Residual analysis and 
collinearity diagnostics were performed to ensure the validity of the linear 
regression model.  
Sample size calculation 
Sample size calculation was conducted based on the assumption that the 
difference in the total BAI score between any 2 groups of patients would be of a 
medium Cohen’s effect size (f) of 0.25.283 Considering a two-sided significance 





52 patients per group was needed. All analyses were performed in SPSS version 
20.0. 
 
2.2.2 Baseline characteristics of patients 
Patients’ characteristics 
A total of 319 patients participated in the study, with 78 patients in the Pre-
CT group, 161 patients in the During-CT group, and 80 patients in the Post-CT 
group (Table 2.4). Majority of the patients were Chinese (80.9%) and their mean 
age was 51.4 ± 9.3 years. Approximately 30% of the patients received tertiary 
education. A total of 244 patients (76.5%) were married and 196 of them (61.4%) 
were unemployed at the time of interview. Most patients were diagnosed with 
stage II breast cancer (49.5%) and majority possessed good performance status 
with an ECOG score of 0 (92.5%). The median fatigue interference score was 3 
(IQR: 0-5). A total of 200 patients (62.7%) underwent mastectomy and 79 of 
them (24.8%) underwent lumpectomy. Approximately half of the patients 
received concomitant analgesics (49.8%) and a smaller proportion (15.0%) 
received concomitant neuropsychiatric medicines.  
Several patient characteristics were found to be statistically different among 
the three groups of breast cancer patients with different treatment status. These 
characteristics included age, employment status, breast cancer staging, ECOG, 





analgesics. The time from diagnosis was the longest for patients within the Post-
CT group (24.3 ± 8.9 months), as compared to the Pre-CT (1.6 ± 0.8 months) and 
During-CT (2.6 ± 1.9 months) groups. Majority of the patients (63.8%) in the 
Post-CT group had received adjuvant radiation treatment at the time of interview. 
All the Pre-CT and During-CT groups did not have prior exposure to adjuvant 
radiation treatment. The median fatigue score of patients in the Post-CT group 
was 4 (IQR: 2-6), which was significantly higher than the Pre-CT (p=0.003) and 
During-CT (p=0.001) groups. A significantly larger proportion of patients (26.1%) 
from the During-CT groups were on concomitant neuropsychiatric medicines as 
compared to the Pre-CT (5.1%; p0.001) and Post-CT (2.5%; p0.001) groups. 
More patients in the Pre-CT (70.5%) and During-CT (60.2%) groups received 
concomitant analgesics as compared to the Post-CT group (8.8%; Pre-CT vs Post-










Table 2.4: Patients’ demographics and characteristics (N=319) 
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Bold: Denotes statistical significance at p<0.05  
CT: Adjuvant anthracycline-based chemotherapy; ECOG: Eastern Cooperative Oncology Group; JC: Junior College; NA: 
Not applicable; SD: Standard deviation 
1 Statistical comparison between groups was not conducted because none of the pre-CT and during-CT patients received 
radiation therapy during the study period 
2Antidepressants, antiepileptics, hypnotics, anxiolytics 





2.2.3 Prevalence and presentation of anxiety symptoms 
Clinically significant anxiety symptoms were experienced by a total of 71 
(22.3%) breast cancer patients. Smaller proportions of patients in the Pre-CT 
group (9.0%) experienced significant levels of anxiety as compared to the During-
CT (29.8%; p<0.001) and Post-CT groups (20.0%; p=0.049). Severity of anxiety 
differed significantly among the three groups of patients too (p=0.005) (Table 
2.5). A larger proportion of patients in the Pre-CT group experienced minimal 
levels of anxiety, relative to the During-CT group (64.1% vs 41.0%, p=0.001). 
More patients in the During-CT group experienced moderate levels of anxiety, as 
compared to the patients within the Pre-CT group (27.3% vs 9.0%, p=0.001).  
The total BAI scores were statistically different among the three groups 
(p0.001) (Table 2.5). Pre-CT patients (median score: 5, IQR: 2-8) experienced a 
lower degree of anxiety as compared to the patients in the During-CT (median 
score: 10, IQR: 5-17; p0.001) and Post-CT (median score: 7, IQR: 3-12.75; 
p=0.008) groups. 
Among the four sub-domains of BAI, patients experienced most anxiety 
symptoms from the neurophysiological and subjective sub-domains.  Anxiety 
scores in the four sub-domains of BAI were statistically different across all three 
groups of patients (p0.001 for all four sub-domains). Patients in the During-CT 
group experienced more anxiety symptoms as compared to patients in the Pre-CT 
and Post-CT groups, particularly those from the neurophysiological (Pre-CT vs 





During-CT, p0.001; During-CT vs Post-CT, p0.001) domains. Similar to the 
total BAI score, patients in the Pre-CT group experienced the least symptoms 
from all four domains among the three groups. (Table 2.5) 
Table 2.5: Anxiety characteristics experienced by breast cancer patients (N=319) 
 









































71 (22.3) 7 (9.0) 48 (29.8) 16 (20.0) <0.001 






























































































Bold: Denotes statistical significance at p<0.05 
IQR: interquartile range 
Follow-up tests (not-shown in this table) were conducted to evaluate the differences between individual groups, using the 
Bonferroni corrected p-value of 0.0167 to denote statistical significance.  
 
 
Similar to findings from the previous Chapter 1.1, this study shows that 
approximately one-fourth of our breast cancer patients experienced significant 





ranging from 30% to 67%, in studies conducted in the Western 
population.
262,271,272
 The difference in prevalence might be contributed by 
methodological inconsistencies; it is important to note that different anxiety 
screening tools were utilised across all studies. BAI was utilised to capture 
anxiety characteristics in our study, whereas the HADS was used in the other 
studies. The definitions of ‘significant anxiety’ were also different among these 
studies, which makes comparisons and interpretations across studies difficult as 
equivalency of these tools to detect anxiety and definitions is not established in 
the literature. Besides methodological issues, the difference may also be attributed 
to the varying prevalence of anxiety that exists among healthy populations of 
different ethnic groups.
284,285
 Asians, in particular, were reported to be less prone 
to anxiety than Caucasians.
284,285
 Notably, the prevalence of anxiety symptoms in 
our breast cancer population is comparable to the results from other studies 
conducted in Asia.
13,261,286
 It was reported that the prevalence of anxiety disorder 
was 16.0%, and that of anxiety symptoms was 19.0% in a sample of 300 Thai 
breast cancer patients.
261
 Anxiety was also experienced by approximately one-
fifth (21.1%) of the 218 Chinese women who were undergoing chemotherapy or 
radiotherapy for stage I to III breast cancer in Hong Kong. Generally, a lower 
prevalence of anxiety symptoms is observed in the Asian breast cancer population. 
It is proposed in literature that ethnicity and cultural beliefs may determine one’s 
perception and experience of psychosocial distress.
287
 In future, cross-cultural 
studies can be conducted to ascertain whether cultural experiences can contribute 





Anxiety appeared to be most severe among patients who were undergoing 
chemotherapy at the point of interview, compared to those who did not have prior 
exposure to chemotherapy or cancer survivors who had already completed their 
chemotherapy. Such relationship between chemotherapy and anxiety is in 
accordance with results from previous studies that observed higher rates of 
anxiety symptoms in breast cancer patients who were exposed to chemotherapy, 
as compared to those who received only radiation treatment.
4,13,270,286
 It is 
postulated that treatment-related side effects might have explained the association 
between anxiety symptoms and receipt of chemotherapy; several common side 
effects of chemotherapy are also classified under the neurophysiological 
subdomain of BAI, including numbness, faintness, and dizziness.
106,253,288
 The 
significantly higher number of neurophysiological symptoms experienced by 
During-CT patients seemed to suggest that the high anxiety level may be a result 
of physical toxicities induced by chemotherapy drugs, such as paclitaxel and 
docetaxel (numbness). It has also been reported that physical changes during 
chemotherapy treatment, such as weight gain and hair loss, can elevate one’s risk 
for anxiety.
289,290
 Our local group has previously described that anxiety symptoms 
were predictors of systemic toxicities such as CINV.
21
 Consistently, similar 
anxiety symptoms (such as numbness) were being identified as effective 
predictors, suggesting that patients who were overwhelmed by chemotherapy 
toxicities had a higher predisposition to more severe state anxiety.
21
 With this 
understanding on the relationship between chemotherapy and anxiety, patients 





psychosocial distress. Appropriate management of chemotherapy-related 
toxicities, involving prophylaxis or treatment strategies, may curb the occurrence 
of such distress.   
 
2.2.4 Characteristics associated with anxiety 
On univariate analysis, a number of patient characteristics were revealed to 
associate with a higher BAI score, which included the concurrent receipt of 
chemotherapy (p0.001), higher fatigue score (r=0.593, p0.001), a younger age 
(r=-0.264, p=0.049) and the receipt of concomitant neuropsychiatric medicines 
(p0.001). Time from diagnosis (in months) correlated negatively with BAI 
scores (r=-0.108, p=0.050) in the univariate analysis; our results showed that the 
Pre-CT and During-CT patients who were recently diagnosed with breast cancer 
experienced more anxiety than the Post-CT-patients. 
After the inclusion of documented clinically-relevant factors, the best-fitted 
regression model identified fatigue to be strongly associated with anxiety 
(B=0.936, 95% confidence interval (CI): 0.763 to 1.438; p<0.001); fatigued 
patients experienced more anxiety than patients who were not (Table 2.6). 
Results suggested that there was a 4.172-point (95% CI: 2.649 to 5.494; p<0.001) 
increase in BAI total score in a patient who was receiving concurrent 
chemotherapy, as compared to a patient who was not (p<0.0001). The receipt of 
concomitant neuropsychiatric medications was also a significant pharmacological 





p=0.017). Other documented clinically-relevant factors, such as age (p=0.258), 
education level (p=0.437), receipt of mastectomy (p=0.630), cancer staging 
(p=0.670), marital status (p=0.134), employment status (p=0.085), time from 
diagnosis (p=0.192) and use of concomitant analgesics (p=0.093) failed to reach 
statistical significance. The total variance (R
2
) explained by the best-fitted 
regression model was 24.1% (p0.001).  
 
 









B SE t 95% CI p-value 
Age 0.049 -0.093 0.049 -1.883 (-0.261, 0.452) 0.258 
 
Education level 
- Low education level (no 
education, primary, 
secondary) 




0.463 -0.092 0.986 -0.093 (-1.035, 1.022) 0.437 
Marital status 
  - Married 
  - Not married 
(Single/widowed/divorced) 
 
0.340 -1.384 0.921 -1.502 (-3.197, 0.430) 0.134 
Employment status 
  - Employed  
  - Unemployed 
(retired/medical 
     leave) 
 
0.961 -1.411 0.817 -1.725 (-3.019, 0.198) 0.085 
Stage of cancer 
  - Stage I and II 
  - Stage III 
 
0.321 -1.842 1.002 -1.838 (-3.814, 0.130) 0.670 
Time from diagnosis 
 

















Multiple linear regression 
 
B SE t 95% CI p-value 
Prior receipt of adjuvant 
radiation 
  - Yes 
  - No 
 
0.414 -0.451 0.339 -1.423 (-1.317, 1.281) 0.165 




















0.690 -1.290 0.769 -1.678 (-1.684, 0.946) 0.093 
Fatigue interference score 
 
0.001 0.936 0.146 6.364 (0.763, 1.438) 0.001 
Bold: Denotes statistical significance at p<0.05 
B: beta; CI: confidence interval; SE: standard error 
1Antidepressants, antiepileptics, hypnotics, anxiolytics 
2Paracetamol, non-steroidal anti-inflammatory drugs, opioids 
 
Fatigue was shown to strongly associate with anxiety occurrence. It is also 
observed that Post-CT group experienced more fatigue than the Pre-CT and 
During-CT patients. Such relationship is substantiated by a previous study, which 
has demonstrated that a reduction in fatigue can lead to a decrease in anxiety 
levels.
291
 Recent studies have shown that cancer-related fatigue and mood 
changes, such as anxiety, are prominent components of residual symptom clusters 
experienced by cancer patients who have undergone chemotherapy 
treatment.
292,293
 Although the relationship between fatigue and anxiety was 
previously established, a paucity of research limited our understanding in the 
pathophysiology of their association.
291





to impair patients’ daily functioning and decrease their quality of life13,264,286,294,295, 
an understanding of their pathophysiological association is important so that 
necessary actions can be taken for the reduction of fatigue and anxiety 
experiences in breast cancer patients.  
Other clinical characteristics were also examined with their relationship 
with anxiety. Patients receiving concomitant neuropsychiatric medicines 
experienced a higher level of anxiety, as compared to patients who were not. This 
is unexpected as neuropsychiatric medicines, such as antidepressants, 
antiepileptics, hypnotics, were found to possess anxiolytic effects.
296-298
 Patients 
receiving these medications might be more anxious on baseline, than those who 
were not using these medicines, as these medications are frequently prescribed to 
treat co-existing neuropsychiatric conditions associated with anxiety, such as 
depression, epilepsy and insomnia. As expected, radiation therapy did not impact 
the occurrence of anxiety (p>0.05) as cancer patients typically experience short-
term anxiety during the radiation period, and these symptoms typically subside 
after the cessation of radiation therapy.
299
 Patients with poorer prognosis or 
advanced stages of cancer experience more psychological distress than early-stage 
cancer patients.
270,274,300
 However, cancer staging was not associated with anxiety 
in our study as our sample consisted of a homogenous cohort of patients (all 
early-stage breast cancer) with similar, positive prognosis. Previous studies have 
also demonstrated a relationship between education level and anxiety, this 
relationship was not found to be statistically significant in our study. Conflicting 





educational level and anxiety.
262,263,271
 Two studies have demonstrated that less 
educated patients presented with significantly higher levels of anxiety.
271,272
 
However, it is also interesting to note that the results from another study showed a 
different relationship between education level and anxiety, with more educated 
patients experiencing more anxiety. The difference in these relationships 
established may be explained by the different ways that information on education 
level was captured and stratified. For our study, we did not find meaningful 
associations between education level and anxiety despite stratifying the data into 
stages of education or the number of years of education in our exploratory 
secondary analysis.  
The weak collective association of the variables with anxiety in this study 
implies that their relationship might not be linear in nature, hence possibly 
accounting for the small proportion of variance explained by the independent 
variables in our best-fitted model. The current model is best fitted with numerous 
clinically relevant parameters that are associated with anxiety. Besides that, other 
factors associated with anxiety in breast cancer patients might be lacking in our 
model. Other possible determinants of anxiety included poor social support and 
shame from changes in physical appearances.
261,273
 Inclusion of these data may 
improve the total variance that can be explained by the regression model as 
previous studies have shown that the provision of psychosocial care may decrease 
the anxiety experiences of breast cancer patients.
301,302
 However, the effect of 
these variables on anxiety is disputable as research on these psychosocial 





exist among psychological, psychosocial and demographic factors, but to what 
extent these interacting effects may affect anxiety have not been well expounded 
within existing studies. Future research should further delineate the interacting 
effects of these variables and to recognise their contribution to state anxiety in 
cancer patients.  
 
2.2.5 Limitations of study 
Due to the cross-sectional nature, there were three different patient groups 
representing the different stages of chemotherapy. Typically, changes in patient 
characteristics, such as anxiety, can only evaluated if the same group of patients is 
followed through a certain period of time. As a result of the nature of our study 
design, the evaluation of anxiety changes across the different stages was not 
possible. To evaluate anxiety changes across the different stages of chemotherapy, 
future studies can be designed as longitudinal studies. The same group of patients 
can be followed through all three stages of chemotherapy treatment thereby 
tracking the changes of anxiety severity and presentation over time. Another 
limitation of our study is the use of the single-item fatigue interference score to 
evaluate patients’ fatigue experiences. Although validated to be reliable267, the 
simplicity of rating one single scale might have resulted in an underestimation of 
fatigue. Patient’s perception of their fatigue experience might be affected by how 
they felt during the interview as the fatigue interference score did not require 





item fatigue symptom inventory, which may more holistically evaluate the 
different aspects of fatigue. The limitation of a single-item interference scale has 
been discussed previously in Chapter 2.1.4. 
 
2.2.6 Summary of important findings 
One-fourth of the Asian patients diagnosed with breast cancer experience a 
significant degree of anxiety in this study, and anxiety was more pronounced 
while patients were undergoing chemotherapy. Toxicities of chemotherapy may 
have contributed to the clinical presentation of anxiety symptoms. Furthermore, 
fatigue, concurrent receipt of chemotherapy and concomitant use of 
neuropsychiatric medicines were associated with occurrence of anxiety. This 
would enable healthcare professionals to accurately identify breast cancer patients 
who may be at risk of experiencing anxiety during chemotherapy treatment. 
Appropriate psychosocial support may be offered to minimise the occurrence of 
anxiety and potential anxiety-related symptoms (such as CINV and cognitive 





Chapter 3 - Relevance and perceptions of cognitive changes in oncology 
practitioners and Asian breast cancer patients  
Specific methodologies and background information pertaining to this 
potential neurocognitive toxicity of chemotherapy are scarce. The preliminary 
findings in Chapter 2 revealed that clinical and psychosocial factors related to 
cognitive changes are prevalent in Asian breast cancer patients. The difference in 
the prevalence of anxiety in the Asian and Western breast cancer populations 
may suggest a cultural element in the understanding and experience of 
psychosocial distress. This chapter aims to preliminarily assess the relevance of 
the problem of chemotherapy-associated cognitive changes in Asian breast 
cancer patients. In resource-limited research and healthcare settings, it is of 
paramount importance to perform an initial evaluation of the relevance of this 
problem before conducting large scale epidemiological studies. It is anticipated 
that through the process of gathering background information from important 
stakeholders who are the oncology practitioners and breast cancer patients, 
improvement in the understanding of the “chemobrain” phenomenon can be 
achieved.   
The specific research questions that this chapters aims to answer are:  
- Do oncology practitioners perceive chemotherapy-associated cognitive 
changes as an important and relevant supportive care problem in Asian 
breast cancer patients? 
- Do Asian breast cancer patients perceive chemotherapy-associated 









 Studies in the literature have revealed that patients with cancer seek 
reassurance and validation of their experiences with post-chemotherapy cognitive 
disturbances, but there seems to be a lack of acknowledgement by the medical 
community.
53,54,304
 However, a significant proportion of patients have reported 
that clinicians tend to disregard the existence of such changes and often attribute 
these cognitive deficits to other rational causes, such as aging or lack of mental 
activity.
53
 Seeking perceptions from oncology practitioners is essential in order to 
address the cognitive and psychological distress experienced by these patients. To 
date, however, perceptions of oncology practitioners on this issue are not well 
investigated and documented in the literature. 
 In this study, a comprehensive survey of oncology practitioners who were 
directly involved with the management of cancer patients was conducted to 
evaluate their perceptions of the relevance and impact of cognitive changes in 
cancer patients, the causes of this phenomenon, and their awareness of monitoring 
and coping strategies. It is anticipated that findings from this survey would 
provide valuable insights into clinicians’ perceptions of the cognitive difficulties 
experienced by cancer patients and should improve the awareness of this 
phenomenon within the medical community. 
 The objective of this study was to investigate oncology practitioners’ 





patients, 2) the causes for this phenomenon, and 3) their awareness of monitoring 
and coping strategies.  
 
3.1.1 Methodology 
Study design and setting 
This was a multi-centred, cross-sectional survey conducted between 
September and October 2011. Approval by the CIRB was obtained and written 
informed consent was waived as oncology practitioners’ completion of this survey 
was indicative of their agreement to participate in this study.  
Participants 
Respondents were recruited based on 2 main approaches. The first approach 
was to recruit oncology practitioners from the four major cancer centres in 
Singapore and Thailand. These cancer centres included NCCS, National 
University Cancer Institute, John Hopkins Singapore International Medical Centre 
and Srinagarind Hospital, Khon Kaen University. The second approach involved 
the recruitment of oncology practitioners from an annual regional cancer meeting, 
the Best of American Society of Clinical Oncology (ASCO) 2011 meeting which 
took place in Singapore on 2
nd
 September 2011. During one of the keynote 
seminars in the meeting, a fixed known number of questionnaires were given to 
the attendees and they were invited by the Chairperson of the seminar to complete 
the questionnaire. For both approaches, a scripted set of instructions was given to 





for this survey, respondents had to meet the following criteria: 1) a practicing 
physician, pharmacist, or nurse; 2) practicing in a cancer centre or oncology 
department of a medical institution located in Southeast Asia; and 3) providing 
clinical care to and interacting with cancer patients. These criteria ensured that we 
targeted a homogeneous sample of Asian practitioners who were directly involved 
in the management of cancer patients. 
Questionnaire 
A questionnaire (Appendix 4) was designed, based on the existing literature, 
to assess the prevalence, presentation, contributing factors, and coping strategies 
of cognitive changes in cancer patients.
17,41,88,93,102,108,175,226,288,305-310
 The 
questionnaire began with a statement that defined the terms “chemobrain” and 
“chemofog”, and described the overall objective of the study. The questionnaire 
comprised two sections. The first section collected information about the 
respondents’ demographic details and clinical experience, including age, gender, 
years of healthcare practice, and specialisation of tumour types. The second 
section consisted of eight questions that were designed to gather information on 
respondents’ perceptions of post-chemotherapy cognitive changes. The first four 
questions were presented as statements, and respondents were asked to indicate 
their responses based on a five-point Likert scale (strongly agree, agree, neutral, 
disagree, strongly disagree). The other four questions were presented with choices, 
as outlined in Appendix 4. The survey was formulated in English and required 







Descriptive statistics were used to present the results of the oncology 
practitioners’ responses to each question. For questions 1 to 4, secondary analyses 
using inferential statistics (Pearson’s Chi-square test) were conducted to compare 
responses between the following predefined groups: (1) physicians (defined as 
medical, surgical, and radiation oncologists, and haematologists) and non-
physicians (defined as nurses, pharmacists, and patient advocates); (2) 
practitioners with more or less than ten years of healthcare experience; and (3) the 
geographical locations of their healthcare practices. All analyses were conducted 
using SPSS version 20. 
 
3.1.2 Baseline characteristics of respondents 
Three hundred questionnaires were distributed in total, of which 145 and 
155 questionnaires were distributed at the four major centres and the Best of 
ASCO meeting, respectively. In total, 210 questionnaires were collected and the 
overall response rate was 70.0%. Seventeen questionnaires were voided because 
they were either incomplete (n=2) or did not fulfil the inclusion criteria (n=15). 
Overall, 193 questionnaires were analysed. Half of the oncology practitioners who 
completed the questionnaire were nurses (51.3%). The other respondents were 
oncologists (35.2%) and pharmacists (13.5%). The demographic information and 
clinical experience of the healthcare respondents are presented in Table 3.1. The 
majority of the practitioners practiced in Singapore (71.5%) and the Philippines 





majority of the healthcare respondents were female (77.2%) and between 30 and 
39 years of age (39.9%). Approximately half of the practitioners (45.6%) 
possessed more than 10 years of experience in healthcare and specialised in 
breast, colorectal, or lung cancers. 
Table 3.1: Demographic details and clinical experiences of respondents who 
completed the oncology practitioners’ perception questionnaire (N=193) 
Demographics  Frequency (%) 
Age (years) 20 – 29 
30 – 39 
40 – 49 












    Medical oncologist 
    Radiation oncologist 
    Haematologist 
    Surgical oncologist 
Non-physicians 
    Nurse 
    Pharmacist 
68 (35.2) 
    57 (29.5) 
    7 (3.6) 
    3 (1.6) 
    1 (0.5) 
125 (64.8) 
    99 (51.3) 
    26 (13.4)  
Location Singapore 
Others 
    The Philippines 
    Thailand 
    Indonesia 
    Malaysia 
    Not specified 
138 (71.5) 
55 (28.5) 
    33 (17.0) 
    9 (4.7) 
    6 (3.1) 
    3 (1.6) 
    4 (2.1) 
Seniority 
(years of healthcare 
practice) 
<5 
 5 – 10 
11 – 20 
 21 – 30 












Top five tumour 
specialisation 
(Respondents were allowed 
















3.1.3 Oncology practitioners’ perceived relevance and impact of cognitive 
changes in cancer patients 
Half of the practitioners agreed that cognitive impairment was a frequent 
complaint among cancer patients (Figure 3.1, Question 1). The most commonly 
reported presentations of these cognitive changes were loss of memory (77.1%) 
and reduced ability to concentrate (74.6%). Other presentations, such as 
complaints about lapses in learning, planning abilities, and loss of verbal function 
were reported by 37.3%, 31.8%, and 30.4% of the respondents, respectively. The 
onset of cognitive impairments was perceived to occur both during (52.2%) and 
after (57.2%) chemotherapy. A small proportion of the respondents perceived the 
onset of cognitive impairment as occurring prior to chemotherapy (17.6%). The 
reduction in the patients’ HRQoL was largely viewed as a potential effect of 
cognitive impairment (Figure 3.1, Question 2). The secondary analyses showed 
that there were no significant differences between the healthcare professions or 
between geographical locations in the responses to these questions (Table 3.2). 
However, it is important to note that the sample size might be of adequate power 







Figure 3.1: Perceptions of oncology practitioners on cognitive changes in cancer 





The oncology practitioners in this study expressed a variety of contrasting 
perspectives on the cognitive complaints reported by cancer patients. Half of the 
respondents reported that cognitive impairment was frequently reported by cancer 
patients, whereas the other half reported neutral or negative responses. This 
inconsistency may mean either that some cancer patients are oblivious to or 
unaffected by cognitive changes in their daily lives, or that some oncology 
practitioners do not specifically seek cognitive-related information from their 
cancer patients. Previous studies have revealed that oncologists are inherently 













Question 4, "Routine monitoring of cognitive
function in cancer patients using neuropsychological
assessment tools is necessary"
Question 3, "Chemotherapy is a major causative
factor of cognitive impairment in cancer patients"
Question 2, "Cognitive impairment can significantly
depreciate quality of life of cancer patients"
Question 1, "Cognitive Impairment is a frequent
complaint among cancer patients"





effects of cancer treatment than with psychosocial and psychological issues.
311
 
This might explain the medical community’s lack of acknowledgment of 





3.1.4 Causative factors of cognitive changes as perceived by oncology 
practitioners 
Chemotherapy was not recognised to be a major cause for cognitive decline 
in half of the respondents (Figure 3.1, Question 3). Further analysis suggested 
that after excluding the respondents who answered “neutral”, more physicians 
disagreed chemotherapy as the main causative factor of cognitive changes, 
comparing to other health care professionals (25.0% vs. 9.8%, p=0.038). Such 
divergence might be attributed to the explanation that different healthcare 
professionals may perceive and formulate distinctive insights on chemotherapy-
associated symptoms.  
Aging was most frequently perceived as a contributing factor to cognitive 
changes in cancer patients (Figure 3.2). Other identified factors included anxiety, 
cancer condition, fatigue and lack of mental activity. Menopausal status and 
concomitant use of anti-hormonal therapy were viewed by lesser respondents as 







Table 3.2: Secondary analyses on responses from different subgroups of 
oncology practitioners (N=193) 
 













< 10 years 
(n=104)1 






Agree (%) 34 (50.7) 65 (52.4) 51 (49.0) 48 (55.2) 73 (53.3) 26 (48.1) 
Disagree (%) 10 (14.9) 17 (13.7) 14 (13.5) 13 (14.9) 21 (15.3) 6 (11.1) 
Neutral (%) 23 (34.4) 42 (33.9) 39 (37.5) 26 (29.9) 43 (31.4) 22 (40.8) 
 













< 10 years 
(n=105) 






Agree (%) 61 (89.7) 106 (84.8) 89 (84.8) 78 (88.6) 115 (83.3) 52 (94.5) 
Disagree (%) 2 (2.9) 3 (2.4) 3 (2.9) 2 (2.3) 4 (2.9) 1 (1.8) 
Neutral (%) 5 (7.4) 16 (12.8) 13 (12.3) 8 (9.1) 19 (13.8) 2 (3.7) 
 













< 10 years 
(n=105) 






Agree (%) 23 (33.8) 46 (37.1) 34 (32.4) 34 (39.1) 50 (36.5) 18 (32.7) 
Disagree (%) 17 (25.0) 12 (9.7) 13 (12.4) 17 (19.5) 20 (14.6) 10 (18.2) 
Neutral (%) 28 (41.2) 66 (53.2) 58 (55.2) 36 (41.4) 67 (48.9) 27 (49.1) 
 
Question 4: “Routine monitoring of cognitive function in cancer patients using neuropsychological 













< 10 years 
(n=104)1 






Agree (%) 36 (53.7) 88 (71.5) 68 (65.4) 56 (65.1) 88 (64.7) 36 (66.7) 
Disagree (%) 6 (9.0) 4 (3.3) 4 (3.8) 6 (7.0) 9 (6.6) 1 (1.9) 
Neutral (%) 25 (37.3) 31 (25.2) 32 (30.8) 24 (27.9) 39 (28.7) 17 (31.4) 
1One missing data 







Figure 3.2: Perceptions of oncology practitioners on the other contributing 





A significant proportion of the respondents in this study did not 
acknowledge chemotherapy as a major causative factor of cognitive impairment. 
This might be due to oncology practitioners being aware that cognitive 
impairment in cancer patients is complex and multifactorial; numerous other 
factors, such as aging, fatigue, anxiety, surgery, concomitant therapies, and other 
co-morbidities, can potentially lead to the occurrence of cognitive impairment. 
Aging has often been perceived as the cause of cognitive impairment, as cognitive 
decline in cancer patients is more likely to increase with age.
97
 Studies have also 
shown that patients diagnosed with breast, head and neck, and testicular 
malignancies suffer from cognitive impairment before the receipt of 
chemotherapy.
312,313














Lack of physical activity
Concomitant radiation therapy
Lack of social support
Concomitant neurodegenerative medication





Proportion of oncology practitioners (%) 





study were more likely to perceive well-documented contributing factors to 
cognitive changes such as aging, fatigue, and psychological distress, rather than 
chemotherapy.  
The role of chemotherapy in cognitive decline has yet to be elucidated in 
the literature. Interestingly, our results revealed that physicians were more likely 
than other healthcare professionals to disregard chemotherapy as a main 
contributor to cognitive changes. Previous studies have reported that most 
physicians focus on the acute side-effects of chemotherapy, such as vomiting and 
mucositis, whereas nurses tend to empathise with patient’s emotional discomfort 
and troubles related to both the cancer and chemotherapy.
314
 Interestingly, despite 
the preponderance of evidence in the literature supporting the neurocognitive 
toxicity of anti-hormonal therapy in breast cancer patients, the respondents did not 
perceive post-menopause and concomitant use of oestrogen receptor antagonists 
as contributors to cognitive changes.
79,260,315
 Therefore, it can be inferred that 
oncology professionals are not certain of the causes of cognitive impairment.  
 
3.1.5 Oncology practitioners’ awareness of monitoring and coping strategies 
Sixty-five percent of the respondents believed in the necessity to 
incorporate routine monitoring of cognitive function in cancer patients (Figure 
3.1, Question 4). Coping strategies were broadly classified as pharmacological 
and non-pharmacological based. Psychosocial therapy (72.1%) and mental 
exercises (59.2%) were the most recognised non-pharmacological interventions 





complementary alternative medicine (CAM) usage was a coping strategy adopted 
by their patients for cognitive impairment.  
Several potential pharmacological and non-pharmacological interventions 
have been investigated to help cancer patients cope with cognitive impairment 
after chemotherapy.
225,226,228-230,316,317
 However, as the results of this survey have 
shown, many practitioners are not aware of pharmacological interventions such as 
neuro-protective drugs and CAM. There are many reasons why these strategies 
have not been widely adopted, including a lack of evidence-based efficacy data 
for CAM, and other tangible issues related to poly-pharmacy and the potential 
reduction in the efficacy of anti-cancer treatments.
317
 Furthermore, there is an 
increasing trend for cancer patients to use CAM as an adjunct to their prescribed 
treatments, sometimes without the advice of their physicians.
318,319
 To bridge 
these gaps, evidence-based recommendations for pharmacological interventions 
and the adoption of better communication strategies between oncology 
practitioners and cancer patients are needed. 
Non-pharmacological interventions such as psychosocial therapy and 
mental exercises are recognised by oncology practitioners as coping strategies. 
Psychosocial therapy is an important component of survivorship care. One study 
suggested that adopting a multidisciplinary approach in survivorship care will 
allow for better communication between oncology practitioners, cancer patients, 
and family members, especially for chemotherapy-associated concerns, such as 
cognitive impairment and psychological distress.
320
 However, there is also 





reduction in cancer patients.
321
 Conducting interventional studies involving non-
pharmacological therapies poses major practicality challenges, as blinding may 
not be feasible. For example, in a recent study that evaluated the effects of 
medical qigong on cognitive function and HRQoL, the treatment group self-
reported significantly improved cognitive functioning compared with the control 
group who did not receive any intervention.
235
 The anti-inflammatory effects of 
qigong were substantiated by a statistically significant reduction in the baseline C-
reactive protein level in the treatment group.  
 
3.1.6 Limitations of study 
It is worthwhile to note that our results may have been influenced by 
priming or by pre-existing knowledge of the “chemobrain” schema, which could 
lead to over-reporting of cognitive complaints by both cancer patients and 
oncology practitioners.
322,323
 It is possible that some of our respondents did not 
have sufficient clinical experience in neuropsychology to identify changes in 
specific cognitive domains. Patients also tended to relate more to obvious and 
recognisable cognitive complaints, such as loss of memory and reduced ability to 
concentrate, than to other cognitive domains such as executive functioning and 
verbal fluency. This might have resulted in both under- and over- reporting of 
cognitive changes.  
As it was intended to be an exploratory study, sample size calculation was 
not conducted a prior. The non-response rate of 30% might have resulted in a 





subject or had experienced this problem during their clinical practice might tend 
to respond, as compared to those who declined to participate in this study. Our 
sample of respondents was also heterogeneous, consisting of different healthcare 
professionals and nationalities. This approach was taken as we were interested in 
the general view of oncology professionals (physicians, pharmacists, and nurses) 
on this important issue. To note, non-physicians were over-represented in this 
sample. Studies have shown that different healthcare professionals may focus on 
different aspects of a patient’s treatment. Therefore, future studies may investigate 
the perceptions of this problem in specific groups of healthcare professionals. We 
would like to emphasise that this study is to be interpreted as an effort to 
understand the perceptions of the medical community and their views, and should 
not be regarded as the primary and sole evidence on any aspect of this subject 
matter.  
 
3.1.7 Summary of important findings 
To our knowledge, this is the first survey in the literature that has evaluated 
practitioners’ perception of the relevance and impact of cognitive changes in 
cancer patients, and the possible monitoring and interventional strategies they 
were aware of. Our findings have provided valuable insights on the global 
medical community’s perception of this pertinent issue. 
As cancer mortality rates improve with medical advances, there is an 
increasing focus on patient-reported outcomes and survivorship issues. In general, 





changes, however, perceived causative factors remain debatable among 
practitioners of different professions. There is an urgent need to provide 
comprehensive information on the potential neuro-cognitive effects of cancer 
treatment, and oncology practitioners should be informed of the latest scientific 
and clinical evidence of cognitive studies in cancer patients. It is proposed that the 
development of a clinically-feasible neuropsychological assessment might be 







3.2 Evaluating Asian breast cancer patients’ experiences of cognitive 
changes: A qualitative approach
324
 
In the previous Chapter 3.1, we have established that oncology 
practitioners viewed “chemobrain” as a relevant and important supportive care 
problem in cancer patients. Currently, there is a lack of exploration in the 
psychosocial consequences and emotional, psychological and social impact of this 
condition in the Asian breast cancer patients. Research has demonstrated that 
one’s personal experience, including the culture in which he is raised, influences 
attention and thought processes that can impact cognitive and social processes.
92
 
Cross-cultural research has also demonstrated that cultural differences can 
influence episodic memory and cognitive correlates across ethnic groups.
91,325
 
Thus, there is a crucial need to evaluate the impact and psychosocial ramifications 
of cognitive changes in the words of Asian breast cancer patients. 
In view of this research gap, this qualitative study was conducted to gather 
in-depth descriptions from multi-ethnic Asian breast cancer patients on their 
perception and experience of cognitive changes, impact on their family and 
working lives, and their coping strategies.
324
 It is anticipated that results from this 
study would reflect Asian breast cancer patients’ experiences with this 
phenomenon, and provide directions for the amelioration of post-treatment quality 







Study design and setting 
This is a qualitative study which involved focus group discussions held at 
NCCS. Recruitment of patients occurred from January 2011 to July 2011. The 
focus group discussion was held on 6 August 2011. This study was approved by 
the CIRB and written informed consent was obtained from participants. 
Patients 
Patients were recruited based on the following inclusion criteria: 1) a 
diagnosis of breast cancer made by a medical oncologist, 2) age above 21 years, 3) 
able to read and understand either English or Chinese, 5) had completed or 
currently receiving chemotherapy treatment for breast cancer. Patients were 
excluded if they were unable to speak coherently and provide informed consent, 
or if they had brain metastasis that may impair their judgment.  
Study procedures 
Four English-speaking and four Chinese-speaking structured focus groups 
were conducted over a single day within the NCCS campus. This is configured to 
minimise the effects of priming that could occur if the sessions were held on 
multiple days, as patients who participated in the earlier focus groups could have 
disseminated the discussion questions to other prospective participants who had 
yet to attend theirs.
322,323
 
Prior to the discussion, grouping of participants was based on (in the order 





Chinese), stage of breast cancer, last receipt of cancer treatment and education 
status. The focus group discussion was designed to be 60 to 80 minutes long. 
Each focus group consisted of 4 to 6 participants and was led by two English-
speaking or Chinese-speaking trained facilitators who were psychosocial 
oncologists, and assisted by a notetaker who was either a pharmacist or a research 
assistant.  
Discussions were designed to utilise an open-ended approach. They 
proceeded from the most general to specific questions, thus minimising the 
influence of probing by facilitators. Two training sessions were held prior to the 
focus group discussions to ensure consistency in the facilitation of the groups. In 
each session, facilitators would first gather their participants’ unpleasant 
experiences with acute and delayed toxicities of chemotherapy. Subsequently, the 
objectives of the focus group discussion were introduced and specific details 
about cognitive changes were gathered.  At the end of the session, participants 
completed a brief self-administered questionnaire on: 1) their demographics 
information, 2) their perception of the top five causes of their cognitive changes, 
and 3) how receptive are they, from a scale of 1 to 10 (“1” being the least 
receptive and “10” being the most receptive), to receive chemotherapy if 
chemotherapy-associated neuro-cognitive toxicity was indeed scientifically 
proven. At the end of the session, participants were remunerated with a SGD$30 







Data analysis  
Focus group discussions were voice recorded, transcribed verbatim, and 
analysed using thematic analysis.
326
 Non-English transcripts were translated and 
reviewed by two bilingual research team members. The open-ended discussion 
guide and data-driven analytic methods adopted in this study were based on 
elements of the grounded theory.
327
 From the data collected, key points were 
marked with a series of codes, which were extracted from the raw data. Codes that 
described similar manifestations were grouped into concepts and themes. In this 
study, two coders first familiarised themselves with the transcripts and met to 
generate initial codes independently. They met to discuss and reach a consensus 
on the codes. This process resulted in a final list of codes which were used to code 
all the transcripts by a group of five research team members who reviewed each 
other’s transcripts subsequently. Discrepancies were resolved using a consensus 
method. The codes were then collated into potential themes and reviewed by the 
research team to produce a description of the focus group findings. Qualitative 
analysis was conducted using qualitative research software, Atlas.ti. Quantitative 
data was analysed using SPSS Version 20.  
 
3.2.2 Baseline characteristics of patients 
A total of 128 invitation cards were distributed. Forty-three patients 
(response rate of 33.6%) participated in the study (Figure 3.3). Majority of the 
participants were Chinese (83.7%). The median age of the participants was 52.0 





individuals. Majority of the participants were early stage breast cancer patients 
(95.4%) who had completed their anthracycline-based chemotherapy within 
twelve months (Tables 3.3 and 3.4). 
 
Figure 3.3: Patient disposition flowchart for the focus group study 
Invitation cards were distributed to breast cancer patients at the ambulatory clinic of National 















 Diagnosed with breast cancer made by a medical oncologist 
 Aged above 21 years 
 Able to read and understand either English or Chinese 
 Had completed or currently receiving chemotherapy treatment for breast cancer. 
Not recruited because patients:  
(N=85) 
 
 Did not express interest. 
 Had prior family or work 
commitments. 
 Were unwell after 
chemotherapy treatment. 
 Were overseas. 
 Did not return a reply to 
investigators. 
 Had religious duties to 
fulfill (the focus group 
discussion fell within the 







Table 3.3: Baseline characteristics of participants in the focus group study (N=43) 
 
Demographic information N (%) 
Age (years) Median age (range) 52.0  
(27.0-66.0) 
--- 
    
Education No formal education 1 (2.3) 
 Primary (Elementary) 14 (32.6) 
 Secondary (Junior high school) 16 (37.2) 
 Pre-university (Senior high school) 1 (2.3) 
 University degree 10 (23.3) 
 Post-university degree 1 (2.3) 
    
Race Chinese 36 (83.7) 
 Non-Chinese 
1 7 (16.3) 
    
Marital Status Single 13 (30.2) 
 Married 25 (58.1) 
 Divorced 4 (9.4) 
 Widowed 1 (2.3) 
    
Occupation Currently working 17 (39.5) 
 Homemaker 16 (37.2) 
 Retired 6 (13.9) 
 On medical leave 4 (9.4) 
    
Medical information N (%) 
  Frequency % 
Breast cancer staging 1 8 (18.6) 
 2 19 (44.2) 
 3 14 (32.6) 
 4 2 (4.6) 
    
Chemotherapy status Completed cytotoxic chemotherapy 39 (90.6) 
 Currently receiving cytotoxic chemotherapy 4 (9.4) 
    
Chemotherapy protocol AC- based 24 (55.8) 
 FEC- based 8 (18.6) 
 Others 11 (25.6) 
    
Receipt of anti-hormonal 
therapy 
No 14 (32.6) 
Yes   
  Tamoxifen   20   (46.5) 
  Aromatase inhibitor   9   (20.9) 
  Median duration of anti-hormonal therapy         18.3 months  
           
Menopausal status Pre-menopausal 16 (37.2) 
 Post-menopausal 27 (62.8) 
 
1Other races included Filipino, Indian, Malay and Papua New Guinean participants 































(40 to 62) 
Early 9 to 12 months 
post-treatment 
11 3 homemakers 
1 retiree 







(42 to 62) 
Early > 12 months post-
treatment 
10 2 homemakers 
1 retiree 







(36 to 55) 
Late Currently 
receiving treatment 
11 1 homemaker 
2 on medical leave 







(27 to 51) 
Early Currently 
receiving treatment 
and < 3 months 
post-treatment 
 
13 2 homemakers 
1 retiree 
3 employed (software 
consultant and 







(52 to 60) 
Early > 12 months post-
treatment 
8 1 homemaker 
3 employed (hawker, 







(45 to 54) 
Early Currently 
receiving treatment 
9 2 homemakers 
2 on medical leave 






(43 to 66) 
Early 6 to 9 months post-
treatment 
10 2 homemakers 
2 retirees 
2 employed (senior 






(50 to 60) 
Late 9 to 12 months 
post-treatment 
10 3 homemakers 
1 retiree 





1 Prior to the discussion, grouping of participants was based on (in the order of descending importance) preferred 
conversational language (English or Chinese), stage of breast cancer, last receipt of cancer treatment and education status. 
 
2 Early-staged breast cancer is defined as Stage I to Stage IIIA. Late-staged breast cancer is defined as Stage IIIB to Stage 
IV. 
 
3Advice was given by the Ethics Committee to arrange participants of similar cancer stages and cancer treatment status in 
the same group. This approach was adopted to prevent potential negative/unpleasant statements from the late-stage patients 
or patients who have completed cancer treatments from instilling fear or discouragement into patients who had not 








A total of 74 open codes were created and categorised into 3 main broad 
themes: “participants’ experience with cognitive changes”, “impact of cognitive 
changes”, and “coping strategies”. A summary of the themes, subthemes, sample 
codes used in thematic analysis and representative quotes are presented in Table 
3.5. 
 
3.2.3 Patients’ perception of the term “chemobrain” and cognitive changes 
The term “chemobrain” or chemotherapy-associated cognitive issues were 
unfamiliar to most participants. It was observed that Chinese-speaking 
participants had difficulties comprehending the terms “ren zhi gong neng” (認知
功能) and “hua liao nao” (化療腦) (the Chinese equivalent of “cognitive function” 
and “chemobrain”, respectively).328 Moderators needed to provide explanations 
and practical examples of cognitive function domains. Participants were rather 
averse to the term “chemobrain”, which had led to common misconceptions 
associated with this term. Some participants thought that “chemobrain” referred 
to the metastasis of the breast cancer to the brain. Some participants viewed 
“chemobrain” as a risk factor for dementia. Many participants, however, were 
able to identify the connection between chemotherapy and its adverse effects on 
brain cells. Participants also claimed that they were not warned by oncology 







Table 3.5: Summary of selected themes, subthemes, sample codes and representative quotes identified from the focus group study 
 











 Not heard of CB  
 
 Misconceptions of 
CB  
 "’Chemobrain’, is there such a word? I don’t know…" – 46 year-old (yo), Chinese, bus 
attendant. 
 
 "I was wondering whether for people like us who have ‘chemobrain’, will we have dementia 
or more chances of getting dementia? (Other participants agreed) Just wondering?" – 50yo, 
Chinese, pastoral care worker. 
 
 “Chemobrain? Chemo-the-brain? So [does this mean that] the chemo went to the brain?”- 
36yo, Chinese, volunteer worker  
 






 CB observed before  
chemo  
 
 CB observed 
during chemo 
 
 CB observed after 
chemo 
 
 CB worsened after 
chemo 
 
 CB improved after 
chemo 
 "When I started receiving chemotherapy and radiation therapy, my family was helping so I 
didn’t notice these [cognitive changes]. After chemotherapy when I had to do things myself, I 
realised that my memory declined." – 46yo, Chinese, bus attendant. 
 
 "Maybe that during chemotherapy, all of us were suffering [from the physical side effects], 
hence we did not notice such details. We wanted to rest and sleep. After chemotherapy, we 
are not suffering as much, it is then we will notice such [cognitive] problems." – 58yo, 
Chinese, homemaker. 
 
 "[The cognitive changes occurred only] during chemotherapy. After chemotherapy it is not so 
serious. After that, I led a normal life. After chemotherapy, I feel that there is a difference.  I 
become ok. After stopping [chemotherapy] for a week, life returned to normal." – 54yo, 
Chinese, homemaker. 
 
 "After chemotherapy, it is the same. I have completed my chemotherapy treatment last 
August, up till now, my memory is still as bad, it has almost been a year. It is still the same." 


















 Age as a cause 
 
 Fatigue as a cause 
 
 Mood change as 
cause 
 
 Physical side 





 Holistic view of 
causes 
 
 "I feel that that the drug is not affecting the brain; it is first affecting the body, and also 
affecting the vitality and psychological aspect too, like the body becomes weaker. I feel that it 
is not the drug that affected the memory, but the entire body that has been affected, and hence 
affect me in these other things." -47yo, Chinese, senior engineer. 
 
 "First thing is about forgetfulness. Every first week of each treatment, I got into depression, 
so I felt very miserable about myself, very lousy, so I started forgetting things. So I went out 
of my house, I forget my keys. I forget my wallet, so I didn’t get to eat. I felt very lousy." - 
36yo, Chinese, volunteer worker. 
 
 "I feel that I am worse now, but I don’t know whether it is because of chemotherapy, or 
because of my age, because when we come to a certain age, we will naturally slow down. 
Many things will deteriorate, like learning new things. I have [similar experiences] with 
[forgetting to turn off] the stove but I am always not sure if it is because I am not working 
now, not practicing, and my age as well—is it directly because of my age or is it because of 







 Negative impact on 
spouse 
 




 Good family 
support 
 "Especially the spouse, because my husband doesn’t believe I am like that you know. He said 
‘you just never bother to remember’. Men are like that you know? (Laughter from the floor). 
It’s true. Men are very practical people.” – 51yo, Chinese, homemaker. 
 
 "Yes. Before [chemotherapy], I used to teach my daughters and sons, but now I can’t teach." 
– 42yo, Indian, homemaker. 
 
 "Because people in the family, they understand that you are receiving chemotherapy so they 

























 Negative impact of 
concentration 
problems on work 
 
 Negative impact of 
impaired decision 
making on work 
 
 Negative comments 
from colleagues 
 "After chemotherapy treatment, I returned to work. As I work in the food industry, I need to 
go into the kitchen to take things. When others start talking to me, I will forget what I intend 
to do, so I will go out [of the kitchen]. It is only then that I will remember what I want to take, 
so I will go back [into the kitchen] again to take it. But if someone talks to me again, I [will] 
get distracted, I will forget what I want to take." – 52yo, Chinese, hawker. 
 
 "My job requires me to make decisions every day, every time. So I realise that my decision 
making has slowed down. I need time to think. Previously it was like spot on, it was 
immediate, I can make the decision. And because I manage the whole department, I can come 
out with the decisions quickly, but now it has slowed down a little, like I have to tell them to 
give me time and I will come back. And I have to scribble down all my appointments." – 46yo, 
Indian, manager. 
 
 "Affected me so much that I got to leave my job. [I] couldn’t remember what my boss asks me 
to do. [He] gave many instructions that I had no time to take down.  I can’t perform well so 








 Loss of confidence 
 







 "[I am] more anxious now. I always forget. When I go for my lessons, [I feel] a little nervous, 
I can’t write out simple things so I kept asking my classmate. After a while she felt strange, 
‘why does she keep asking me about [about] things?’ I felt embarrassed." – 46yo, Chinese, 
bus attendant. 
 
 "For example, normally when you do things, you are very smooth. During [chemotherapy] 
that time, you became forgetful, you did think [about] what you were doing. Your heart felt 
empty, and sometimes you felt disappointed. You wanted to do things but you cannot be as 
good as last time when you did it quicker and better." – 66yo, Chinese, retiree. 
 
 “It seems like this ‘chemobrain’ lasts a long time, the memory doesn’t come back, I feel that 
it doesn’t come back…So, it is quite frightening." – 54yo, Chinese, part-time accountant. 
1 Examples of codes used in thematic analysis of the transcribed data. Codes were created through the process of independent coding and consensus by investigators 






Most participants experienced cognitive changes after receiving 
chemotherapy. Although participants acknowledged that they had experienced 
experience minor cognitive deficits before their breast cancer diagnosis, they 
agreed that their cognitive functioning had deteriorated after they had completed 
chemotherapy. However, a small group of participants claimed that they did not 
experience any cognitive changes while they were receiving chemotherapy. They 
suggested that the physical side effects (such as numbness and vomiting) had 
over-dominated the cognitive side effects. Many could identify and articulate 
vividly their experiences once moderators provided minimal probing.  Difficulties 
in concentration, memory, speech and language, decision making, and learning 
new concepts or tasks were experienced by our participants (Table 3.6). There 
was a lack of agreement on whether participants' cognitive function improved, 
remained the same or deteriorated after completion of chemotherapy.  
Similar to the results obtained from another focus group study conducted 
among Caucasian breast cancer population, participants were not aware of this 
potential adverse effect before they received chemotherapy. One study 
highlighted that a majority of the interviewed breast cancer women complained a 
lack of acknowledgement by the medical community when they described their 
cognitive disturbances.
53
 Participants also expressed that they were too 
overwhelmed by the physical side effects of chemotherapy that they were 
oblivious to the cognitive changes. Our results revealed that patients were likely 
to be aware of the impact of those cognitive changes, rather than the change itself. 






they experienced limitations in their daily functioning after they had completed 
chemotherapy. These findings reflect that cancer patients require different 
specialised forms of supportive care at various stages of their cancer treatment. 
The challenge lies ahead in the provision of a comprehensive and holistic 
supportive care plan that addresses not just the management of physical 
symptoms, but also cognitive, psychosocial and spiritual aspects. One example of 
an instrument that is currently undergoing validation to detect psychological 
















“[I returned to work after ] a few months [of medical leave]. If a colleague’s [Chinese] name has two 
[characters], I will just remember one. I need others to remind me.” – 52yo, Chinese, customer service provider. 
 
Places “I remembered the wrong church. I keep thinking that it’s this church [that I am attending] but actually my elder 
daughter told me, ‘No Mummy, we went to the other church’, I said, ‘No, I am very sure.”, Then she said, ‘My 
goodness you can’t even remember…No Mummy, it’s the other church [that you are referring to].’” – 51yo, 
Chinese, homemaker. 
 
Tasks "Whenever I go out [of the house], I have to find my phone and keys. I took a long time just to set off. After finding 







they were distracted 
while doing their 
activities of daily 
living. 
"When I am cooking and someone asked me something, I will forget about what I cooked a while ago. All of a 
sudden I will forget, only after calming down will I recall what I was doing. If I am doing something, and if 
someone beside me were to ask me something, I will forget what I am doing." – 41yo, Chinese, homemaker. 
 
"Nowadays when I play mahjong -- when I reshuffle the tiles, my mind is still stuck at the previous set of tiles at the 





complained that they 
took a longer time to 
make decisions that 
they used to make 
easily before they 
received 
chemotherapy. 
"Sometimes, decision making, you sometimes ponder, ponder. Decision making. Spend more time. Difficult in 
decision making. Used to make signals quickly, like go straight, when I do marketing, last time [I] used to choose 
quickly, but now maybe I can’t decide." – 50yo, Chinese, software consultant. 
 
"There was a time I made an appointment with my mother to meet at the front of bus interchange, as a result, she 
was at the front, I was at the other side. We waited for a long time, I thought, ‘why have I become so stupid? I 
actually said “the front of the bus interchange?”, I thought I was correct but I realised that actually, I was wrong. 












Participants used the 
terms "blocked" and 
"yi pian kong bai" 
(blanked) to describe 
the condition of their 
mind when others 
were talking to them. 
They also slowed 
down in their speech 




"When I see this paragraph of words, my brain wants to explain these words, but it seems like there is a blockage 
in my brain. Sometimes, like a simple [Chinese] word, ‘siang shin’. After thinking for a long time, you can’t recall 
the word and can’t write. This is a simple word and commonly used and written, but I simply cannot recall it. You 
feel that your brain has something that is blocking." – 59yo, Chinese, retiree. 
 
"Maybe speech-- not as fluent. I have problems trying to [speak]. The words are there but it is not coming out 
fluently as before. Usually I can speak really fluently and the flow of words is easy and it is there. But now I made 







in understanding and 
learning new things. 
“ When [I am] reading newspapers, I don’t know what I am reading, it seems like nothing goes in. I am just 
passing my time. Last time, I could understand the news. Now, if you ask me what I have read, I can’t remember. It 
seems like nothing goes into my mind. " – 57yo, Chinese, homemaker. 
 
" I find that I am slower in the uptake [of instructions] when [it] comes to very technical stuff nowadays. When 







3.2.4 Causes of cognitive changes as perceived by patients 
Participants stated that multiple factors have contributed to this 
phenomenon. The main cause of their cognitive changes was inconclusive. Many 
attributed this phenomenon to the physical adverse effects of chemotherapy, 
which led to mood changes, psychological disturbances and consequently, 
cognitive changes. This view had been mentioned across almost all focus groups.  
Besides chemotherapy, other causes that were considered as contributing 
factors to cognitive changes included cancer-related fatigue, mood changes and 
lack of mental and physical activity (Figure 3.4). Participants agreed that 
chemotherapy, being "toxic" and "potent", could affect their brain cells but that 
should not be the sole cause. Participants perceived cancer-related fatigue or 
tiredness as a significant contributor to cognitive decline. They rationalised that 
whenever they were tired, they could not concentrate and could get distracted 
very easily. Mood changes, such as anxiety and depression, affected few 
participants mentally, emotionally and psychologically. During chemotherapy, 
participants faced treatment-related anxiety and psychological disturbances that 






Figure 3.4: Perceptions of focus group participants on the contributing factors of 




3.2.5 Impact of cognitive changes on patients’ lives 
Impact on family and working life 
Discussion on the impact of cognitive changes to the family invited a wide 
range of responses from the participants. As Asians value communal living and 
kindred spirit, many participants expressed that their family members had 
provided them good psychosocial support. Patients claimed that their family 
members were forgiving and patient towards them. However, a few participants 
conveyed that their spouses needed to be more understanding towards their 
conditions. Much of the negative impact on the family originated from their own 
expectations of themselves, as they were unable to fulfil their duties as mothers 
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groups could vividly describe the impact of cognitive changes on their work life, 
regardless of their occupations. Although the consequences of the cognitive 
changes were negligible, these changes limited their working capabilities. 
This is in contrast to what was observed in the focus groups studies 
conducted in the United States where participants had fewer problems in relating 
with these terms.
53,54,304
 Asian participants attributed this phenomenon to the 
physical adverse effects of chemotherapy, which led to mood changes, 
psychological disturbances and cognitive changes. This view is parallel to a well-
received Asian’s holistic approach to medicine which interpreted the well-being 
of humanity as a balance of body, mind and spirit.
330
 Older married participants 
also expressed negative emotions associated with the impact of cognitive changes 
in their daily lives. Their recounts were reflective of typical Asian housewives 
whose conservative roles were to provide care and support for the spouse and 
children. Even though many had stated that their families empathised with them, 
participants still felt disappointed and guilty that they were not able to perform 
their duties at home up to their expectation. Reactions from Caucasian breast 
cancer patients of another focus group study were drastically different. They 
expressed that their negative emotions were inflicted from family members who 











Participants’ emotional responses towards cognitive changes 
Participants were anxious and frightened when they realised that they were 
unable to perform well, comparing to their pre-chemotherapy state. Some 
expressed embarrassment about these cognitive changes, which occurred during 
their daily interactions with colleagues and friends. A few participants mentioned 
that they have lost their confidence when they returned to work because they were 
not as mentally fit as they used to be.  
Participants reported that if the existence of chemotherapy-induced neuro-
cognitive toxicity were to be scientifically proven, it would not affect their 
willingness to accept chemotherapy treatment. Majority of participants (57.1%) 
assigned a receptivity score of 7 to 10, indicating that they were still very willing 
to receive chemotherapy. Only a minority (11.9%) revealed that the cognitive 
changes had disrupted their lives to the extent that they were resistant (score of 1 
to 3) to chemotherapy.  
 
3.2.6 Patients’ coping strategies for cognitive changes 
Participants adopted self-help strategies to prevent deterioration and cope 
with their cognitive changes (Table 3.7). Psychological management was the 
most commonly identified coping strategy. The importance of family support and 
engaging in communal activities such as cancer support groups surfaced through 






Table 3.7: Coping strategies of cognitive changes adopted by participants of the 








 Nutritional products  Vitamins (eg: Vitamin B complex) 
 Health supplements (eg: antioxidants and Omega-3) 
 
 Complementary and 
alternative medicine 
 Traditional Chinese medicine 






 Healthy lifestyle practices  Sleeping well 
 Having a balanced diet 
 Physical activities  Exercises 
 Qi gong 
 Mental acitivites  Reading 
 Playing mahjong 
 Tasks that stimulate their memory and concentration 
(eg: recalling the steps in sewing and cooking; 
chanting religious prayers) 
 Psychosocial management  Controling mood and expectations 
 Family support 






 Written reminders  Keeping a journal/diary 
 Using sticky notes or “fridge-notes” 
 Reviewing old photographs to recall faces and names 
of individuals 
 Technology  Inputting reminders into handphones/smartphones 
 Playing mind-stimulating intellectual games  
 
 
Being a Chinese-dominated population, CAM, such as Traditional Chinese 
Medicine (TCM), was popular among participants. Many believed that TCM, 
such as walnut and ginkgo extracts, helped in improving their alertness because 
TCM preserves their "qi" or energy. Participants also claimed that physical and 





speaking participants shared their experiences in practicing qi gong and playing 
mahjong, a mind-stimulating game that involves memory of tiles discarded by 
their opponents, fast reaction and flexibility of the mind to strategise their moves 
in order to win the game.  
Despite the awareness of the potential neuro-cognitive adverse effects, 
majority of participants indicated that they are still receptive to chemotherapy and 
are amenable to coping strategies of their cognitive changes. Usage of CAM and 
psychosocial interventions are popular among Asian cancer patients.
319
  Several 
culturally-related solutions were extensively utilised by our Chinese participants. 
It is worthwhile to note that Asian participants valued the benefits that CAM, qi 
gong and mahjong may bring to their health. Chinese participants believed that 
usage of CAM and practicing qi gong can improve their “qi” (energy) and blood 
circulation to the brain. One study showed that playing mahjong produced 
consistent gains across cognitive performance measures and on the MMSE.
331
 A 
review of studies of mindfulness therapy in oncology had documented its 
potential for improving mood, fatigue, psychological functioning and enhanced 
well-being in cancer patients.
239
 Participants were unfavourable to 
pharmacological options or “Western medications”. Moreover, polypharmacy in 
oncology has been associated with non-adherence, drug interactions and adverse 
reactions.
332,333
 Oncologists and pharmacists play an important role in the 
management of chemotherapy-associated symptoms experienced by cancer 





designed randomised controlled trials in the evaluation of non-pharmacological 
management of cognitive changes.  
 
3.2.7 Limitations of study 
Selection bias might exist as breast cancer patients were recruited from a 
non-randomised sample and the response rate was considerably low. To note, we 
acknowledge that Malay breast cancer patients were probably under-represented 
as the focus groups were conducted during the fasting month of Ramadan on the 
Muslim calendar. As the objective of the study was briefly made known to 
participants when they provided informed consent, participants might have been 
predisposed to the priming effects and pre-existing knowledge of 
“chemobrain”.322,323 The focus groups also contained participants with 
heterogeneous cancer treatment status.  
Currently, there are limited guidelines or consensus on an appropriate 
sample size for qualitative research. Typically, researchers use saturation as a 
guiding principle for sample size determination in qualitative studies. It is 
proposed that based on the grounded theory approach, a sample size of 20 to 30 
subjects should be adequate to reach saturation.
334,335
 Hence we justify that our 
current sample size of 43 subjects was sufficient as consistent themes were 
observed throughout all eight focus groups. Given that this was an exploratory 
qualitative investigation, we feel that these shortcomings were acceptable and 





3.2.8 Summary of important findings 
Qualitative results from our study showed that cognitive changes are highly 
relevant to Asian breast cancer patients. This is the first qualitative study that has 
examined the impact of chemotherapy-associated cognitive changes on Asian 
breast cancer patients. Thus far, there have not been any robust studies in the 
literature that have evaluated Asians’ experience with the phenomenon of 
“chemobrain”. It is alarming that the concept of this phenomenon is unfamiliar to 
most Asian cancer patients, yet cognitive changes have significantly impacted 
their daily lives. 
There is a need to adopt a culturally-relevant approach in the viewing of this 
phenomenon. It is evident that Asian breast cancer patients, especially those who 
were Chinese-speaking, were not familiar with the terms “cognitive function” and 
“chemobrain”. It can be reckoned from our results that patients’ cultural 
experiences are important in the understanding of the nature and impact of this 
phenomenon. Cross-cultural adaptation is hence an important process in the 
development and translation of subjective neuropsychological tools and cognitive-
related quality of life instruments.  
In summary, post-chemotherapy cognitive changes have significantly 
impacted Asian breast cancer patients’ family and working lives. Well-designed 
epidemiological studies are needed to quantify the prevalence, severity and 
impact of this problem in Asia. Our results suggested that a culturally-relevant 





and implementation of culturally-accepted coping strategies, should be adopted to 





This chapter summarises two background studies that were conducted in 
two important groups of stakeholders: oncology practitioners and breast cancer 
patients. It can be inferred from the findings that both groups acknowledged the 
relevance and importance of this “chemobrain” phenomenon as a supportive care 
problem in oncology. Patients can vividly describe their experiences with these 
cognitive changes in their daily lives and oncology practitioners can identify with 
the cognitive complaints from their patients. Both agreed that cognitive 
functioning can play a vital role in cancer patients’ HRQoL. 
However, breast cancer patients and healthcare professionals seem to differ 
in the perceived contributors to this potential neurocognitive toxicity. While 
breast cancer patients reasoned that the chemotherapy treatment was one of main 
factors that had elicited their cognitive changes, oncology practitioners seemed to 
attribute this problem to the normal process of aging and cancer progression. In 
particular, oncologists did not view chemotherapy as the main cause of cognitive 
impairment.  
As for coping strategies, interestingly, patients were more amendable to 
TCM, nutritional products, and other forms of CAM while oncology practitioners 
indicated that they were not aware of pharmacological interventions such as 
neuro-protective drugs and CAM for evidence-based treatment or prevention of 
cognitive changes in cancer patients. 
Lastly, the most critical information drawn from these two studies was the 
agreement that knowledge pertaining to this area was in its infancy. There is an 





potential neurocognitive effects of cancer treatment to bridge this gap. The 
perspectives gathered from these stakeholders may have important clinical 
implications for the development of interventional strategies for breast cancer 





Chapter 4 – Translation, rigorous validation and the threshold of important 
clinical difference in a subjective neuropsychological tool 
Findings from the focus group study (Chapter 3.2) and evidence from the 
literature have shown that ethnicity, language and cultural preferences can 
influence patients’ perception of cognitive functioning.91,92 It is important to 
incorporate patients’ reported outcomes into cognitive studies for cancer patients. 
The validation of self-reported or subjective neuropsychological tools is essential 
to determine whether the results can be used with confidence in future 
epidemiological studies and clinical trials. This chapter aims to optimise the 
subjective neuropsychological tool used for the assessment of perceived cognitive 
changes in breast cancer patients. 
 
4.1 Introduction of the Functional Assessment of Cancer Therapy- Cognitive 
Function (FACT-Cog) 
The English FACT-Cog, currently in its third version, is a questionnaire that 
evaluates patients’ self-reported perceptions of their cognitive abilities and the 
effects of these cognitive changes on their HRQoL.
55,224,336,337
 (Appendix 2) The 
FACT-Cog distinguishes itself from other available subjective 
neuropsychological tests because the questionnaire focuses on the functional 
interference and noticeability of the multiple specific cognitive domains. FACT-








  The FACT-Cog contains 37 items, with subscales created by the developers 
consisting of: (1) patients’ perceived cognitive impairments, (2) perceived 
cognitive abilities, (3) noticeability or comments from others and (4) impact of 
cognitive changes on quality of life. A global or summary score is obtained by 
summing all the item scores. The items are rated for the previous week, including 
the day of administration. Each item is rated on a 5-point Likert scale ranging 
from 0 (“Never” or “Not at all”) to 4 (“Several times a day” or “Very much”). 
The total score for FACT-Cog is 148 points, with a higher score indicative of 
better perceived cognitive functioning.  
For the validation procedure in this thesis, items in the above subscales (1) 
and (2) were regrouped into their respective cognitive domains according to the 
developer’s original classifications and the expertise of a clinical 
neuropsychologist in our research team.
55,224,337
 This approach was adopted so as 
to facilitate the mapping of patient-reported cognitive outcomes from FACT-Cog 
with the individual cognitive domains of objective neuropsychological test 
performances.
43
 The six reclassified cognitive domains of interest are: mental 
acuity, attention and concentration, memory, verbal fluency, functional 
interference and multitasking ability (Table 4.1). 
The English version of the FACT-Cog was translated into Simplified 
Chinese (Appendix 3) by investigators who are proficient in both languages. The 
translation closely followed the guidelines stipulated by the Translation and 
Cultural Adaptation-Principles of Good Practice.
340
 The questionnaire was 





underwent cognitive pre-testing with a representative and culturally homogeneous 
sample of 30 bilingual Singaporean patients that participated in a previous local 
study (Chapter 3.2) to identify items that were offensive and/or structurally 
difficult to understand within the local context.
324
 The final reconciled version 
was approved by the Functional Assessment of Chronic Illness Therapy (FACIT).  
  
 








Table 4.1: English and Chinese versions of FACT-Cog, in their re-classified cognitive domains and subscales 
 
Domain Item No. Content 
  English Simplified Chinese 
Memory CogM9 I have had trouble finding my way to a familiar place 我曾在对于寻找熟悉的地方有困难 
CogM10 I have had trouble remembering where I put things, 
like my keys or wallet 
我曾有困难记起我把东西（如我的钥匙或皮夹）放在何处 
CogM12 I have had trouble remembering new information, like 
phone numbers or simple instructions 
我曾在记住新的信息（如电话号码或简单的指示时有困难 
CogC33c I have had to use written lists more often than usual so 
I would not forget things 
为了不让自己忘记事情，我比平常更需要用到写好的字条 
CogPM1 I have been able to remember things, like where I left 
my keys or wallet 
我能够记起事情，如我把钥匙或钱包放在何处 
CogPM2 I have been able to remember to do things, like take 
medicine or buy something I need 
我能够记得我要做的事情，如吃药或买我需要的物品 
CogPCH2 My memory is as good as it has always been 我的记忆力如往常一样好 
Concentration CogC7 I have had trouble concentrating 我曾在集中注意力方面有困难 
CogC31 I have had to work harder than usual to keep track of 
what I was doing 
我需要比平常更加努力地专注我所做的事 
CogPC1 I have been able to concentrate 我能够集中精神 
CogPF1 I am able to pay attention and keep track of what I am 












Domain Item No. Content 
  English Simplified Chinese 
Mental acuity CogA1 I have had trouble forming thoughts 我曾在想东西时有困难 
CogA3 My thinking has been slow 我在想东西时较慢 
CogC32 My thinking has been slower than usual 我的思维比平常慢 
CogPCH1 My mind is as sharp as it has always been 我的头脑如往常一样敏锐 
Verbal CogV13 I have had trouble recalling the name of an object 
while talking to someone 
当我和别人交谈时，我曾有困难记起某个物件的名字 
CogV15 I have had trouble finding the right word(s) to express 
myself 
我曾有困难寻找正确的词来表达自己 
CogV16 I have used the wrong word when I referred to an 
object 
我曾用过错误的词汇来指某个物件 
CogV17b I have had trouble saying what I mean in 
conversations with others 
当我与别人交谈时，我会有困难表达我想要说的话 
CogC33a I have had to work harder than usual to express myself 
clearly 
我需要比平常更加努力来清楚地表达自己 
CogPV1 I have been able to bring to mind words that I wanted 















Domain Item No. Content 
  English Simplified Chinese 
Functional 
Interference 
CogF19 I have walked into a room and forgotten what I meant 
to get or do there 
我曾走进房间时忘了自己在房间里是要拿或做什么事 
CogF23 I have had to work really hard to pay attention or I 
would make a mistake 
我需要更加努力地集中注意力，否则我会犯错 
CogF24 I have forgotten names of people soon after being 
introduced 
我会很快忘记刚被介绍给我认识的人的名字 





CogMT1 I have trouble keeping tracking of what I am doing if I 
am interrupted 
如果我受到干扰，我会有困难再专注我正在做的事 
CogMT2 I have trouble shifting back and forth between 
different activities that require thinking 
我在来回做两种需要动脑筋的事情时有困难 
CogPMT1 I am able to shift back and forth between two 
activities that require thinking 
我能够来回做两种需要动脑筋的事情 


















Domain Item No. Content 
  English Simplified Chinese 
Noticeability CogO1 Other people have told me I seemed to have trouble 
remembering information 
其他人曾说我似乎在记住信息方面有困难 
CogO2 Other people have told me I seemed to have trouble 
speaking clearly 
其他人曾说我似乎在把话说清楚方面有困难 
CogO3 Other people have told me I seemed to have trouble 
thinking clearly 
其他人曾说我似乎在清楚思考方面有困难 
CogO4 Other people have told me I seemed confused 其他人曾说我看起来似乎很困惑 
Impact on 
quality of life 
CogQ35 I have been upset about these problems 我曾为这些问题而感到苦恼 
CogQ37 These problems have interfered with my ability to 
work 
这些问题曾干涉到我的工作能力 
CogQ38 These problems have interfered with my ability to do 
things I enjoy 
这些问题曾干涉到我所享受事情的能力 
CogQ41 These problems have interfered with the quality of my 
life 
这些问题曾干涉到我的生活质量 
The translation from English to Chinese closely followed the guidelines stipulated by the Translation and Cultural Adaptation-Principles of Good Practice. The questionnaire was 
forward- and backward translated and reconciled by independent parties, and underwent cognitive pre-testing with a representative and culturally homogeneous sample of 30 bilingual 
Singaporean patients to identify items that were offensive or structurally difficult to understand within the local context. 









There is currently limited data on the psychometric properties of FACT-
Cog. An older version of FACT-Cog (version 2) was validated within the 
hematopoietic stem cell transplant population.
339
 The current version of FACT-
Cog (version 3) is also available in French and it has yielded good linguistic 
validation results within the French cancer patients.
338
 However, the English and 
Chinese versions of the FACT-Cog have not been validated for use in research 
and clinical settings within Asian breast cancer patients. Specific research on the 
reliability and other measurement properties of the Chinese version of FACT-Cog 
has also not been published in the literature. Establishing the equivalence between 
the English and Chinese versions of the FACT-Cog will also allow the results 
from both languages to be pooled for future research. Hence, this study was 
designed to evaluate the validity of the English and Chinese versions of the 
FACT-Cog in the context of a multi-ethnic Asian breast cancer population, and to 
determine the measurement equivalence between these two versions. 
 
4.2.1 Overall methodology 
Study design and setting 
This prospective study was conducted at the outpatient clinics of the NCCS 
between November 2010 and August 2012. This study was approved by the CIRB 






The patients who were recruited to participate in this study had to be 1) 
diagnosed with breast cancer by a medical oncologist, 2) at least 18 years old, 3) 
ambulatory in nature (defined as having an ECOG performance status score of 0 
or 1, 3) spoke English or Chinese as their mother-tongue, and 4) willing to give 
informed consent. Patients were excluded from the study if breast cancer was a 
secondary malignancy, or patients presented with evidence of brain metastasis, 
psychosis or any underlying neuropsychiatric illness that might impair their 
cognitive abilities. Patients’ medical histories and medication records were 
reviewed to ensure that they had not been prescribed with neuropsychiatric or 
psychotropic medications.  
Patients were classified into English-speaking and Chinese-speaking based 
on their indicated mother tongue or preferred choice of language for routine 
reading (eg. newspapers and books), writing and communication.  
Study procedures 
The patients’ demographic and medical information was obtained from the 
existing electronic databases available at the NCCS. Data on patients’ cancer 
treatment, chemotherapy protocol and the use of CAM such as TCM and vitamins 
or other nutritional products were also collected. Three questionnaires – the 
FACT-Cog, the EORTC-QLQ-C30 and the BAI were administered to patients by 
interviewers upon recruitment. English and Chinese versions were available for 





Chinese-speaking groups respectively. All interviewers were bilingual and 
underwent training to ensure consistency in questionnaire administration. 
Study tools 
i. FACT-Cog 
This is the questionnaire of interest for this validation study. Description of the 
FACT-Cog has been presented in the previous Chapter 4.1. This study involved 
the validation of the six reclassified cognitive domains of interest from the 
original subscales (1) and (2): mental acuity, attention and concentration, memory, 
verbal fluency, functional interference and multitasking ability; and the validation 
of general subscales (3) and (4), which were not specific to any cognitive domains.  
ii. EORTC-QLQ-C30 
The EORTC-QLQ-C30 (referred to as QLQ-C30 hereafter) is a questionnaire 
developed to assess cancer patients’ HRQoL.221 The QLQ-C30 was utilised to 
evaluate the convergent validity of FACT-Cog (Section 4.2.4). It contains 30 
items that are grouped into five functional domains (physical, role, cognitive, 
emotional and social), three symptom domains (fatigue, pain and 
nausea/vomiting), a global quality of life domain and six individual items 
(dyspnoea, insomnia, anorexia, diarrhoea, constipation and financial stability). 
Items are rated for the previous week, including the present day. Each of the items, 
with the exception of the global quality of life domain, is rated on a 4-point Likert 
scale ranging from 1 (“Not at all”) to 4 (“Very much”). The global quality of life 





“excellent”. The maximum score for each domain is 100 points. Higher scores in 
the functional and global quality of life domains are indicative of better 
functioning or health status, while higher scores in the symptom domains and 
individual symptom items are indicative of worsen symptoms. Both the English 




Of interest to this study is the EORTC-cognitive functioning (EORTC-CF) scale, 
which contains two items that investigate memory (“Have you had difficulty 
remembering things?”) and attention deficits (“Have you had difficulty in 
concentrating on things, like reading a newspaper or watching television?”) in the 
past week. This QLQ-C30 cognitive functioning scale is used as an anchor for the 
evaluation of test-retest reliability of FACT-Cog.  
iii. BAI 
The BAI is a validated questionnaire comprising 21 self-reported anxiety-
associated symptoms. The BAI was utilised to evaluate the convergent validity of 
FACT-Cog (Section 4.2.4). Description of the BAI has been presented in the 
Chapter 2.1.1.  
Statistical analysis 
Missing values in the FACT-Cog, the QLQ-C30 and the BAI were managed 
as stipulated by the respective questionnaire manuals.
344-346
 Descriptive statistics 
were used to describe the demographic and clinical characteristics of the sample. 





English- and Chinese-speaking groups using independent t-tests or Mann-
Whitney U tests for continuous measures and chi-square or Fisher’s exact tests for 
differences in categorical measures. All of the two-tailed significance tests were 
conducted using a significance level of p<0.05.  
 
4.2.1.1 Measurement equivalence 
The equivalence of English and Chinese FACT-Cog was evaluated by 
examining whether score differences between these versions were clinically 
important. Using methodology for assessing therapeutic equivalence in clinical 
trials, the 95% CI of FACT-Cog total and cognitive domain score differences 
were compared with pre-defined equivalence margins to determine if differences 
in scores were clinically important or unimportant.
343,347,348
 A multiple regression 
analysis was performed to estimate the comparability of the means scores 
obtained from both versions after adjusting for demographic and health 
differences and known related constructs that might prompt a change in patients’ 
cognitive functioning. It was important to adjust for the influence of these 
variables when assessing influence of language, as observed differences in FACT-
Cog scores might be caused by these determinants rather than by questionnaire 
language. Clinically relevant factors that were decided a priori for adjustment 
included age, years of education, receipt of CAM (gingko, TCMs, vitamins and 
nutritional products), menopausal status, haemoglobin levels, receipt of 
chemotherapy, anxiety (depicted by BAI scores), fatigue (depicted by QLQ-C30 





cancer stage and receipt of anti-hormonal therapy. 17,41,88,93,102,108,175,226,288,305-310 To 
adjust for the other exploratory variables in the model, these variables must be 
statistically significant at a cut-off p-value of 0.05 in the univariate analysis and 
considered clinically relevant and postulated to contribute to the clinical 
presentation of cognitive impairment in cancer patients, based on the consensus 
among the clinicians in the research team. This approach was adopted to prevent 
detraction from the statistical power by including clinically irrelevant variables in 
the model. Equivalence was established if the 95% CI of the adjusted mean 
difference fell within the equivalence margin of 0.25 SD. Should the 95% CI fall 
out of 0.25 SD, the equivalence is still acceptable if it does not exceed 0.5 SD, 




Concurrent validity was performed by evaluating the strength of correlation 
between the QLQ-C30 cognitive functioning scale and the total FACT-Cog score. 
The QLQ-C30 cognitive functioning scale was used because it has been 
previously validated in multiple international studies and in Singapore.
221,342,349-352
 
We hypothesised that the FACT-Cog scores would correlate positively with the 








Convergent validity analysis was performed to determine whether the 
FACT-Cog total score correlated with its known related constructs. Studies have 
shown that fatigue, anxiety and a poorer global health status have a negative 
effect on cancer patients’ cognitive abilities.11,93,102,353 Using the QLQ-C30 fatigue 
scale and global health status rating, we hypothesised that a lower FACT-Cog 
score would correlate with patients exhibiting a higher level of fatigue and a 
decreased global health status rating. Using the total score from the BAI, we 
hypothesised that a lower FACT-Cog score would correlate with patients 
exhibiting higher BAI scores or more severe anxiety.  
In all of the above correlation tests for concurrent and convergent validities, 
an absolute correlation coefficient value of 0.7 and above was indicative of a 
strong correlation. An absolute value of 0.4 to 0.7 indicated a moderate 





Known-groups validity means to test the hypothesis that two or more 
groups of respondents differing in perceived cognitive status should have different 
self-reported scores as measured by the neuropsychological tool. Known-group 
validity was performed to determine the significance of the differences between 
the FACT-Cog scores of the groups known to have varying degrees of perceived 





patient descriptions of cognitive problems post-chemotherapy
55,224
, we 
hypothesised that patients who had completed chemotherapy at the point of 
survey administration would report poorer cognitive functioning, reflected by 
lower FACT-Cog scores, than those who were not exposed to chemotherapy (also 
termed as “chemotherapy-naïve” patients). 
 
Factor analysis 
A principal component factor analysis was conducted to ascertain the one-
factor structure of each cognitive domain. Uni-dimensionality would be 






Reliability refers to the degree to which an instrument yields reproducible or 
consistent scores each time it is administered. 
 
Internal consistency and item-to-scale correlation 
Internal consistency reliability refers to the degree to which the items of the 
subscale/subdomain are interrelated. The internal consistency reliability between 
the individual items of the same cognitive domain was evaluated using 
Cronbach’s α.359 A Cronbach’s α of 0.7 and above represented satisfactory 





with the other items in the domain, an item-to-domain correlation analysis was 
also performed. The corrected item-to-scale correlation was calculated for each 
item by removing the contribution of the item to the domain score. Any items 
with a correlated item-to-scale correlation of less than 0.5 were identified. 
Test-retest reliability 
Test-retest reliability refers to the degree to which the subjective 
neuropsychological tool yields repeatable self-reported cognitive functioning 
scores if it is administered at different points of time to subjects with stable 
perceived cognitive status. Approximately 4 to 6 weeks after baseline assessment, 
a random sample of patients who were recruited between May to October 2012 
were invited to complete the FACT-Cog and respond to two anchor questions that 
were obtained from the QLQ-C30 cognitive functioning domain in the same 
language again through interview during their scheduled follow-up consultation at 
clinic. The test-retest reliability was investigated by determining the intraclass 
correlation coefficient (ICC) of the scores for the patients who completed the 
follow-up assessment within 45 days and stated “no change” to the two anchor 
questions.
360,361
 This time frame was chosen as oncology practitioners in our 
cancer institution typically arrange for follow-up consultations with patients at 
least once every 45 days, and based on clinical observation that ambulatory breast 
cancer patients commonly do not experience significant changes in their HRQoL 
and cognitive functioning within a span of 45 days. For individual patient 
assessment, an ICC of 0.7 or higher is considered as “satisfactory”. The mean 





cognitive domain scores were evaluated. As there is no established minimal 
clinically important difference (MCID) for FACT-Cog, we defined MCID as the 
conservative margin of ¼ SD of the total FACT-Cog and cognitive domain scores. 
If the mean difference of the baseline and follow-up scores exceed 0.25 SD of the 
total FACT-Cog or cognitive domain score, test-retest reliability would be 
considered as “non-satisfactory”. 
 
Sample size 
Currently, there is limited theoretical basis for determining sample size in 
the validation of patient-reported outcomes questionnaires. As this validation 
exercise involved the use of factor analysis, it is recommended that the sample 
size should be at least 5 to 10 times the number of items in the questionnaire of 
interest.
362
 As FACT-Cog contains 37 items, the required sample size was 
estimated to be from 185 to 370 patients. All statistical analyses were conducted 







4.2.2 Baseline characteristics of patients 
Patients’ characteristics  
A total of 328 patients participated in the study, of which 185 (56.4%) were 
English-speaking and 143 (43.6%) were Chinese-speaking (Table 4.2). The mean 
age of all of the patients was 51.89.7 years. The majority of the patients were 
Chinese (86.2%) with early-stage breast cancer. Statistically significant 
differences were not observed among the demographic and clinical characteristics 
such as marital status, haemoglobin level, presence of comorbidities, cancer 
staging, ECOG, receipt of anti-hormonal therapy, chemotherapy and CAM. 
However, the Chinese-speaking patients were older than their English-speaking 
counterparts (55.18.3 vs. 49.310.0 years, p<0.001). Compared to the English-
speaking patients, the Chinese-speaking patients generally had fewer years of 
education (11.81.0 vs. 7.42.5, p<0.001), were unemployed (44.9% vs. 60.8%, 
p=0.005) and largely post-menopausal (51.9% vs. 63.6%, p=0.034). These 
demographic and health differences could be attributed to the disparity in ages 


























Frequency (%) Frequency (%) Frequency (%)  p-value  
Age (years) 
 
Mean ±SD 51.8 ±9.7 - 49.3 ±10.0 - 55.1 ±8.3 - 
<0.001 
Age  21 to 30  8 (2.5) 8 (4.3) 0 (0.0) 
<0.001 
(range of years) 31 to 40 39 (11.9) 32 (17.3) 7 (5.0) 
 41 to 50 90 (27.4) 60 (32.4) 29 (20.2) 
 51 to 60 131 (39.9) 60 (32.4) 71 (49.7) 
 >60 60 (18.3) 25 (13.6) 36 (25.1) 
         
Education (years) 
 
Mean ±SD 9.9 ±3.9 - 11.8 ±1.0 - 7.4 ±2.5 - 
<0.001 
Education (levels) Low education 
     None 
85 
    10 
(25.9) 
   (3.0) 
12 
    0 
(6.5) 
     (0.0) 
73 
   10 
(51.1) 
     (7.0) 
<0.001 
      Elementary/Middle     75    (22.9)    12      (6.5)    63      (44.1) 
 High education 
     Junior high 
243 
   151 
(74.1) 
   (46.0) 
173 
   91 
(93.5) 
     (49.2) 
70 
   60 
(48.9) 
     (42.0) 
      Senior high    38    (11.6)    32      (17.3)    6      (4.2) 
       Graduate/post-graduate 
 
   54    (16.5)    50      (27.0)    4      (2.7) 
Race Chinese 257 (86.2) 114 (61.6) 143 (100) 
<0.001 
 Non-Chinese   
   Malay 
71 
  46 
(13.8) 
   (15.4) 
71 
   46 
(38.4) 





    Indian   14    (4.7)    14     (7.6) 0 (0.0) 
    Others 
  
  11      (3.7)    11     (5.9) 0 (0.0) 
Marital status Single 61 (18.6) 35 (18.9) 26 (18.2) 
0.673 
 Married 242 (73.8) 135 (73.0) 107 (74.8) 
 Divorced 16 (4.9) 11 (5.9) 5 (3.5) 
 Widowed 
 
9 (2.7) 4 (2.2) 5 (3.5) 
Employment status Employed 158 (48.2) 102 (55.1) 56 (39.2) 
0.005 

























11.8 ±2.2 - 11.6 ±2.4 - 12.0 ±1.8 - 0.057 
Menopausal status Pre-menopausal 187 (57.0) 89 (48.1) 52 (36.4) 
0.034  Post-menopausal 
 
141 (43.0) 96 (51.9) 91 (63.6) 
Presence of 
comorbidities  




232 (70.7) 139 (75.1) 93 (65.0) 
Cancer staging 1 74 (22.6) 44 (23.8) 30 (21.0) 
0.658 
 2 147 (44.8) 78 (42.2) 69 (48.3) 
 3 84 (25.6) 48 (25.9) 36 (25.2) 
 4 23 (7.0) 15 (8.1) 8 (5.6) 
Time since 
diagnosis (months) 








 0 270 (82.3) 154 (83.3) 116 (81.1) 
0.662 
 1 58 (17.6) 31 (16.7) 27 (18.9) 
Medication information        
Receipt of anti-
hormonal therapy 
No 259 (79.0) 149 (80.5) 106 (74.1) 
0.499 Yes 69 (21.0) 36 (19.5) 37 (25.9) 
 Time since anti-hormonal 











Completed  No 173 (52.7) 100 (54.1) 73 (51.0) 
0.739 
chemotherapy Yes 155 (47.3) 85 (45.9) 70 (49.0) 
        AC-based   98    48    50   
         FEC-based   32    17    15   
        Others   25    20    5   
Receipt of CAM  No 155 (47.3) 93 (50.3) 62 (43.4) 
0.184 
Yes 173 (52.7) 92 (49.7) 81 (56.6) 
Bold: Denotes statistically significant (p<0.05); AC-based: doxorubicin and cyclophosphamide-based; CAM: Complementary alternative medicine: refers to Traditional Chinese 
Medicine (herbal supplements, concentrated extracts or herbal concoction prescribed by a Chinese physician or bought from a Traditional Chinese Medicine pharmacy; ECOG: 






Summary of patients’ HRQoL and anxiety scores 
The mean cognitive functioning scores from the QLQ-C30 showed no 
statistical differences between the English- and Chinese-speaking groups 
(88.117.9 and 89.614.2, respectively) (Table 4.3). However, statistically 
different scores were observed between the English- and Chinese-speaking 
patients in the following HRQoL domains of the QLQ-C30: physical functioning 
(p=0.003), role functioning (p=0.0001), emotional functioning (p=0.002), social 
functioning (p=0.004), fatigue (p<0.0001) and pain (p=0.036). 
The BAI detected more anxiety symptoms among English-speaking patients, 
compared to their Chinese-speaking counterparts (9.19.1 vs. 7.35.9, p = 0.038) 






Table 4.3: Comparison of HRQoL and anxiety between English- and Chinese-
speaking patients 
 










 Mean ±SD Mean ±SD Mean ±SD p-value  
EORTC-QLQ-C30  
 





Global health status 
69.3 18.8 69.7 18.3 68.9 19.5 0.668 
Functional 
1 Physical 84.4 15.3 82.2 17.6 87.2 11.0 0.003 
 Role 85.4 18.7 80.9 20.9 91.1 13.4 0.000 
 Emotional 79.3 19.8 76.4 22.4 83.0 14.9 0.002 
 Cognitive 88.8 16.4 88.1 17.9 89.6 14.2 0.364 





Fatigue 28.0 21.2 32.3 23.1 22.5 17.1 0.000 
Nausea and vomiting 3.4 9.8 5.1 12.0 1.3 5.3 0.000 




Dyspnoea 11.8 19.9 14.8 23.0 7.9 14.2 0.002 
Insomnia 24.4 30.5 27.0 33.9 20.7 25.0 0.054 
 Appetite 12.1 22.8 13.9 24.4 10.0 20.6 0.145 
 Constipation 11.2 22.1 10.6 22.0 11.9 22.2 0.627 
 Diarrhoea 3.8 13.1 3.1 12.3 4.7 14.0 0.263 
 Financial 
 
32.1 34.2 32.3 34.9 31.9 33.3 0.931 
Beck Anxiety Inventory  
 
    
 Total
3 8.3 8.0 9.1 9.1 7.3 5.9 0.038 
* Bold: Denotes statistically significant (p<0.05).  All variables that are statistically different between the two groups were 
adjusted in the regression model for evaluating measurement equivalence between English and Chinese versions (Table 
4.4), with the exception of the variables “nausea and vomiting” and “dyspnoea” as it is irrelevant or logical to demonstrate 
that they contribute to the subtle cognitive impairment in cancer patients. 
1 A higher score is indicative of a better functioning/health status. The theoretical range for the global and functional scales 
is 0 to 100. 
2 A higher score is indicative of more symptoms/difficulties. The theoretical range for the symptom scales and single items 
is 0 to 100. 






4.2.3 Measurement equivalence 
All clinically-relevant variables that were decided a priori under the 
methodological section and all statistically significant variables in Tables 4.2 and 
4.3 were adjusted in the regression model for evaluating measurement 
equivalence between English and Chinese versions (Table 4.4), with the 
exception of the variables “nausea and vomiting” and “dyspnoea” as it is 
irrelevant or logical to demonstrate that they contribute to the subtle cognitive 
impairment in cancer patients. The final regression model showed that significant 
difference was not observed between the two groups in the FACT-Cog total 
scores; the cognitive domains of memory, verbal ability, concentration, mental 
acuity and functional interference; or in the subscales of noticeability and 
influence on quality of life. Ninety-five per cent of the CIs for the adjusted 
difference between the scores of both languages fell within the 0.5 SD margin. 
However, the 95% CI of the difference in scores between the English and Chinese 
versions in the multitasking domain fell outside the 0.25 SD equivalence margin 
and exceeded the 0.5 SD threshold or upper limit for a small detectable change. 
This suggests that the equivalence between the English and Chinese versions was 





















English vs. Chinese 











95% CI of 
adjusted 
difference 





126.57 17.9 4.89 9.78 3.06 -1.12 to 7.25 
Domains 
 
       
Memory (0 – 28) 23.5 ±4.1 23.7 4.3 23.3 3.9 1.03 2.06 0.66 -0.31 to 1.63 
Verbal ability (0 – 24) 21.2 ±3.5 21.2 3.6 21.1 3.3 0.86 1.72 0.35 -0.50 to 1.19 
Concentration (0 – 16) 13.5 ±2.7 13.7 2.8 13.2 2.5 0.67 1.34 0.61 -0.74 to 1.21 
Mental acuity (0 – 16) 13.5 ±2.8 13.5 3.0 13.5 2.5 0.69 1.38 0.33 -0.30 to 0.95 
Functional interference (0 –16) 13.7 ±2.5 13.7 2.8 13.6 2.4 0.62 1.24 0.20 -0.41 to 0.80 
Multitasking  (0 – 16) 13.1 ±2.8 13.4 2.8 12.6 2.7 0.70 1.41 0.85
 
0.19 to 1.51 
Noticeability (0 – 16) 15.2 ±1.7 15.2 1.6 15.2 1.6 0.42 0.84 0.09 -0.33 to 0.51 
Impact on quality of life (0 – 16) 13.4 ±3.8 12.8 4.3 14.1 2.9 0.94 1.89 -0.06 -0.85 to 0.74 
Bold: Denotes that the 95% CI exceeded both the 0.25 SD equivalence margin and 0.5 SD equivalence margin threshold. 
CI: confidence interval; SD: standard deviation 
 
1Mean difference adjusted to clinically-relevant variables that were decided a priori: age in years, education in years, receipt of complementary alternative medicines, menopausal status, 
haemoglobin level, receipt of chemotherapy, anxiety, fatigue,  global health status, stage and receipt of anti-hormonal therapy, and variables that showed statistical differences between the 
English- and Chinese-speaking groups in Tables 4.2 and 4.3: race (Chinese vs non-Chinese), work status (Employed vs unemployed), presence of comorbidities, physical functioning, role 





4.2.4 Validity of FACT-Cog  
Concurrent validity 
A moderate-to-strong correlation between the FACT-Cog total score and 
the QLQ-C30 cognitive functioning scale score was observed for both the English 
and Chinese versions (r=0.725 and 0.646, respectively).   
 
Convergent validity 
The QLQ-C30 fatigue scale and the FACT-Cog total scores were 
moderately-to-poorly correlated for the English and Chinese versions (r=-0.376 
and -0.448, respectively). The correlations between anxiety scores (the BAI total 
score) and the FACT-Cog total scores for the English and Chinese versions were 
moderate (r=-0.589 and -0.567, respectively). The correlations between the QLQ-
C30 global health status score and the FACT-Cog total scores were moderate 
among the English-speaking patients (r=0.580) and Chinese-speaking patients (r = 
0.511).  
For both language versions, the correlations between individual cognitive 
domains and the known-related constructs of fatigue, global health status and 








Both versions of FACT-Cog were able to discriminate between patients 
who had completed chemotherapy and those who were not exposed to 
chemotherapy. Both English-speaking and Chinese-speaking patients who 
received chemotherapy reported more cognitive disturbances than patients who 
had no prior exposure to chemotherapy (English-speaking: 123.123.8 vs. 
130.917.0, p=0.010; Chinese-speaking: 122.017.9 vs. 131.017.0, p=0.008).  
With regards to the individual cognitive domains, patients receiving 
chemotherapy reported consistently lower scores than those who were not 
exposed to chemotherapy (all p<0.01). However, known group validity between 
chemotherapy-receiving and non-chemotherapy receiving patients was not 
achieved for the subdomain of “noticeability” for both English- and Chinese 
speaking patients (English-speaking: 14.9±2.2 vs. 14.4±1.3, p=0.064; Chinese-
speaking: 15.1±1.4 vs. 15.3±1.6, p=0.082). 
 
Factor analysis 
For both language versions, uni-dimensionality was derived from factor 
analysis for the domains of “concentration”, “verbal ability”, “functional 
interference”, “multitasking”, “noticeability” and “impact on quality of life”, 
suggesting the individual items within these domains could be summed to 





domains accounted for 67.3% to 74.2% of the total variance for both languages 
and the loadings of the items on each single domain were similar and high.  
However, uni-dimensionality was not confirmed for the memory and mental 
acuity domains. It was noted that two items (CogM9 and CogA1) were poorly 
loaded to their respective domains of memory and mental acuity.  
 
4.2.5 Reliability of FACT-Cog 
Internal consistency and item-to-scale correlation 
The Cronbach’s α for the English- and Chinese-speaking patients’ FACT-
Cog cognitive domain scores ranged from 0.707 to 0.929 (Table 4.5). The 
Cronbach’s α for the Chinese version was generally observed to be lower than 
that for the English version for all domains. However, there were satisfactory 
internal consistencies within each of the domains for both languages.  
The item-to-domain analyses identified four items that had poor correlations 
(r<0.500) with the other items in the same domain: CogM9 and CogM12 from the 













Table 4.5: Internal consistencies and item-to-scale correlations of FACT-Cog cognitive subdomains/subscales 
 Item  
 
Combined FACT-Cog English and 
Chinese versions (N=328) 
FACT-Cog English Version 
(N=185) 
FACT-Cog Chinese version 
(N=143)  





























CogM10 0.590 0.587 0.595 
CogM12 0.497* 0.514 0.469* 
CogC33c 0.575 0.608 0.533 
CogPM1 0.645 0.655 0.631 
CogPM2 0.607 0.584 0.643 









CogV15 0.702 0.746 0.674 
CogV16 0.640 0.677 0.584 
CogV17b 0.737 0.729 0.752 
CogC33a 0.705 0.707 0.702 









CogC31 0.648 0.660 0.632 
CogPC1 0.644 0.692 0.582 









CogA3 0.717 0.736 0.689 
CogC32 0.704 0.739 0.644 





























 Item  Combined FACT-Cog English and 
Chinese versions (n=328) 
FACT-Cog English  
Version (n=185) 

































CogMT2 0.589 0.550 0.611 
CogPMT1 0.628 0.547 0.722 
CogPMT2 0.582 0.550 0.599 









CogO2 0.584 0.592 0.578 
CogO3 0.633 0.685 0.561 
CogO4 0.492* 0.526 0.451* 
        
Impact on 








CogQ37 0.801 0.837 0.781 
CogQ38 0.793 0.863 0.697 
CogQ41 0.822 0.878 0.765 
 
* Denotes items with relatively poor item-to-domain correlation (adjusted r <0.500). 
FACT-Cog: Functional Assessment of Cancer Therapy – Cognitive Function 
1 The corrected item-to-scale correlation was calculated for each item by removing the contribution of the item to the domain score. 
2 The four items in the “Multitasking ability” domain were not previously scored under the original FACT-Cog scoring algorithm because they were added to the tool only after the 





A total of 152 patients were approached for the follow-up assessment, of 
which 145 patients (95.4%) completed the FACT-Cog questionnaire for the test-
retest reliability analysis. Of those 145 patients, seventy (48.3%) patients 
indicated “no change” to the anchor questions from QLQ-C30 cognitive 
functioning scale, and their results were considered valid for analysis. Thirty-nine 
(55.7%) were English-speaking patients and 31 (44.3%) were Chinese-speaking 
patients. The mean duration from baseline to follow-up assessment was 40.921.2 
days. The ICC values for the FACT-Cog total score were satisfactory for both 
English and Chinese versions (ICC: 0.762 and 0.697, respectively). The mean 
difference between the baseline and follow-up total FACT-Cog scores was -1.01 
points (95% CI: -3.98 to 1.95), which was much lower than the pre-defined MCID 
of 4.90 points (¼ SD of the total FACT-Cog score). 
The test-retest reliabilities for the individual cognitive domains were fairly 
satisfactory, as indicated by ICC values ranging from 0.673 to 0.793. All the ICC 
values for the individual cognitive domains were above 0.7, with the exception of 
the Chinese “mental acuity” domain (ICC: 0.673). For all cognitive domains, the 
mean differences between the baseline and follow-up cognitive domain scores 
ranged from 0.08 to 0.19 SD and all fell within the pre-defined minimal clinically 






4.2.6 Discussion  
The results obtained from the concurrent validity analysis demonstrated that 
the English and Chinese FACT-Cog total scores had strong and moderate 
correlations, respectively, with the validated QLQ-C30 cognitive functioning 
scale. The convergent validity analysis revealed that the correlations between the 
FACT-Cog total scores and patients’ anxiety, fatigue and global quality of life 
level were weak to moderate. Similar results were observed in the validation of 
the English FACT-Cog version 2 in 101 cancer patients who underwent 
hematopoietic stem cell transplantation; the correlation between FACT-Cog total 
scores and the constructs of depression, anxiety and fatigue were weak to 
moderate (|r|=0.36 to 0.60).
339
 A strong correlation was not obtained, likely due to 
the multi-factorial nature of cognitive impairment, which consists of various 
clinical, pharmacological and psychosocial confounders such as depression, 
receipt of neuro-degenerative drugs, distress, mood changes and the patients’ 
genetic predispositions.
87,93,102
 Therefore, no single attribute is sufficient to create 
a strong correlation with greater perceived cognitive impairment. In the validation 
study, the choice of fatigue, anxiety and HRQoL as the constructs of interest was 
valid because these variables have been substantially described in the literature as 
associated with perceived cognitive functioning. 
Results from known-group validity analysis suggested that both versions of 
FACT-Cog were able to discriminate patients based on their chemotherapy 
treatment status. Choice of known-groups in the assessment of perceived 




chemotherapy was selected as the basis for comparison instead of other potential 
choices, such as, presence of brain metastases, receipt of brain radiation therapy, 
and other severe neuropsychiatric disorders such as dementia or Alzheimer’s 
disease.
231,363-366
 These conditions can potentially lead to cognitive decline in 
patients. However, as this study aims to validate the capability of FACT-Cog to 
detect subtle cognitive changes in cancer patients, neuropsychological conditions 
that drastically impact brain functioning may generate extreme results and are not 
suitable for this purpose. To complement our results, it is recommended that 
future work should consider administering FACT-Cog to healthy individuals in 
order to obtain normative values from the general population.  
The validity, reliability and measurement equivalence of a subjective 
neuropsychological assessment based on its cognitive domains were evaluated in 
this study, instead of its originally proposed subscales or a global scale. It is noted 
that self-reporting tools most commonly employ the use of a global or summary 
scale rather than the specific domains of cognitive complaints. Although earlier 
studies have shown that the results of objective and subjective neuropsychological 
assessments do not correlate, some research has suggested otherwise when results 
are compared according to specific domains rather than overall scores.
43,61,120,367
 
In future research, the criterion validity of the FACT-Cog could be conducted by 
examining the relationship between the specific domains of subjective cognitive 
complaints and objective neuropsychological batteries. 
Both versions of the FACT-Cog have demonstrated satisfactory internal 




analyses and item-to-domain correlations have also revealed that the majority of 
the items in the FACT-Cog relate well to the constructs of their respective 
cognitive domains. However, CogM9 and CogM12 were highlighted as 
problematic items within the memory domain. As these results were observed in 
both the English and Chinese versions, the poor item-to-domain correlations 
could be due to problems with the original item, rather than translation errors. For 
CogM12, we postulate that using patients’ ability to remember ‘phone numbers’ 
and ‘simple instructions’ to assess memory may not be relevant in today’s context. 
Most patients need not remember such information, given the prevalence of 
technologies (e.g., mobile phones) that provide easy information storage and 
recall. We also observed that within the memory domain, CogM9 was identified 
as a problematic item that deviated from its underlying construct of memory. This 
could be due to the ambiguous nature of the content outlined by the item. The 
patients’ inability to find their way to a ‘familiar place’ might be indicative of a 
severe or clinically significant cognitive impairment, instead of the mild or subtle 
cognitive changes often observed in cancer patients. Furthermore, many patients 
may have difficulty understanding the term ‘familiar place’ because it is poorly 
defined and not tied to concrete examples.  
Poor item-to-domain correlations were also observed with CogO1 and 
CogO4 for both language versions. A similar validation study of the French 
version of the FACT-Cog also identified CogO1 as having a poor item-to-total 
correlation within the subscale of ‘noticeability’ (r=0.320).338 Moreover, the 




patients who had completed chemotherapy and those that were not exposed to 
chemotherapy. This could be due to the sensitive nature of these items, which 
seek to obtain a third party’s opinion of the patient’s cognitive ability. When 
applied in the context of an Asian population that values communal living and 
kindred spirits, these comments are expected to be poorly received. In Chapter 
3.2, the Asian breast cancer focus group participants expressed that their family 
members provided them with good psychosocial support during their 
chemotherapy treatment, and were generally “forgiving and patient towards them” 
when they displayed cognitive lapses. Thus, the responses to CogO1 and CogO4 
would not be accurately reflected.  
It was observed that the test-retest reliability is only fairly satisfactory 
(ICC=0.673) for the mental acuity domain. CogA1 was also identified by the 
factor analysis as relating poorly to the constructs of the mental acuity cognitive 
domains, especially within the Chinese version of the FACT-Cog. Poor item-to-
domain correlation observed with the Chinese FACT-Cog, which was not 
observed with the English FACT-Cog, suggests that cultural differences might 
have led to differential interpretations of the same item. Despite repeated attempts 
to rephrase and refine this item during the pre-testing stage, the phrase ‘trouble 
forming thoughts’ is potentially open to misinterpretation and difficult to 
understand by patients. This was also observed with the validation of the French 
FACT-Cog, which required modifications to the translation of ‘forming thoughts’ 
in the pre-testing phase.
338
 To improve comprehensibility and to ensure 




of CogA1 is needed. Caution must be taken in the interpretation of the mental 
acuity domain, particularly the Chinese version.  
The measurement equivalence between the English and Chinese versions of 
the FACT-Cog was expounded in this validation study. Although most cross-
cultural patient-reported outcome study groups had undergone a vigorous 
translation process to ensure the content and semantic equivalence of the 
translated tool, it is imperative to evaluate the comparability and equivalence 
between the English and non-English versions of the FACT-Cog, because there is 
no assurance that the translated tool is equivalent to the original English version 
unless the comparability in the psychometric properties of the two tools is 
performed.
341,368
 Measurement equivalence is necessary to facilitate the pooling of 
results from multi-national clinical trials and identify problematic items that differ, 
in semantic structure, from the original language version.
341,368
 FACT-Cog scores 
in this validation study were adjusted based on both clinically relevant and 
statistically significant demographic and health differences between both groups 
to evaluate the measurement equivalence of both versions. With the 
understanding that cognitive impairment in breast cancer patients is a multi-
factorial phenomenon, we considered that known related constructs could enhance 
the accuracy of the equivalence measure. Our analysis demonstrated that both 
versions are equivalent for the total score and all of the cognitive domains, with 
the exception of the multitasking domain. Poor equivalence could be due to 
translation errors or differences in the cultural understanding of the items. The 




ability to effectively perform tasks that require simultaneous thought. Hence, the 
difficulty and choice of tasks could be influenced by patients’ lifestyles and 
cultural preferences. Caution must be taken when pooling the results of both 
language versions for this domain. Retranslation and refinement of the items are 
needed to improve their equivalence with the English source. 
 
4.2.7 Limitations of study 
This study has a few limitations. In the concurrent validity analysis, the 
QLQ-C30 cognitive functioning scale consisted of only two items to evaluate 
patients’ perceived concentration and memory. This could be seen as a 
methodological limitation, as QLQ-C30 is not the perfect standard for evaluating 
the concurrent validity of the FACT-Cog. The FACT-Cog’s cognitive domains 
and items include additional domains that are not examined in the QLQ-C30. 
However, our choice of the QLQ-C30 in this validation exercise is well justified 
because there are no other validated questionnaires currently available that assess 
all of the domains of perceived cognitive impairment in local cancer patients. 
Finally, there was a lack of published validation studies on the FACT-Cog for 
cross-referencing our results. This is the first study to analyse the items in the 








4.2.8 Summary of important findings 
This section attempts to evaluate the validity, reliability and equivalence of 
the English and Chinese versions of the FACT-Cog. An adaptation of the FACT-
Cog in the socio-cultural context of an Asian population and the evaluation of its 
psychometric properties is essential to the accurate interpretation of results in 
clinical studies.  
FACT-Cog is a valid and reliable instrument for assessing perceived 
cognitive functioning in Asian breast cancer patients. However, a few items 
within the “memory”, “mental acuity” and “noticeability” domains feature content 
or examples that are culturally irrelevant or inappropriate and one should be 
cautious interpreting results of these problematic items. The English and Chinese 
versions of the FACT-Cog have also demonstrated measurement equivalence. In 
addition, caution must be taken when the results of both versions are pooled for 
items within the multitasking domain. These items should undergo cross-cultural 
adaptation and re-translation to improve comprehensibility across cultures and 
languages. Overall, the validity, reliability and measurement equivalence between 
the English and Chinese versions complement and support the use of FACT-Cog 
as a tool for future clinical research. 
Future studies should evaluate the longitudinal validity and responsiveness 
of FACT-Cog to cognitive changes within the breast cancer patients across 




score changes, identification of MCID can guide the clinical interpretation of 





4.3 Determining the Minimal Clinically Important Difference (MCID) for 
FACT-Cog in Asian Breast Cancer Patients
369
  
The previous section has successfully delineated the psychometric 
properties of FACT-Cog as the subjective neuropsychological tool of choice 
utilised in this thesis. Conventionally, the results of patient-reported outcomes are 
analysed and interpreted using statistical testing in clinical research. Tests of 
statistical significance are used to determine whether an observed difference is 
attributable to chance alone. While such statistical comparisons can reflect a 
statistical change in the measured outcome, they do not indicate whether the 
difference is clinically relevant to patients.  
In essence, the clinical meaning of cognitive deterioration cannot be 
adequately determined from statistical significance alone. To facilitate the 
interpretation of the clinical relevance of score changes, the concept of MCID was 
proposed.
370
 For a given instrument, the MCID represents the smallest difference 
in scores that is considered clinically significant. Identification of the MCID can 
guide the clinical interpretation of patient-reported cognitive changes by 
providing recognisable endpoints. In the literature, two approaches are identified 
to estimate the MCID: (1) the anchor-based approach; and (2) the distributional 
approach.
371-373
 The anchor-based approach uses an external criterion and 
calculates the MCID by comparing the scores of patients in distinct anchor-
defined groups. Conversely, the distribution approach uses the underlying 
statistical property of a dataset to establish the clinically meaningful change. Both 




MCID estimates. Establishing the MCID for FACT-Cog is expected to aid in the 
assessment of the clinical significance of cognitive changes observed in clinical 
trials and sample size estimates for future studies. Through adopting the anchor-
based and distribution-based approaches, this study was designed to identify the 
MCID estimates for validated FACT-Cog in breast cancer patients. 
 
4.3.1 Overall methodology 
Study design and setting 
This was a prospective, longitudinal study conducted at the outpatient 
clinics of NCCS between November 2010 and December 2012. The study 
protocol was approved by the CIRB and written informed consent was obtained 
from all participants. 
Patients 
Inclusion criteria were a diagnosis of breast cancer and an age of over 21 
years. Patients were excluded if they were diagnosed with brain metastasis and/or 
any neuropsychiatric illness that might impair their cognitive function. 
Study procedure 
Clinical data, such as patient demographics and current medications for 
cancer treatment and concurrent medical conditions were retrieved from the 
clinical database.   
All of the recruited patients were evaluated at baseline (T1), and at a follow-




clinicians at our institution arrange follow-up consultations with stable 
ambulatory patients at least once every 3 months after the completion of 
chemotherapy, and every 6 to 12 months thereafter. In addition, observations 
suggest that these breast cancer patients may experience small but significant 
changes in their HRQoL and cognitive functioning within a span of 3 
months.
324,374
 To maximise the follow-up rate, patients were approached during 
their follow-up appointment at NCCS for the completion of T2 of this study. For 
patients who did not show up during their follow-up appointment, they would be 
contacted and asked to arrange for a new appointment time at NCCS. At both T1 
and T2, the patients completed three questionnaires, available in both English and 
Chinese:  
Study tools 
i. FACT-Cog (version 3) 
Description of the FACT-Cog has been presented in the previous Chapter 4.1. 
ii.  QLQ-C30 
Description of the QLQ-C30 has been presented in the previous Chapter 4.2.1. 
Statistical analysis 
Descriptive statistics were used to characterise patient demographics, 
clinical variables, and score distributions for FACT-Cog and EORTC-CF. The 
scoring of the questionnaires was performed according to the manuals published 




For the comparison of scores across T1 and T2, paired t-test and Wilcoxon 
signed rank test were used for parametric and non-parametric data, respectively. 






The anchor-based approach uses an external criterion and calculates the 
MCID by comparing the scores of patients in distinct anchor-defined groups. The 
EORTC-CF was used as an external criterion against which changes in FACT-
Cog were anchored and calibrated. Spearman’s rank correlation coefficient was 
used to quantify the association between FACT-Cog and EORTC-CF. To 
establish an MCID, it has been recommended that the change scores of the anchor 
and the instrument being examined have a correlation threshold of r ≥|0.30|.373 
Change scores in the EORTC-CF could range from -100 to 100, with 13 possible 
change values across the range. The delineation of clinically distinct anchor-
defined categories was based on a one-step change from baseline, corresponding 
to the smallest possible change score of 16.67. Each patient was assigned to one 
of these categories, accordingly: “much worse” (< -16.67), “minimally worse” (-
16.67), “no change” (0), “minimally better” (16.67), or “much better” (> 16.67). 
In one landmark study that evaluated the clinical significance of QLQ-C30 score 
changes, it was observed that for patients who indicated "a moderate" change 
either for better or for worse, the mean change in scores was between 10 to 20 
points.
378,379




valid estimate to capture a significant change of cognitive functioning status. To 
obtain the MCID for deterioration, the mean difference in scores for “no change” 
was subtracted from the mean difference in scores for “minimally worse.” 
Likewise, the average difference in scores for patients classified as “minimally 
better” was compared with those for “no change” to compute the MCID estimate 
for improvement. The associated effect sizes (ES) were determined for the 
respective clinical categories by dividing the mean change in scores by the overall 
baseline SD for the sample. To avoid overestimating the MCID, FACT-Cog 
change scores corresponding to the “much worse” and “much better” categories 
were not considered in the analysis. 
Another anchor-based method used involved a sensitivity- and specificity-
based analysis.
377
 Receiver operating characteristic (ROC) curves were 
constructed and the area under the curve (AUC) represents the ability of the 
instrument to distinguish between patients who did and did not undergo a 
clinically important change. The ROC cut-off point with the highest sensitivity 
and specificity corresponds to the optimal FACT-Cog change score that best 
discriminated between patients who changed and those who showed no change on 









The distribution approach uses the underlying statistical property of a 
dataset to establish the clinically meaningful change. Both approaches are 
frequently used in complement to ensure the robustness of the MCID estimates. 
The magnitude of the MCID for the FACT-Cog total scores was estimated 
with ES. An ES is a standardised index of change that represents the number of 
SDs by which the scores have changed from T1 to T2. Cohen developed 
benchmarks to facilitate the interpretations of ES; a value of ½ SD was associated 
with a medium-sized effect and has been suggested as a default threshold for 
defining important patient-perceived change on HRQoL measures.
380,381
 Based on 
previous MCID determination studies for other neuropsychological tools and 
FACIT instruments, ⅓SD and ½ SD were considered likely approximations of the 
MCID.
372,382,383
 Thus, ⅓ SD and ½ SD were calculated at T1, at T2, and for the T1 
to T2 score changes, and the mean values were computed. Additionally, the SEM-
based criterion was used to provide an MCID estimate that exceeded the 
measurement imprecision of the instrument.
384
 SEM was computed using the 
following formula: SEM = σ√(1 - rxx), where σ denotes the SD of the FACT-Cog 
scores and rxx is the test-retest reliability of the instrument.
384,385
 The value of rxx, 
0.737, was obtained from the previous validation study for FACT-Cog (Chapter 
4.2). A 1-SEM standard has been shown to closely approximate the minimum 
clinically important intra-individual change.
385
 The SEM was calculated for T1 





4.3.2 Baseline characteristics of patients 
Patients’ characteristics 
Three hundred thirty breast cancer patients participated at baseline (T1), of 
whom 220 (66.7%) completed the follow-up assessment (T2), and were included 
in the analysis (Table 4.6). Analysis of non-respondents’ characteristics showed 
that their demographics (age, race and education status) were similar to those of 
the respondents. Patients were lost to follow up mainly because they were not 
interested to continue the study at T2, had moved to another country or cancer 
institution, or they had defaulted follow-up consultation. Overall, the mean age ± 
SD was 50.9±9.5 years. Most of the patients were Chinese (79.6%) and married 
(73.2%). Approximately half of the patients were stage II patients (47.3%), 
post-menopausal (53.2%), and were receiving anti-hormonal therapy (45.5%). 
The mean duration from T1 to T2 was 9.7±6.8 months. Over half of the 
assessments (59.5%) were completed in English. 
Summary of FACT-Cog and QLQ-C30 scores 
The score distributions for the FACT-Cog, the EORTC-CF, and the BAI at 
both time-points are summarised in Table 4.7. The mean total scores of the 
FACT-Cog at T1 and T2 were 127.6±18.1 and 119.0±23.3, respectively, with an 
average change score of 8.6±20.4 (p<0.001). For the EORTC-CF, the mean 
scores were 89.8±14.8 and 82.0±19.6 at T1 and T2, respectively. The mean 
change in the FACT-Cog total scores did not differ significantly, after stratifying 




Table 4.6: Baseline characteristics of patients in the FACT-Cog MCID study 
(N=220) 
Demographic information  Frequency (%) 
Age (years) Mean ± SD 
 
50.9 ± 9.5 --- 
Education No formal education 4 (1.8) 
 Elementary 48 (21.8) 
 Junior high school 102 (46.4) 
 Senior high school 25 (11.4) 
 University/Post-university degree 
 
41 (18.6) 
Ethnicity Chinese 175 (79.6) 
 Malay 26 (11.8) 
 Indian 9 (4.1) 
 Others: Filipino, Burmese, and Arab 
 
10 (4.5) 
Marital status Single 43 (19.5) 
 Married 161 (73.2) 
 Divorced 9 (4.1) 
 Widowed 7 (3.2) 
    
Clinical information  Frequency (%) 
Breast cancer staging 0 2 (0.9) 
 I 45 (20.4) 
 II 104 (47.3) 
 III 57 (25.9) 
 IV 12 (5.5) 
    
ECOG status 0  186 (84.5) 
 1  34 (15.5) 
    
Comorbidity Presence of comorbidity 84 (38.2) 
 Types of comorbidity 
1   
 Cardiovascular 72 (85.7) 
 Gastrointestinal 6 (7.1) 
 Endocrine 6 (7.1) 
 Respiratory 3 (3.6) 
 Others 3 (3.6) 
    
Receipt of antihormonal therapy 
 
Tamoxifen or aromatase inhibitors 100 (45.5) 
Complementary alternative medicine 
(CAM) 
 





Post-menopausal 117 (53.2) 
Receipt of chemotherapy Baseline (T1) 161 (73.2) 
 Follow-up (T2) 203 (92.3) 
Chemotherapy protocol (T2) AC-based 120 (59.1) 
 FEC-based
 27 (13.3) 
 Taxane-based 47 (23.2) 
 Others 9 (4.4) 
Haemoglobin level (g/dL) Mean ± SD 11.5 ± 1.2 --- 




Methodological information  Frequency (%) 
    
Duration between T1 to T2 (months) Mean ± SD 9.7 ± 6.8 --- 
Language of administration English 131 (59.5) 
 Chinese 89 (40.5) 
    
AC: doxorubicin and cyclophosphamide; ECOG: Eastern Cooperative Oncology Group; FEC: 5-fluorouracil, 
epirubicin, and cyclophosphamide; SD: standard deviation 
 
1 Percentages add up to more than 100% due to some patients having more than one comorbidity. 
 
 
Table 4.7: Perceived cognitive functioning and HRQoL of patients in the MCID 
study (N=220)   
Instrument scales Baseline (T1) Follow-up (T2) Average change 




















8.6 (20.4) <0.001 
FACT-Cog 
domains/subscales 
      
Memory (0-28) 23.7 (3.9) 25.0 
(21.0-27.0) 
21.9 (4.7) 23.0 
(10.0-26.0) 
1.8 (4.5) <0.001 
Concentration (0-16) 13.7 (2.7) 14.0 
(12.0-16.0) 
12.6 (3.1) 13.5 
(10.0-15.0) 
1.1 (3.2) <0.001 
Mental acuity (0-16) 13.6 (2.6) 14.0 
(12.0-16.0) 
12.3 (3.2) 13.0 
(10.0-15.0) 
1.3 (3.1) <0.001 
Verbal fluency (0-24) 21.3 (3.2) 22.0 
(20.0-23.8) 
19.9 (4.1) 21.0 
(18.0-23.0) 
1.3 (3.7) <0.001 
Functional interference 
(0-16) 
13.7 (2.4) 14.0 
(13.0-15.0) 
13.1 (2.8) 14.0 
(11.3-15.0) 
0.6 (2.4) <0.001 
Multitasking ability  
(0-16) 
13.1 (2.6) 14.0 
(11.3-15.0) 
12.0 (3.4) 12.5 
(10.0-14.0) 
1.1 (3.2) <0.001 
Noticeability (0-16) 15.3 (1.7) 16.0 
(15.0-16.0) 
14.9 (2.1) 16.0 
(15.0-16.0) 
0.4 (2.1) 0.006 
Impact on quality of 
life (0-16) 
13.4 (3.7) 15.0 
(12.0-16.0) 
12.5 (3.9) 14.0 
(10.0-16.0) 
0.9 (4.4) 0.004 






7.7 (18.5) 0.001 
EORTC-CF: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 
Cognitive Functioning scale; FACT-Cog: Functional Assessment of Cancer Therapy – Cognitive Function; IQR: 
interquartile range; SD: standard deviation 






4.3.3 Anchored-based approach results 
There was a moderate correlation between the change scores of the FACT-
Cog and the EORTC-CF (r=0.43, p<0.001). The EORTC-CF-anchored MCID 
estimates are shown in Table 4.8. The FACT-Cog was markedly more responsive 
to deterioration than improvement, as demonstrated by ES of -0.66 for “minimally 
worse” versus an ES of <0.20 for “minimally better.” These ES represented 
moderate and negligible effects, respectively. The MCID for deterioration was 
actually statistically significant. A decrement of 9.6 points (95% CI: 4.4 to 14.8) 
in the FACT-Cog total score corresponded to a minimal important change, 
defined in the EORTC-CF. For improvement, an increase of 2.2 points (95% CI: -
5.8 to 10.3) in the FACT-Cog total score corresponded to a minimal important 
improvement in patients’ cognitive functioning, but statistical significance was 
not observed between the adjacent categories of “minimally better” and “no 
change”, as well as “much better” and “no change”. 
Table 4.8: Anchor-based (EORTC-CF) MCID estimates (N=220) 
EORTC-CF Category N Mean change (SD) MCID (95% CI) ES 
     
Much better 8 0.3 (13.2) 3.4 (-2.9 to 11.2) 0.006 
Minimally better 20 -0.1 (17.8) 2.2 (-5.8 to 10.3) -0.003 
No Change 109 -2.3 (16.5)  -0.127 
Minimally worse 56 -11.9 (14.8) -9.6 (-14.8 to -4.4) -0.658 
Much worse 27 -15.8 (16.6) -15.8 (-19.7 to -6.5) -0.897 
Bold: MCID and 95% CI indicate statistically significant differences between mean changes of FACT-Cog scores of 
adjacent categories. 
EORTC-CF: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 
Cognitive Functioning scale; ES: effect size; MCID: minimal clinically important difference; SD: standard deviation; 95% 






Consequently, a ROC analysis was only performed to identify an MCID 
estimate for deterioration (Figure 4.1). The AUC anchored by the EORTC-CF for 
all of the FACT-Cog change scores was 0.75 (95% CI: 0.67 to 0.82), suggesting 
that the FACT-Cog can fairly distinguish between patients who deteriorated and 
those who did not change on the EORTC-CF. The optimal MCID cut-off of 7.5 
points for deterioration in perceived cognitive functioning on the FACT-Cog 




Figure 4.1: Receiver operating characteristics curve for FACT-Cog change scores 
anchored by EORTC-CF. 
 
 
4.3.4 Distribution-based approach results 
The means for ⅓ SD and ½ SD produced MCID estimates that ranged from 
6.9 to 10.3 points (Table 4.9), respectively. The 1-SEM criterion resulted in an 
MCID estimate of 10.6 points for the FACT-Cog total score. 
Sensitivity: 75.6%  
Specificity: 68.8% 
























     
Baseline (T1) 18.1 6.0 9.1 9.3 
Follow-up (T2) 23.3 7.8 11.6 11.9 
Baseline to follow-up 20.4 6.8 10.2  
Mean 20.6 6.9 10.3 10.6 




4.3.5 Estimation of overall MCID and sub-domain MCIDs 
Estimation of the Overall MCID 
To account for the method-dependent and sample-dependent variations, it is 
recommended that a plausible range of MCIDs is presented, rather than an 
absolute single threshold.
386
 Thus, an MCID range was derived based on a 
combination of anchor- and distribution-based approaches. 
Collectively, the MCID estimates established using different approaches 
suggest that a decrease of 6.9 to 10.6 points (4.7 to 7.2% of the total score) in the 
FACT-Cog corresponds to the threshold for clinically significant cognitive 
deterioration in breast cancer patients. Dividing the MCID estimates by the 
number of items in the FACT-Cog yields an average of 0.19-0.29 points per item. 
 
Estimation of the Domain MCID 
Because the EORTC-CF anchor only consists of two items assessing the 
domains of memory and concentration, each domain-specific item was used as an 




domains of the FACT-Cog. A one-step change, corresponding to a 1-point 
difference on the domain-specific item, was considered a minimal significant 
change. Patients were categorised into the respective anchor-defined categories 
accordingly. 
The association between the change scores in the FACT-Cog memory 
domain and the memory-specific EORTC-CF anchor was moderate (r=-0.41, 
p<0.001), whereas for the FACT-Cog concentration domain, the observed change 
correlation was relatively weak (r =-0.27, p<0.001). Anchoring the deterioration 
scores of the FACT-Cog memory domain against the corresponding items in the 
EORTC-CF yields an MCID estimate of 3.2 points (95% CI: 1.9 to 4.5). For the 
FACT-Cog concentration domain, the threshold result was 1.8 points (95% CI: 
0.7 to 2.9). These MCID values translated to 11.4% and 11.3% of the domain 
ranges for the worsening of the memory and concentration domains, respectively. 
 
4.3.6 Discussion 
The primary significance of establishing an MCID for the FACT-Cog is to 
enhance the clinical interpretability of patient-reported cognitive changes. In 
addition to achieving statistical rigor, the outcome that is more practical in trials 
that evaluate cognitive endpoints is whether the decline in scores is clinically 
relevant. Concerning this research interest, one potential application of the MCID 
is to help investigators assess the clinical significance of the score differences 
observed between groups receiving different types or doses of chemotherapy 




proportion of patients experiencing clinically meaningful deterioration in each 
treatment arm can be meaningfully interpreted. Furthermore, knowledge of the 
MCID can also be used to guide sample size calculations in future trials. In 
designing a clinical trial, investigators may use a known MCID to estimate the 
minimum number of subjects needed in each study arm to detect a clinically 
significant change in cognition. 
The anchor- and distribution-based approaches complement one another, 
because they each possess advantages and disadvantages.
387
 Basing the MCID 
entirely on distributional approaches has been criticised as reflecting little clinical 
relevance in the change.
377,387,388
 Thus, it is recommended that an anchor-based 
estimate be given greater emphasis when determining the MCID because it is 
directly linked to patients’ perceptions of change.373,389 It was observed that the 
MCID estimates derived from ½ SD and 1 SEM were in close agreement with the 
EORTC-CF-anchored MCID, supporting the two distributional criteria to 
approximate the minimal threshold of clinically relevant change. The results also 
present important evidence demonstrating the responsiveness of the FACT-Cog to 
cognitive deterioration. The ES associated with “no change” (ES=-0.13), 
“minimally worse” (ES=-0.66), and “much worse” (ES=-1.79) corresponded to 
negligible, moderate, and large effects, respectively, indicating that the 
magnitudes of mean change scores were in the expected direction. 
The findings of previous studies illustrate the stability of MCID estimates 
for FACIT scales and subscales across patient populations.
371
 This consistency 




instruments. A rule of thumb for the MCID of the FACIT total scale is 0.15 to 
0.25 points per item and 4 to 6% of the instrument scale breadth.
371
 The MCID 
range identified in this study equates to 0.19 to 0.29 points per item and 4.7-7.2% 
of the instrument range, consistent with the guidelines. The FACT-Cog MCID 
range is also in line with a percentage change of 5 to 10% in the QLQ-C30 scales, 
which was proposed as a minimal clinically significant change.
351,379
 A 
remarkable convergence of MCID estimates on ½ SD or 6 to 7% of the 
instrument range across a variety of disease conditions and HRQoL measures was 
observed.
378
 In common with these findings, the EORTC-CF-anchored MCID 
was 6.5% of the total FACT-Cog score, further supporting the validity of our 
estimates. The degree of concordance between our results and the work of others 
is consistent with the notion that patients may be able to recognise a constant 
change using different instruments.
390
 
The MCID for the individual cognitive domains of the FACT-Cog was also 
determined. It is important to note that both of the MCID estimates for the 
memory and concentration domains were approximately 10% of the domain range, 
suggesting that this threshold of minimally significant difference may be 
extrapolated to other cognitive domains. The identification of domain MCIDs 
enables the interpretation of FACT-Cog score differences pertinent to individual 
cognitive domains, which may be useful in trials targeting the examination of 
specific cognitive domains. 
Available literature has asserted the presence of asymmetry between 
improvement and deterioration in patient-reported outcomes.
390-392




among patients with cancer, it was observed that MCID estimates for 
deterioration were larger than those for improvement across the subscales of the 
FACIT instruments.
390,392,393
 Although cognitive improvement did not achieve 
statistical significance in our study, the results showed similar tendency, 
suggesting that the meaningfulness of change is dependent upon the direction of 
change. For comparable EORTC-CF level, a larger degree of worsening is 
required to constitute clinical relevance than that of improvement. One 
explanation that has been postulated concerning the difference in meaning 
patients placed upon change, is associated with the response shift in individuals’ 
perceptions of change.
394
 The challenging ordeal of undergoing cancer therapy 
may have led patients to readjust their expectancies of perceived HRQoL in 
general. As observed in the previous focus group study (Chapter 3.2), many 
breast cancer patients have adopted self-help or compensatory strategies to cope 
with their cognitive changes, thereby attenuating the impact of perceived 
cognitive deterioration on their HRQoL. Taken together, we reason that this 
change in patients’ internal reference standards over time may have caused them 
to adaptively downplay the perceived impact of cognitive changes. 
 
4.3.7 Limitations of study 
A longitudinal anchor-based approach was adopted to assess the 
significance of cognitive changes within individuals over time. Objective 
neuropsychological instruments may provide readily interpretable scores. 




and objective cognitive dysfunction and this precludes objective measures as 
useful anchors for considering the possibility of underestimating the 
MCID.
87,102,395
 Thus, the psychometrically validated EORTC-CF was selected to 
prospectively measure the change in patients’ perceived cognitive status. The 
EORTC-CF consists of only two domain-specific items, regarding memory and 
concentration. Nonetheless, the anchor is deemed credible because these domains 
are clinically tied to the endpoint being evaluated. Patients’ judgment of change 
may be heavily influenced by the perception of their state at the follow-up point in 
time. Patients’ self-evaluation of cognition may have been guided by their pre-
existing knowledge of chemotherapy-associated cognitive changes, resulting in an 
overestimation of the cognitive deterioration they actually experienced.
322,323
 It is 
also noted that the time frame of assessment varied among patients, ranging from 
3 to 22 months. However, a clear trend in the magnitude and direction of score 
changes, with respect to time passed from baseline, was not observed. A 
minimum duration of 3 months between assessments was considered suitable to 
quantify a subtle yet important change. 
Some studies compare scores of the construct of interest to the patients’ 
answers to another subjective assessment for the purpose of evaluating patient-
reported outcomes, typically a global assessment rating in which the patients rate 
the status of that particular construct of interest as ‘‘better,’’ ‘‘unchanged,’’ or 
‘‘worse’’.373,388,396 Although this is a recommended approach by the United States 
Food and Drug Administration,
396
 a global rating assessment was not adopted in 




(Chapter 3.2), it was found that Asian breast cancer patients had difficulty 
comprehending what constitutes “cognitive functioning”. Chinese-speaking 
patients, in particular, had difficulties comprehending the terms “ren zhi gong 
neng” (the Chinese equivalent of “cognitive function”). Having considered this 
observation, it is decided that the use of global ratings is not the ideal within the 
context of our patient population. Moreover, global rating assessment is also 
limited by its unknown validity and reliability,
388
 and patients’ judgment of 
change in that particular construct (in this case, cognitive functioning) may be 
heavily influenced by the perception of other health status (such as physical 
functioning, pain and emotional functioning) at the follow-up point in time. 
However, it is recommended for future studies conducted on other cancer 
populations or ethnic groups, the use of a global rating assessment can be adopted. 
Lastly, we acknowledge that a drop-out rate of 33.3% for this study was 
considerably high, although attempts were made to contact those patients who had 
defaulted follow-up consultations or had declined to continue the study. This 
might cause a selection bias as patients who tended to be sicker or had poorer 
health states might tend to drop-out from the study.  
 
4.3.8 Summary of important findings 
To the best of our knowledge, this is the first reported study to establish an 
MCID for the FACT-Cog. Our findings suggest that a reduction of 6.9 to 10.6 
points on the FACT-Cog is the smallest difference that constitutes clinically 




two assessments reach 4.7-7.2% of the instrument range, the change can be 
considered clinically significant. No MCID estimate was established for cognitive 
improvement because the associated ES was too small (ES<0.2) to merit 
consideration and the number of patients demonstrated cognitive functioning 
improvement was too small in this study. Moreover, the outcome of clinical 
interest lies in the trajectory of cancer- or chemotherapy-associated cognitive 
deterioration and the resulting effect on cancer patients’ quality of life. 
It is believed that the identified estimates are clinically and 
methodologically valid because they were derived using a combination of 
approaches. A reasonable range for the MCID is provided and the estimates can 
be applied as a yardstick to aid in the interpretation of clinical relevance in 
patient-reported cognitive changes and sample size estimates for future studies. 
These estimates of meaningful difference will also provide further insights into 
the effect that cancer patients’ perceived cognitive deterioration has on their 




Chapter 5 – Cognitive disturbances in chemotherapy-receiving and non-
chemotherapy Asian breast cancer patients: A cross-sectional evaluation 
397
 
Thus far, we have established that among breast cancer patients, cognitive 
disturbances and psychosocial distresses are common psychological burden 
experienced by patients treated with chemotherapy. In the previous chapter, the 
psychometric properties of a neuropsychological tool, FACT-Cog, was evaluated. 
It is concluded that both the English and Chinese versions of FACT-Cog are valid, 
reliable and culturally acceptable among Asian breast cancer patients. The 
threshold of change for a clinically important change in perceived cognitive 
functioning on the FACT-Cog is also established.  
Pertaining to the contributors of cognitive changes, qualitative findings 
from Chapter 3.2 observed the significant impact of psychosocial distress on 
cognitive disturbances. Asian breast cancer patients portrayed chemotherapy as 
"potent" and "toxic", and they alleged “their brain cells were affected by 
chemotherapy”, leading to perceived cognitive disturbances. More importantly, 
patients perceived that cancer-related fatigue and anxiety have heavily contributed 
to their cognitive decline. Treatment-related mood changes, such as anxiety and 
depression, have affected them mentally, emotionally and psychologically.  
However, there is conflicting evidence on the effect of chemotherapy on 
psychosocial distress and cognitive changes in cancer patients. Furthermore, it has 
been proposed that interacting effects might exist among psychological, 
psychosocial and demographic factors,
300




effects may affect cognition have not been well expounded within existing 
psycho-oncology studies. 
This chapter aims to compare the severity of perceived cognitive 
disturbances in chemotherapy-receiving and non-chemotherapy receiving breast 
cancer patients. Through the use of the validated FACT-Cog, the research 
questions that this chapter will answer are: 
- Do Asian breast cancer patients who had received chemotherapy suffer 
from more severe perceived cognitive disturbances than breast cancer 
patients who did not? 
- What are the demographic, clinical and psychosocial factors associated 
with perceived cognitive disturbances in Asian breast cancer patients? 
 
It is anticipated that this study would provide an exploratory examination 
of the associated factors of perceived cognitive disturbances. As it is costly and 
resource- consuming to conduct large scale epidemiological studies, we propose 
that an initial evaluation of the associated factors through the use of a cross-
sectional study may provide directions for future cohort studies where baseline 
measurements of psychosocial and clinical variables can be conducted to 








Study design and setting 
This was a single-centred, cross-sectional, observational study conducted at 
the ambulatory clinics of NCCS. This study was approved by the CIRB and 
written informed consent was obtained from all participants.  
Patients 
All eligible patients must be: (1) diagnosed with breast cancer by a medical 
oncologist (Stages I to III), (2) above 21 years old, (3) have good performance 
status (defined as an ECOG score or 0 or 1), and (4) able to read and understand 
either English or Mandarin. Two groups of breast cancer patients were recruited 
in this study: one group consisted of patients who had received chemotherapy (CT) 
and another group consisted of patients who did not receive chemotherapy (non-
CT) group. Specifically, the CT arm consisted of patients who were receiving 
anthracycline-based chemotherapy at the point of recruitment or within the past 
one year. The non-CT arm was formed by eligible patients who did not have prior 
exposure to chemotherapy.  
Patients were excluded if they had brain metastasis, or were mentally 
incompetent to give informed consent.  
Study procedure 
Patients’ demographics and clinical information, such as cancer stage, 
ECOG performance, haemoglobin level at the point of recruitment and 




minute interview was privately conducted with the patient upon recruitment by 
trained investigators. During the interview, patients completed three sets of self-
reporting tools, available in both English and Chinese: 
Study tools 
i. FACT-Cog (version 3) 
Description of the FACT-Cog has been presented in the previous Chapter 4.1. 
ii. QLQ-C30  
Description of the QLQ-C30 has been presented in the previous Chapter 4.2.1. 
 
iii. BAI 
The BAI is a validated questionnaire comprising 21 self-reported anxiety-




Sample size calculation was conducted prior to initiation of this study. The 
QLQ-C30 reference manual showed that the mean score for EORTC-CF scale in 
breast cancer population was 81.5 (±22.5) points.
398
 In another study that 
evaluated the clinical significance of QLQ-C30 score changes, it was found that 
for patients who indicated "a little" change either for better or for worse, the mean 
change in scores was between 5 to 10 points.
379




significance level of α=0.05 and a power of 80% (β=0.20), a calculated sample 
size of 80 CT and 80 non-CT patients was needed to observe a 10-point difference 
of the QLQ-C30 cognitive functioning score between the 2 groups. 
Descriptive statistics were used to describe demographic and clinical 
characteristics of the sample. Comparison of baseline characteristics between CT 
and non-CT arms was conducted using independent-t test or Mann-Whitney-U-
test for continuous measures. Chi-square or Fisher’s exact tests were used for 
testing differences in categorical measures. Standard protocols provided by 
FACIT and EORTC were used to tabulate the total scores for FACT-Cog and 
QLQ-C30, respectively. Mann-Whitney-U-test was conducted to evaluate 
difference in QLQ-C30 cognitive functioning and FACT-Cog scores between CT 
and non-CT arms. All two-tailed significance tests were conducted using a 
significance level of p-value <0.05. 
The effect of associated factors on perceived cognitive functioning, which 
was depicted by the total FACT-Cog score, was evaluated using linear regression 
analysis. Documented clinically-relevant factors, such as age, menopausal status, 
baseline intelligence (education level as the surrogate marker), fatigue, anxiety 
and receipt of anti-hormonal therapy, were included in the linear regression 
analysis. 22,69,106,113,117,178,227,263-270 In order for other exploratory variables to be 
included in the linear regression model, it must be statistically significant at a cut-
off p-value of 0.1 in the univariate analysis and considered clinically-relevant, 




adopted to prevent detraction from the statistical power by including clinically-
irrelevant variables in the model.  
Exploratory univariate analysis was also applied to identify potential 
statistically significant and clinically-relevant interacting variables that might be 
associated with perceived cognitive functioning. The pairs of variables involved 
in the exploratory analysis were: (1) fatigue and anxiety, (2) fatigue and 
chemotherapy status (defined as currently receiving chemotherapy at the time of 
recruitment), (3) anxiety and chemotherapy status, (4) post-menopausal status and 
fatigue, and (5) fatigue and haemoglobin level at the point of 
recruitment.
10,70,102,106,250
 To reduce collinearity in the regression model, the 
interacting terms that showed statistical significance on univariate analysis were 
entered into the regression model using mean deviations based on the following 
formula:       ̅̅ ̅        ̅̅ ̅ , where   and    represent two interacting 
independent variables. Residual analysis and collinearity diagnostics were 
performed to ensure the validity of the linear regression model. All statistical 
analyses were performed using the SPSS version 20.0. 
 
5.2 Baseline characteristics of patients 
Baseline characteristics of patients 
A total of 166 patients participated in the study, including 85 CT patients 
and 81 non-CT patients. Baseline characteristics are presented in Table 5.1. 




Patients in the non-CT group were older relative to the CT patients (54.1±10.2 
versus 51.0±9.2 years; p=0.042). Statistically significant differences were not 
observed among the demographics and clinical characteristics, including race, 
education level, menopausal status and ECOG status, with the exception that the 
non-CT patients possessed a higher mean haemoglobin level than CT patients 
(12.7±1.5 g/dl versus 11.5±1.3 g/dl; p<0.0001). There were more Stages I and II 
breast cancer patients among those who did not receive chemotherapy (84.0% 
versus 48.2%; p=0.012). Majority of the CT patients had completed 





Table 5.1: Baseline characteristics of chemotherapy-receiving and non-
chemotherapy-receiving patients (N=166) 
 





 Demographic information 
  
Frequency (%) Frequency (%)  
Age (in years) Mean ±SD 51 ±9.2 --- 54.1 ±10.2 --- 0.042 
Education  
(in years) 
Mean ±SD 9.7 ±4.3 --- 9.7 ±3.6 --- 0.760 
Education  
(in levels) 
None 4 (4.7) 3 (3.7) 0.640 
Primary (Elementary) 22 (25.9) 17 (21)  
 Secondary (Junior high) 35 (41.2) 42 (51.9)  
 Pre-University (Senior high) 8 (9.4) 8 (9.9)  
  Graduate/post-graduate 16 (18.8) 11 (13.6)  
Race Chinese 65 (76.5) 66 (81.5) 0.630 
 Indian 1 (1.2) 2 (2.5)  
 Malay 14 (16.5) 7 (8.6)  
  Others 5 (5.9) 6 (7.4)  
Marital Status Single 19 (22.4) 8 (9.9) 0.047 
 Married 57 (67.1) 66 (81.5)  
 Divorced 8 (9.4) 3 (3.7)  
 Widowed 1 (1.2) 4 (4.9)  
Medical information 
  
Frequency (%) Frequency (%)  
Cancer staging 0 0 0 2 (2.5) 0.043 
 I 11 (12.9) 26 (32.1)  
 II 30 (35.3) 42 (51.9)  
 III 34 (40) 8 (9.9)  
  IV 10 (11.8) 3 (3.7)  
ECOG 
2
 0 59 (69.4) 64 (79.0) 0.280 
 1 26 (30.6) 17 (21.0)  
Anti- hormonal 
treatment 
Receipt of anti-hormonal 
treatment 
59 (69.4) 2 (2.5) 0.012 
Menopausal 
status 
Post-menopausal 46 (54.1) 43 (53.1) 0.850 
Chemotherapy 
status 
Completed  59 (69.4)    
Still receiving 26 (31.7)    
Chemotherapy 
regimens 
AC-based 64 (75.4) --- --- --- 
FEC-based 15 (17.7)    





Mean ±SD 11.5±1.3 --- 12.7±1.5 --- <0.0001 
Bold: Denotes statistical significance at p<0.05  
 
AC-based: doxorubicin and cyclophosphamide-based; ECOG: Eastern Cooperative Oncology Group; FEC-based: 5-
flurouracil, epirubicin and cyclophosphamide- based; SD: standard deviation 
 




Health related- quality of life 
Statistical differences of the QLQ-C30 scores were not detected between the 
CT and non-CT patients, with the exception of the cognitive functioning scale, 
fatigue scale and dyspnoea (Table 5.2). Non-CT patients reported better 
perceived cognitive functioning than CT patients (100.0 versus 83.3 points; 
p<0.001). The median score for the QLQ-C30 cognitive functioning score was 
100 for the non-CT patients, indicating that a significant proportion of non-CT 
patients perceived that they had an intact cognitive function (Table 5.2). CT 
patients experienced considerably more fatigue than non-CT patients, as observed 
by the moderately large difference of 10.1 points in the median QLQ-C30 fatigue 
scale (33.3 versus 22.2 points; p=0.005).  
 
Anxiety 
Patients in this study manifested varying degree of anxiety states (Figure 
5.1). Overall, CT patients experienced more anxiety-related symptoms than the 
non-CT patients. Patients in the CT group achieved a higher median BAI score 
(9.5 versus 5 points, p<0.001) than those patients in the non-CT group. It is also 
noted that more CT patients experienced moderate to severe anxiety, as compared 
to the non-CT group (21.9% versus 8.6%; p=0.002). With regards to the BAI 
subscales, CT patients reported marginally more anxiety-related panic, 
















































Severity of anxiety 
Chemotherapy-receiving arm (n=82  ) Non-chemotherapy-receiving arm (n=81)
Scoring range: 






Table 5.2: Comparison of quality of life and anxiety between chemotherapy-













     
Cognitive 2 83.3 (66.7-100.0) 100.0 (83.3-100.0) <0.001 
Emotional 2 83.3 (66.7-91.7) 83.3 (66.7-95.8) 0.197 
Physical 2 86.7 (76.7-93.3) 86.7 (80.0-93.3) 0.281 
Role 2 100 (83.3-100.0) 100 (83.3-100.0) 0.501 
Social 2 100 (66.7-100.0) 83.3 (66.7-100.0) 0.905 
Global health status2 66.7 (50.0-83.3) 66.7 (58.3-83.3) 0.262 
Fatigue 3 33.3 (11.1-44.4) 22.2 (11.1-33.3) 0.005 
Nausea & vomiting 3 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.669 
Pain 3 16.7 (0.0-33.3) 16.7 (0.0-16.7) 0.096 
Appetite 3 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.415 
Constipation 3 0.0 (0.0-33.3) 0.0 (0.0-0.0) 0.138 
Diarrhoea 3 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.819 
Dyspnoea 3 0.0 (0.0-33.3) 0.0 (0.0-0.0) 0.005 
Financial 3 33.3 (0.0-66.7) 33.3 (0.0-66.7) 0.638 
Insomnia 3 33.3 (0.0-66.7) 0.0 (0.0-33.3) 0.183 
BAI      
Total score 3 9.5 (4.0-14.3) 5.0 (2.0-8.0) <0.001 
Autonomic  1.0 (0.0-3.0) 0.0 (0.0-1.0)  
Neuropsychological  2.0 (1.0-5.0) 1.0 (0.0-2.0)  
Panic  1.0 (0.0-6.0) 0.0 (0.0-2.0)  
Subjective  3.0 (0.0-6.0) 2.0 (0.0-5.0)  
FACT-Cog      
Total score 4 110.0 (94.5-121.5) 124.0 (113.5-129.0) <0.0001 
Perceived cognitive 
impairment 
63.0 (51.5-68.0) 68.0 (63.0-71.0) 
 
Comments from others 16.0 (14.0-16.0) 16.0 (15.6-16.0)  
Perceived cognitive 
abilities 
21.0 (16.0-23.5) 25.0 (21.0-28.0) 
 
Impact on quality of life 14.0 (10.5-16.0) 13.5 (13.5-16.0)  
BAI: Beck Anxiety Inventory; EORTC-CF: European Organization for Research and Treatment of Cancer Quality of 
Life Questionnaire Core 30 Cognitive Functioning scale; FACT-Cog: Functional Assessment of Cancer Therapy – 
Cognitive Function; IQR: interquartile range 
1Maximum score for all EORTC-QLQ-C30 subscales is 100 
2A higher score is indicative of better functioning/health status 
3A higher score is indicative of more symptoms/difficulties. Maximum total score is 63 





5.3 Comparison of severity of cognitive disturbances in chemotherapy-
receiving and non-chemotherapy-receiving breast cancer patients 
Generally, CT patients reported more perceived cognitive disturbances than 
non-CT patients (Figure 5.2). The median FACT-Cog scores for the CT patients 
were 14 points lower than the non-CT group (110 versus 124 points; p<0.0001). 
This 14 points difference exceeds the FACT-Cog MCID of 6.9 to 10.6 points, 
indicating that it has surpassed the minimal threshold of a small but important 
difference. Analysis of the FACT-Cog subscales revealed that “perceived 
cognitive impairment”, “reduced cognitive abilities” and poorer cognitive-
impairment associated quality of life were more prevalent in CT patients (Table 
5.2). 
Figure 5.2: Comparison of FACT-Cog total scores between CT and non-CT 
patients (N=166)  
 







































5.4 Factors associated with cognitive disturbances 
On univariate analysis, perceived cognitive disturbances was significantly 
correlated with anxiety (r=-0.58; p<0.0001), fatigue (r=-0.36; p<0.0001), QLQ-
C30 global health status (r=0.47; p<0.0001), QLQ-C30 emotional functioning 
(r=0.52; p<0.0001) and QLQ-C30 cognitive functioning scale (r=0.77; p<0.0001). 
Higher levels of anxiety and fatigue were associated with more perceived 
cognitive disturbances. Although patient specific parameters such as age, 
menopausal status, fatigue and educational status were documented in the 
literature as clinically-relevant predictors, they did not correlate with perceived 
cognitive functioning in our analysis. Patients who were receiving anti-hormonal 
therapy reported more cognitive disturbances than those who did not receive anti-
anti-hormonal therapy (p=0.011). There were not any statistically significant 
associations between perceived cognitive disturbances and staging of the cancer, 
ECOG status, type of chemotherapy regimen (AC-based versus FEC-based), type 
of anti-hormonal therapy (tamoxifen versus aromatase inhibitors) and patients’ 
chemotherapy treatment status (completed chemotherapy versus currently 
receiving chemotherapy).  
Exploratory univariate analysis also identified two pairs of interacting 
variables. Results showed that a significant interacting effect was observed 
between anxiety and fatigue (F=13.47; p<0.0001), and a weaker interacting effect 
between fatigue and haemoglobin level (F=9.32; p=0.048). No statistically 




Associated factors of perceived cognitive functioning were explored using a 
linear regression modelling (Table 5.3). The total variance explained by the linear 
regression model was 65.3%.  
 
Table 5.3: Factors associated with perceived cognitive functioning (N=166) 
 




















     
  Age  
 
-0.09 0.05 -0.14 0.20 -0.06 0.73 
  Years of education 
 
0.03 0.17 -0.42 0.25 0.04 0.23 
Clinical and pharmacological factors: 
 
     
  Haemoglobin level 
 
-0.32 2.45 -1.30 1.45 -0.02 0.56 
  Post-menopausal status 
 
-1.17 1.09 -2.43 2.37 -0.12 0.33 
  Receipt of 
chemotherapy 
 
-8.74 2.45 -9.40 -4.21 -0.24 0.0001 
  Received anti-hormonal 
  treatment 
 
-5.23 2.10 -7.11 -0.21 -0.13 0.021 
Psychosocial factors: 
 
     
  Anxiety (BAI total 
score) 
 
-0.40 0.18 -0.76 -0.05 -0.17 0.037 
  QLQ-C30 Emotional  
  functioning 
  
0.21 0.07 0.06 0.36 0.22 0.002 
  QLQ-C30 Global health 
status 
 
0.18 0.19 0.016 0.28 0.11 0.034 
  QLQ-C30 Fatigue scale 
 
-0.03 0.23 -0.18 0.02 -0.07 0.59 
  Interaction between 
fatigue and anxiety 
  
-0.87 0.01 -0.930 -0.00 -0.29 0.037 
  Interaction between 
fatigue and haemoglobin 
level 
 
-0.01 0.03 -0.07 0.06 -0.02 0.82 





5.4.1 Pharmacological factors associated with cognitive disturbances 
Results suggested that there was an 8.74-point (95% CI: -9.40 to -4.21) 
decrease in FACT-Cog total score in a patient who was exposed to chemotherapy, 
as compared to a patient who was not (p<0.0001). This 8.74-difference falls 
within the MCID range of 6.9 to 10.6, which indicates that the receipt of 
chemotherapy is associated with a clinically significant worse perceived 
functioning, as compared to non-CT patients.  Notably, our findings were in 
contrast with another Asian study which explored the trajectory of perceived 
attentional function from before to 24 months after surgery in 200 Chinese breast 
cancer patients.
90
 It was observed that the mean baseline AFI score was high at 
8.2 (out of a total score of 10 points) and dropped at 1 month after surgery to 6.5. 
After adjusting for covariates, perceived attentional function was not associated 
with adjuvant treatment (p=0.721). However, this study was also limited by a 
small sample size for each treatment modality. 
Concurring with current evidence, our results identified the receipt of anti-
hormonal therapy to be strongly associated with perceived cognitive disturbances 
(B=-5.23, CI: -7.11 to -0.21; p=0.021). One study detected more severe perceived 
cognitive functioning and attentional problems at work in breast cancer patients 
who had been exposed to tamoxifen or aromatase inhibitors, than those who had 
never had any exposures.
260
 Tamoxifen has been advocated as the gold standard 
of anti-hormonal treatment over the past few decades.
399
 Recently, a large 
randomised controlled trial, the Arimidex, Tamoxifen, Alone or in Combination 




as the first-line anti-hormonal therapy for postmenopausal HR-positive breast 
cancer patients.
400
 The receipt of anastrozole has been associated with very low 
levels of circulating oestrogen in breast cancer patients, hence this might be 
expected to result in cognitive dysfunction given the important relationship 
between oestrogen and cognition in the basic science literature.
260,401,402
 However, 
conflicting evidence suggests that aromatase inhibitors have less neurocognitive 
effects on patients than tamoxifen.
248,260,315,401,402
 This is a topic of significant 
value as breast cancer patients who have oestrogen receptors positive cancer cells 
typically receive anti-hormonal therapy. There was no difference in the FACT-
Cog scores observed between patients who received tamoxifen and aromatase 
inhibitors (data not presented). Unfortunately, the sample size of patients who 
were on either anti-hormonal treatment was too small to make a meaningful 
conclusion. Future studies can be targeted at evaluating if aromatase inhibitors are 
indeed associated with less perceived cognitive impairment in breast cancer 
patients.  
 
5.4.2 Demographic and clinical factors associated with cognitive 
disturbances 
Interestingly, several documented clinically-relevant demographical and 
clinical characteristics were not identified to be significant in the regression 
model. Age, menopausal status, educational status and patients’ most recent 
haemoglobin level failed to reach statistical significance after adjusting for other 




age and pretreatment cognitive reserve were related to post-treatment decline in 
processing speed in women exposed to chemotherapy.
97
 Anaemia, particularly a 




It is postulated that the major reason why such deviations from current 
evidence have occurred was because these associations were concluded by studies 
that utilised objective neuropsychological tools and a longitudinal study design to 
detect changes in cognitive functioning. 
 
5.4.3 Psychosocial factors associated with cognitive disturbances 
Psychosocial factors included anxiety, emotional functioning and global 
health status. Although the association between perceived cognitive functioning 
and fatigue alone was not identified to be statistically significant, the interaction 
effect between anxiety and fatigue was found to be moderately associated with 
perceived cognitive disturbances, relative to fatigue alone (β=-0.293; p=0.037 vs. 
β=-0.071; p=0.59, respectively). 
These results suggested that psychosocial factors can play a significant role 
in self-perceived cognitive disturbances. There is strong evidence in the literature 
to support determinants such as psychological distress and cancer-related fatigue 
as predictors for perceived cognitive functioning.
102,395
 However, in this study, the 
severity of fatigue was not associated with perceived cognitive disturbances in the 




This deviation from current evidence can be explained by the large proportion of 
patients who were relatively young, ambulating, early-stage disease, did not suffer 
from clinically-significant anaemia (mean haemoglobin level of 11.5±1.3 g/dl) 
and were not expected to suffer from significant fatigue. Therefore, in the 
presence and influence of other factors in the model, fatigue was not flagged out 
to be statistically significant. However, our results suggested that a breast cancer 
patient who suffered from both cancer-related fatigue and anxiety might have a 
higher risk of suffering from perceived cognitive disturbances. The interacting 
effects between fatigue and anxiety were strongly associated with perceived 
cognitive deficits even though the main effects of both anxiety and fatigue alone 
were not. Due to an insufficiently-powered sample size, we could not eliminate 
the possibility that this piece of finding might be spurious and due to chance. 
However, qualitative results from the focus group study (Chapter 3.2) with 43 
local breast cancer patients did reveal that patients identified anxiety and fatigue 
as top contributing factors to their post-chemotherapy cognitive changes. The 
interacting effect between anxiety and fatigue should be further explored in future 
studies. 
Chemotherapy treatment is shown to cause a negative impact on patients’ 
psychological status, as reflected in the higher levels of anxiety experienced by 
CT patients. This is one of the few studies that utilised BAI to evaluate cancer 
patients’ anxiety symptoms. Albeit only marginal differences in total BAI and 
subdomain scores were detected between the two groups, anxiety could have 




outcomes. One review had demonstrated that elevated anxiety and psychological 
distress in breast cancer women even prior to cancer diagnosis and were strongly 
associated with HRQoL, anxiety, depressive symptoms, and fatigue after cancer 
treatment, and they often exist as a symptom cluster.
106
 Contrary to what was 
expected, patients’ HRQoL aspects did not differ much between the CT and non-
CT groups. This might be due to response shift, which involved changes in the 
internal standards, values and the conceptualisation of HRQoL observed in cancer 
survivors.
394
 Notably, majority of our CT patients who had completed 
chemotherapy might have been the cancer survivors who were responsible for this 
adaptive process. Therefore, a baseline measurement is essential in accurate 
assessment of the effects of chemotherapy on psychological and HRQoL changes. 
Unfortunately, the cross-sectional design of this study did not allow for 
comparison of changes in psychological distress and perceived cognitive 
disturbances within individual patients across different time-points of their 
treatments. It is anticipated that future cohort studies will provide more insights to 
the clinical course of these psychological distress parameters in cancer patients. 
 
5.5 Limitations of study 
Information bias might pose a potential problem to this study as patients 
who had received chemotherapy might be more critical of their cognitive status 
due to effects of priming and pre-existing knowledge of cognitive impairment in 
cancer patients.
322,323
 To note, it is acknowledged that the CT and non-CT differed 




staging and haemoglobin levels. Hence the difference in the severity of perceived 
cognitive disturbances might have been confounded by these factors as they might 
potentially influence patients’ choice to receive or decline chemotherapy 
treatment. Therefore, the strategic choice of using a regression model in this study 
had overcome this limitation by offering a valuable insight on the effect of these 
factors on perceived cognitive functioning, in the presence of other independent 
variables. However, we do recommend that these findings must be interpreted 
with caution as the sample size for this study was powered primarily to detect 
differences in the perceived cognitive disturbances between CT and non-CT 
patients. Therefore, the sample size might not be sufficiently powered for the 
linear regression mode; this might explain why several documented clinically 
relevant variables did not show statistical significant in the multivariate analysis.  
Evidence from the literature has proposed that other factors, such as 
depression, sleep disturbances, emotional distress, lack of physical activity and 
family support, may contribute to cognitive impairment.
10,69,104,192,403-405
 However, 
these other factors that may potentially affect cognition were not evaluated in this 
study as it would require more comprehensive questionnaires and detailed 
interviews. As this study was conducted in an ambulatory setting, the issue of 
“respondent fatigue” from lengthy questionnaires was a major consideration as it 
might compromise the response rate and the quality of the data collected. 
Nevertheless, the inclusion of these factors in future studies may improve our 




Lastly, the cross-sectional design of this study provided an exploratory 
examination of associated factors of perceived cognitive disturbances. Future 
cohort studies with baseline measurements of psychosocial and clinical variables 
should be conducted to explore the casual relationships between these variables 
and perceived cognitive disturbances.  
 
5.6 Summary of important findings 
This chapter sought to delineate the effects of chemotherapy on the severity 
of perceived cognitive disturbances and psychological distress in a sample of 
Asian breast cancer patients. This is one of the first published studies that 
evaluated perceived cognitive disturbances among Asian breast cancer patients. 
Concurring with current evidence, fatigue and psychological distress such as 
anxiety and perceived cognitive disturbances are relevant among Asian breast 
cancer patients. Other than the receipt of chemotherapy, factors associated with 
perceived cognitive disturbances included concomitant receipt of anti-hormonal 
therapy, poor emotional functioning and poor global health status. More 
importantly, our results are novel because we have successfully explored the 
interacting effects of psychosocial factors that are associated with perceived 
cognitive disturbances. The combination effects of anxiety and fatigue were 
identified to impact patients’ perceived cognitive disturbances more strongly than 
each of the individual effect alone.  
In order to further validate these findings, the next phase of this thesis 




subjective and objective neuropsychological assessments to quantify the 
prevalence, severity and impact of this problem in Asia, and to identify its clinical, 




Chapter 6 –Prevalence, severity and determinants of cognitive changes in 
Asian breast cancer patients – A prospective cohort study  
With the aid of a validated subjective neuropsychological tool, we have 
established that Asian breast cancer patients who had received chemotherapy 
experienced more cognitive disturbances than non-chemotherapy receiving breast 
cancer patients in a cross-sectional study. However, based on literature review 
(Chapter 1) and guidelines from the International Cognition and Cancer Task 
Force, it is recommended that a longitudinal, prospective setting is the most 
appropriate study design to test the association between post-chemotherapy 
cognitive impairment and its determinants. Furthermore, the use of both objective 
and subjective neuropsychological tools is needed to evaluate the clinical 
presentation of objective cognitive changes and perceived cognitive disturbances 
that cancer patients experience.  
It is of paramount importance to evaluate the determinants of cognitive 
changes. This will enable clinicians to identify patients who may be at-risk for 
chemotherapy-associated cognitive changes. In Chapter 5, the preliminary cross-
sectional study has found that other than the receipt of chemotherapy, factors 
associated with perceived cognitive disturbances included concomitant receipt of 
endocrine therapy, poor emotional functioning and poor global health status. 
Fatigue and psychosocial characteristics, such as anxiety, are associated with 
cognitive disturbances. However, due to the cross-sectional nature of the study 
design, the relationship between the change in cognitive functioning and the 




Hence, this chapter involves a longitudinal cohort study that was designed 
to answer the following primary research questions: 
i. What are the prevalence, severity and presentation of cognitive impairment 
detected by the objective computerised neuropsychological tool 
(Headminder™) in Asian breast cancer patients? 
ii. What are the prevalence and severity of perceived cognitive changes detected 
by the subjective neuropsychological tool (FACT-Cog)? 
iii. What are the clinical, psychosocial and pharmacological factors as 
determinants associated with objective cognitive changes among the Asian 
population of breast cancer patients? 
iv. What are the clinical, psychosocial and pharmacological factors as 
determinants associated with subjective cognitive changes among the Asian 
population of breast cancer patients? 
The secondary research questions were: 
i. Are there differences in the prevalence, severity and presentation of objective 
cognitive impairment in Asian breast cancer patients who received 
chemotherapy and those who did not? 
ii. Are there differences in the prevalence, severity and presentation of subjective 
cognitive impairment in Asian breast cancer patients who received 
chemotherapy and those who did not? 
iii. Is there any correlation/relationship between specific domains of subjective 




6.1 Methodology  
Study design and settings 
This was a prospective cohort study conducted at NCCS and KK Women’s 
and Children’s Hospital (KKH) between December 2011 and October 2013. The 
study was approved by the CIRB and written informed consent was obtained from 
all participants.  
Patients 
Eligible patients for the chemotherapy group (CT) were approached if they 
were (1) newly diagnosed with breast cancer by a medical oncologist (within 12 
weeks of diagnosis), (2) post-surgery, (3) had no prior exposure to chemotherapy, 
(4) prescribed with standard adjuvant anthracycline-based or taxane-based 
chemotherapy, (5) ambulatory in nature and having good performance status 
(defined as having an ECOG score of 0 or 1), (6) capable of giving informed 
consent and (7) could speak either English or Chinese.  
Non-chemotherapy (non-CT) group consisted of patients who fulfilled the 
following criteria: (1) newly diagnosed with breast cancer or ductal carcinoma in 
situ (DCIS) by a medical oncologist (within 12 weeks of diagnosis), (2) post-
surgery, (3) had no prior exposure to chemotherapy and would not be receiving 
chemotherapy treatment, (4) ambulatory in nature and having good performance 
status (defined as having an ECOG score of 0 or 1), (5) capable of giving 




Patients were excluded from the study if breast cancer was a secondary 
malignancy, or if they exhibited evidence of brain metastasis, psychosis or any 
underlying neuropsychiatric illness that might impair their cognitive abilities. 
Study procedure 
Data collection was performed at three time-points at an interval of 
approximately six weeks each (Table 6.1). Figure 6.1 depicts pictorially the time-
points of assessments for both CT and non-CT patients. For CT patients, the first 
time-point (T1) was conducted at baseline, within 12 weeks of diagnosis, before 
the patients received chemotherapy. The second time-point (T2) was timed to 
occur approximately 6 weeks after T1 which also coincided with Cycle 3 of 
chemotherapy. The third time-point (T3) was conducted approximately 12 weeks 
after T1 upon the completion of standard chemotherapy.  
For non-CT patients, T1 was conducted at baseline, within 12 weeks of 
diagnosis. T2 was timed to occur between 6 to 12 weeks after T1. Lastly, T3 was 
conducted 6 to 12 weeks after T2.  
There is currently limited evidence in the literature to recommend a definite 
time frame for neuropsychological assessments. The above time-points of 
assessment were chosen due to the following reasons: (1) to capture the transient 
changes in cognitive function over the course of treatment from baseline to the 
completion of chemotherapy; (2) to minimise practice effects associated with 
neuropsychological tests; (3) to match the timing of assessments with patients’ 











Table 6.1: Study schema of cohort study on cognitive changes in Asian breast cancer patients 
Chemotherapy- receiving (CT) Non-chemotherapy receiving (non-CT) 
 Time of measurement Rationale  Time of measurement 
Time-
point T1: 
At baseline – measured within 12 weeks of 
diagnosis of breast cancer and prior to the 
receipt of Cycle 1 of chemotherapy 
 




At baseline – within 12 weeks of 
diagnosis of breast cancer (without 




Measured at the end of cycle 2 of AC/ EC/ 
FAC/ FEC/ TC  
 
Approximately 6 weeks from Time-point T1 
This serves as 
measurement of cognitive 








Measured at 3 weeks after cycle 4 (last cycle) 
of AC/ EC/ FAC/ FEC/ TC 
 
Approximately 6 weeks from Time-point T2 
This serves as the 
measurement of cognitive 
function immediately after 




Approximately 6 to 12 weeks from time-
point T2* 
T: Time-point 
AC: Doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) 
EC: Epirubicin (75mg/m2), cyclophosphamide (600mg/m2) 
FAC: Doxorubicin (50mg/m2), cyclophosphamide (500mg/m2) and fluorouracil (500mg/m2) 
FEC: Epirubicin (75-100mg/m2), cyclophosphamide (500mg/m2) and fluorouracil (500mg/m2) 
TC: Docetaxel (75mg/m2) and cyclophosphamide (600mg/m2)  
* Operational and feasibility issues with the study procedure did not allow for a comparable interval between assessments for patients and non-CT patients. The intended duration between 
each time-point was 6 weeks, because CT patients were scheduled for standard chemotherapy treatment at the study site every 3 weeks, it was methodologically feasible for 
neuropsychological tests to be conducted at regular intervals. However, it was not feasible to perform standardised follow-up with the non-CT patients because their follow-up consultations 

































Time-point T1  
 








( 6 to 12 weeks)* Time-point T2 (6 to 12 weeks)* 
 
Time-point T3 
1The first time-point (T1) was conducted at baseline, within 12 weeks of diagnosis, before the patients received chemotherapy.  
  The second time-point (T2) occurred approximately 6 weeks after T1 which also coincided with Cycle 3 of chemotherapy.  
  The third time-point (T3) was conducted approximately 12 weeks after T1 upon the completion of standard chemotherapy. 
2At each time-point, patients completed a computerised neuropsychological battery (Headminder™), the Functional Assessment of Cancer Therapy-Cognitive, EORTC-QLQ-C30, Brief 
Fatigue Inventory and Beck Anxiety Inventory. 
3 A 10ml tube of blood was drawn at each time-point for the chemotherapy patients (Analysis is presented in Chapter 7).  
4 The first time-point (T1) was conducted at baseline, within 12 weeks of diagnosis. 
  The second time-point (T2) occurred 6 to 12 weeks after T1  
  The third time-point (T3) was conducted 6 to 12 weeks after T2 
* Operational and feasibility issues with the study procedure did not allow for a comparable interval between assessments for patients and non-CT patients. The intended duration between 
each time-point was 6 weeks, because CT patients were scheduled for standard chemotherapy treatment at the study site every 3 weeks, it was methodologically feasible for 
neuropsychological tests to be conducted at regular intervals. However, it was not feasible to perform standardised follow-up with the non-CT patients because their follow-up consultations 
with the oncologists varied greatly depending on the condition of their health
Baseline assessment Follow-up assessment 1 Follow-up assessment 2 
 








At T1, baseline demographic data, such as age, race, employment status and 
educational level, was collected. Patients’ medical and medication history such as 
the presence of commodities, concurrent medications and chemotherapy regime 
was also retrieved from existing electronic databases and through patient 
interviews. At each time-point of data collection, patients completed both 
objective and subjective neuropsychological assessments and a set of 
questionnaires to assess their HRQoL, fatigue and anxiety symptoms. All data 
collection tools were available in English or Chinese and were administered by 
trained bilingual interviewers. 
 
Study tools 
i. Objective neuropsychological assessment: Headminder™ 
The Cognitive Stability Index (CSI) by Headminder™ is a validated objective 
computerised web-based neuropsychological battery for examining patients’ 
cognitive domains of processing speed, response speed, memory and attention in 
patients. The advantages of utilizing computerised neuropsychological assessment 
are listed in the previous Chapter 1.5.1 (Table 1.5). Specific to this study, 
Headminder™ is an appropriate choice of neuropsychological tool as our Asian 
breast cancer patients are multi-ethnic. A small proportion of patients may be 
illiterate or do not understand English. The non-language dependent nature of 
Headminder™ test is an eminent advantage over traditional neuropsychological 
tools. Furthermore, as Headminder™ can record and analyse responses of the 





patients’ cognitive performances. There are multiple forms of subtests examining 
the same domain to prevent practice effect. Test-retest reliability of the subtests 
ranges from 0.68 to 0.80 and the concurrent validity with traditional 
neuropsychological tests such as the Trail Making A and B Test, the written 
Symbol Digit Modalities Test, Symbol Search, Buschke Selective Reminding 
Test, and Digit Span, were well established in the literature for the cognitive 
domains of memory, attention, processing speed and response speed.
216
 In another 
independent study conducted by researchers in Canada, the CSI was compared to 
other cognitive screenings in a group of 31 cancer patients who received adjuvant 
chemotherapy.
255
 The CSI was found to be sensitive to cognitive impairment in 
this group, valid for non-English speakers, highly accepted by patients, and more 
accurate in classifying patients compared to the High Sensitivity Cognitive 
Screening test, a paper-pencil screening test.
255
  
A training session was conducted with all investigators to standardise the 
bilingual administration procedures prior to the inception of the study. A pilot 
study was also performed on a heterogeneous sample of 20 breast cancer patients 
with varying educational levels, race and age. Based on this pilot study, the 
instructions and administration procedure were modified and refined.  
 
ii. FACT-Cog (version 3) 
FACT-Cog was used to evaluate patients’ perceived or subjective cognitive 







The QLQ-C30 was used to assess HRQoL in cancer patients. Description of the 
QLQ-C30 has been presented in the previous Chapter 4.2.1. 
iv. Brief Fatigue Inventory (BFI) 
BFI is a 9-item instrument that utilises a single-item fatigue numeric scale to 
evaluate patients’ fatigue severity and interference.406 An 11-point Likert-type 
scale from 0 (“no fatigue” or “does not interfere”) to 10 (“fatigue as bad as you 
can imagine” or “completely interferes”) was used to assess the rate of fatigue 
experienced by patients for the past 1 week. The mean BFI score is tabulated with 
a score range of 0 to 10. Patients are classified into no fatigue (score of 0), mild 
fatigue (score of 1 to 3), moderate fatigue (score of 4 to 6) and severe fatigue 
(score of 7 or more). The BFI was found to have a high internal consistency with 





The BAI is a validated questionnaire comprising 21 self-reported anxiety-




All statistical analyses were performed using the SPSS version 20. 





characteristics of the sample. Standard protocols provided by developers were 
used to tabulate the total scores for FACT-Cog, QLQ-C30, BFI and BAI 
respectively.  
As baseline differences between the 2 groups might account for the 
difference in cognitive functioning, comparison of baseline characteristics 
between the CT and non-CT arms was conducted using independent-t test or 
Mann-Whitney-U-test for parametric and non-parametric continuous measures, 
respectively. Chi-square or Fisher’s exact tests were used for testing differences in 
categorical measures. As it was documented in the literature that anxiety, fatigue 
and HRQoL changes may affect cognitive functioning,64,65,104,105,250,251 patients’ 
QLQ-C30, BFI and BAI scores were compared over the three time-points, using 
repeated measures ANOVA or Friedman’s test for parametric and non-parametric 
continuous measures, respectively. Post-hoc tests were conducted to evaluate the 
differences between two separate time-points, using the Bonferroni corrected p-
values. 
 
i. Objective cognitive impairment within individual breast cancer patients 
For the evaluation of cognitive changes within individual breast cancer patients, a 
reliable change index (RCI) was computed for Headminder™ scores based on 
repeated normative mean and standard error of the difference to adjust for practice 
effect calculated from the reference group. The RCI compares the change in 
individual test scores with changes in a reference group to determine if the change 
is greater than would be expected by measurement error alone.
408





by subtracting the score for the baseline T1 and practice effect from the second 
assessment T2 and then dividing by the standard error of the difference in the 
reference population. The degrees of changes in the individual cognitive domains 
were defined based on: (1) an RCI of higher than -1.5 as “no change”; (2) an RCI 
ranging from -1.5 to -2.5 as “mild impairment” and (3) an RCI of lower than -2.5 
as “severe impairment”. Overall, patients who suffered from mild or severe 
impairment in the domains of attention or memory were classified as experiencing 
“cognitive impairment”. This method of evaluating cognitive changes on 
objective neuropsychological tests has been widely adopted by numerous studies 




ii. Subjective cognitive impairment within individual breast cancer patients 
For the evaluation of perceived cognitive changes within individual breast cancer 
patients, a drop of 10.6 points in the total FACT-Cog score was considered as 
perceived cognitive impairment. This definition is adopted as based on the 
predetermined MCID of FACT-Cog in our cancer patients; it was found that a 
reduction of 6.9 to 10.6 points on the FACT-Cog corresponded to a significant 
deterioration in perceived cognitive functioning (Chapter 4.3). A more 
conservative and stricter value of 10.6 was chosen in order to minimise the 
possibility of identifying a false-positive case. As for FACT-Cog 
subdomains/subscales, a reduction of 10.0% of the subdomain/subscale scores is 






Comparison of group differences in the FACT-Cog scores across the three time-
points was conducted using repeated measures ANOVA or Friedman’s test for 
parametric and non-parametric continuous measures, respectively. Post-hoc tests 
were conducted to evaluate the differences between two separate time-points, 
using the Bonferroni corrected p-values. A graphical approach in the form of a 
box-plot was used to summarise the changes in FACT-Cog scores.  
 
iii. Identifying the clinical/pharmacological/psychosocial determinants of 
objective and subjective cognitive functioning 
Linear mixed models were used to determine factors that are associated 
with objective and subjective cognitive impairments. The analyses were 
conducted for the dependent variables which were the Headminder™ scores of 
the four cognitive domains: processing speed, response speed, memory and 
attention. For subjective cognitive changes, the dependent variables referred to the 
total FACT-Cog scores.  
Using linear mixed modelling method in the identification of determinants 
for cognitive functioning has a number of advantages over traditional statistical 
approaches such as repeated measures analysis of variance.
409
 Linear mixed 
modelling does not automatically exclude every patient from the analysis who has 
a missing data and hence preserving the statistical power. This technique is 
suitable for analysis of repeated measurements and naturally handles uneven 





correlated data. Mixed models can also be extended to non-parametric data and 
account for the effect of time on the dependent variables. 
Aiming to minimise the number of independent variables in the final linear 
mixed model, as a first step, univariate analysis was conducted to examine the 
association between dependent variables and all other variables that might 
confound an association of the dependent variables. Here, dependent variables 
refer to the Headminder™ scores of the individual four objective cognitive 
domains and the FACT-Cog total score for subjective cognitive functioning. 
The independent variables are presented in Table 6.2. They were subjected 
to univariate analysis as there were documented evidence in the literature or 
consensus by clinical experts of the research team that there are potential 
associations between these variables and cognitive functioning. Univariate 
analysis was conducted using independent t-test and Mann-Witney U tests, for 
parametric and non-parametric comparison of scores between two independent 
groups of interest, respectively; ANOVA and Kruskal Wallis tests for parametric 
and non-parametric comparison of scores between three or more independent 
groups of interest, respectively; Pearson and Spearman correlation for parametric 





Table 6.2: List of independent variables that may be associated with 
objective/subjective cognitive functioning (exploratory univariate analysis) 
 





Years of education1 
Body mass index 
Race (Chinese vs. Malay vs. Indian vs. others) 
Employment status (Employed vs. unemployed/medical leave) 
Clinical
38,51,52135,253
 Breast cancer stage (Stages 0 and 1 vs. 2 and 3) 
Haemoglobin level 
ECOG performance status (0 vs. 1) 
Presence of comorbidities (yes vs. no) 
Menopausal status (pre- vs. post-menopausal) 
Surgical treatment (mastectomy vs. lumpectomy) 
Pharmacological
76,80,98,248,249
 Receipt of chemotherapy
3 (yes vs. no) 








EORTC-Global quality of life 
EORTC-Emotional functioning 
EORTC- Physical functioning 
EORTC- Social functioning 
EORTC-Role functioning 
EORTC- Insomnia 
1These factors were not subjected to factor selection as there is extensive evidence in literature to support their effect on 
objective cognitive functioning. 
2These factors were not subjected to factor selection as there is extensive evidence in literature to support their effect on 
subjective cognitive functioning. 
3These factors were not subjected to factor selection for both objective and subjective cognitive functioning as they are 
related to the research questions of interest. 
 
Age and years of education were not subjected to factor selection for 
objective cognitive functioning as these factors have been shown from the 
literature to affect Headminder™ scores.106,114 Fatigue and anxiety, as well as the 





predictors for perceived cognitive functioning (Chapter 5), hence they were also 
decided a prior to be included into the model.64,65,69,102,104,105,250-252 The interaction of 
time with receipt of chemotherapy (yes. vs no) and types of chemotherapy 
(anthracycline- vs. taxane- based) were also not subjected to factor selection as 
they were related to the research questions of interest.  
Finally, a linear mixed modelling using an unstructured covariance structure 
was built using factors that were shown to have an association with the dependent 
variables at significance level of p-value <0.1 on univariate analysis. A p-value of 
<0.1 instead of p-value <0.05 was chosen to reduce the risk of excluding a 
potentially relevant variable.   
 
iv. Association between objective and subjective cognitive changes 
Spearman’s correlation was conducted to evaluate the strength of the relationship 
between changes in self-reported cognitive domains of FACT-Cog (mental acuity, 
memory, concentration, multi-tasking, verbal ability and functional interference 
with activities of daily living) and objective Headminder™ cognitive 
performances (attention, memory, processing speed and response speed). 
 
Sample size determination 
Sample size was determined based on the FACT-Cog estimates obtained 
from the previous cross-sectional study presented in Chapter 5 and the MCID 





80% power at the 0.05 level of significance, a targeted recruitment goal of 101 
patients for each arm was needed to detect a difference of 6.9 points on the 
FACT-Cog across three time points of assessment, assuming that the correlation 
of the repeated measure, ρ, is 1.0.  A stricter estimate of 6.9 was selected to ensure 
that the study is adequately powered to detect a small to moderate difference in 
subjective cognitive functioning.   
 
 
6.2 Baseline characteristics of patients 
Patients’ characteristics 
A total of 233 eligible newly-diagnosed breast cancer patients were 
approached, of which 152 patients were recruited (acquisition rate of 65.2%). 
There were 19 patients (17 CT and 2 non-CT) who were lost to follow up 
primarily due to reasons such as ill health, loss of interest and time constraint 
(Drop-out rate of 14.2%) (Figure 6.2). Overall, 133 patients (105 CT patients and 
28 non-CT patients) completed all three time-points of assessment (Table 6.3).   
The mean age (±SD) of the CT patients was 50.4±8.4 years. Majority of 
patients were Chinese (80.0%) early-stage breast cancer patients. Patients 
generally received secondary school or higher level of education (87.6%) and 
were married (72.4%). Most of the patients received anthracycline-based 
chemotherapy (65.7%).  
The mean age of the non-CT patients was 51.7±10.8 years. Majority of 





generally received secondary school or higher level of education (82.1%) and 
were married (75.0%).  
Not surprisingly, the distribution of cancer staging between the two groups 
of patients was different; there was a higher proportion of CT patients with later 
stages of breast cancer (Stages II and III), compared to non-CT patients 
(p<0.0001). CT patients received more years of education than non-CT controls 
(p=0.048). Majority of the non-CT patients were employed and working at the 
point of recruitment, as compared to CT patients who were either unemployed or 
on medical leave (p=0.005). It was also interesting to note that the baseline body 
mass index (BMI) of the non-CT patients was lower than CT patients (p=0.007). 
A substantial proportion of non-CT patients (78.5%) were receiving anti-
hormonal treatment and radiation therapy at the point of recruitment; notably, 
approximately one-fourth of the non-CT patients were treated concurrently with 
both treatments. Majority of the CT patients received mastectomy as surgical 
treatment (69.5%), while non-CT patients commonly received lumpectomy 
(57.1%) instead (p=0.014). There were no other statistically significant 
differences between the two groups in other demographic or clinical 
characteristics such as age, marital status, presence of comorbidities and baseline 
haemoglobin level. 
Due to operational and logistics issues related to the study procedure, the 
length of time between assessments were different for the CT and non-CT groups; 
the duration between assessments was longer for the latter group for both T1-T2 





Figure 6.2: Patient disposition flowchart for the cohort study 
 
  Eligible patients were approached at the clinics of 
National Cancer Centre Singapore and KK Women’s 
and Children’s Hospital  
(N=233) 
Not recruited due to the following reasons: 
(N=81) 
 
 Did not express interest. 
 Objection from family members. 
 Time constraint. 
 
Chemotherapy group  
Recruited into the study 
(N=122) 
Non-chemotherapy group  
Recruited into the study  
(N=30) 
Chemotherapy group 
Patients that completed 
the study  
(N=105) 
Non-chemotherapy group  




Lost to follow up due to 
the following reasons: 
(N=17) 
 
 Tiredness (N=6) 
 Lost interest (N=4) 
 Time constraint (N=2) 
 Received treatment in 
another cancer 
institutions (N=2) 




Lost to follow up due to 
the following reasons: 
(N=2) 
 
 Loss of interest 
(N=1) 


















Frequency (%) Frequency (%) p-value 
Age (years) Mean ±SD 
 
50.4 (8.4) 51.7 (10.9) 0.513 





13 (12.4) 5 (17.9) 0.048 
Secondary 
(Junior high) 











20 (19.0) 6 (21.4) 
 
Race Chinese 84 (80.0) 24 (85.7) 0.745 
 
Malay 12 (11.4) 3 (10.7)  
 





5 (4.8) 1 (3.6) 
 
Marital status Single 22 (21.0) 6 (21.4) 0.653 
 
Married 76 (72.4) 21 (75.0)  
 
















Frequency (%) Frequency (%) 
p-value 
Cancer staging DCIS 0 (0.0) 13 (46.4) <0.0001 
 I 23 (21.9) 9 (32.1)  
 




31 (29.5) 0 (0.0) 
 













Yes 38 (36.2) 8 (28.6) 0.451 
Mean duration 










 Chemotherapy group 
(n=105) 
Non-chemotherapy 




Frequency (%) Frequency (%) p-value 
Surgery 
treatment 










































Mean ±SD 12.6 (1.3)  12.6 (1.1)  0.932 





Mean ±SD 24.7 (4.4)  22.2 (3.2)  0.007 
Methodological  information 
 











46.7 (7.1)  56.3 (15.1)  0.049 
Between T2 and 
T3 
Mean ±SD 
47.1 (9.8)  75.3 (22.7)  0.001 
Bold: Denotes statistical significance at p<0.05 
ECOG: Eastern Cooperative Oncology Group; SD: standard deviation; NA: not applicable 
1Mean duration from time of diagnosis is refers to the difference (in number of weeks) between date of diagnosis of breast 
cancer or ductal carcinoma in situ and T1 date of assessment  
2 Chemotherapy regimens are defined in Table 6.1 
3 Majority of non-CT patients (88.9%) received tamoxifen 20mg daily, as anti-hormonal treatment 
4 Mediastinal radiation therapy is administered at 1.8 - 2 Gray fractions per session over 5 to 6 weeks  
5 Statistical comparisons between CT and non-CT groups were not conducted because none of the CT patients received 
anti-hormonal and radiation therapies during the study period  
6 Mean duration between assessments refers to the difference (in number of days) between T1 date of assessment and T2 






Changes in HRQoL, fatigue and anxiety in the CT group  
Patients’ global HRQoL differed across the three time-points (p=0.003), of 
which patients reported the poorest health status upon the completion of 
chemotherapy at T3 (Table 6.4). Based on the QLQ-C30, a significant worsening 
of the perceived cognitive functioning was observed (p<0.0001); the drop from 
T1 to T2 was the most significant (92.0±14.2 vs 86.7±16.9; p<0.0001). A change 
of social functioning (p=0.034) and symptoms such as insomnia (p=0.001), loss 
of appetite (p=0.005), constipation (p<0.0001) and dyspnoea (p=0.003) were 
noted from the start to the completion of chemotherapy (Table 6.4). 
The most severe degree of fatigue was observed at T3 upon the completion 
of chemotherapy, as compared to T1 and T2 on both the QLQ-C30 fatigue scale 
and BFI (p<0.0001 and 0.001, respectively). On the QLQ-C30 fatigue scale, 
patients’ overall fatigue score increased by approximately 10 points from T1 to T3 
(24.4±16.1 vs 35.5±21.2; p<0.0001). 
Patients experienced mild anxiety throughout their chemotherapy treatment, 






Table 6.4: Changes in HRQoL, fatigue and anxiety in the CT patients across the 
course of chemotherapy treatment (N=105) 
 
  T1 T2 T3  
 Mean  (SD) Mean  (SD) Mean (SD) p-value 
EORTC-QLQ-C30     
Global QoL1 Global health 
status 
74.3 (17.0) 69.2 (20.5) 67.2 (18.9) 0.003 
Functional 
scales 1 
Physical 87.7 (14.6) 86.4 (13.8) 82.8 (16.3) 0.009 
 Role 86.4 (21.2) 84.3 (20.6) 82.1 (22.3) 0.073 
 Emotional 82.5 (18.7) 84.9 (16.5) 83.7 (16.9) 0.154 
 Cognitive 92.0 (14.2) 86.9 (16.7) 83.7 (19.5) 0.0001 
 Social 83.5 (20.9) 78.9 (22.8) 78.9 (23.6) 0.034 
Symptom 
scales 2 
Fatigue 24.4 (16.2) 29.6 (21.2) 35.5 (21.2) <0.0001 
Nausea and 
vomiting 
2.3 (7.1) 9.9 (17.5) 8.7 (16.5) <0.0001 
 Pain 15.0 (18.4) 19.1 (21.1) 20.8 (23.3) 0.146 
Single items 2 Dyspnoea 7.8 (15.7) 12.8 (18.8) 14.3 (20.6) 0.003 
Insomnia 23.2 (26.5) 32.1 (31.5) 29.8 (29.2) 0.001 
 Appetite 10.1 (20.3) 17.3 (23.7) 18.1 (24.0) 0.005 
 Constipation 5.9 (12.8) 18.6 (26.6) 15.6 (23.6) <0.0001 
 Diarrhoea 2.0 (7.9) 5.1 (15.2) 7.6 (15.5) 0.005 
 Financial 
 
34.0 (35.7) 25.6 (30.9) 25.1 (32.0) 0.027 
Brief Fatigue Inventory     
 Total
3 1.4 (1.6) 2.1 (2.0) 2.6 (9.7) 0.001 
Beck Anxiety Inventory     
 Total4 6.5 (6.2) 8.1 (7.3) 8.2 (7.4) 0.159 
Bold: Denotes statistical significance at p<0.05. Follow-up tests (not-shown in this table) were conducted to evaluate the 
differences between individual groups, using the Bonferroni corrected p-value of 0.0167 to denote statistical significance.  
 
1A higher score is indicative of better functioning/health status. Maximum score for all EORTC-QLQ-C30 subscales is 100. 
2A higher score is indicative of more or worse symptoms. Maximum score for all EORTC-QLQ-C30 subscales is 100. 
3A higher score is indicative of more severe fatigue. Maximum total score for BFI is 10. 






Changes in HRQoL, fatigue and anxiety in the non-CT group 
From T1 to T3, non-CT patients did not report significant changes in their 
HRQoL, fatigue and anxiety (Table 6.5). However, it is important to note that the 
sample size may be too small to detect any statistical differences in the scores 
over the 3 time points.  
Table 6.5: No change in HRQoL, fatigue and anxiety in the non-CT patients 
(N=28) 
 
  T1 T2 T3  
 Mean  (SD) Mean  (SD) Mean (SD) p-value 
EORTC-QLQ-C30     
Global QoL
1
 Global health 
status 
75.6 (19.7) 75.6 (18.1) 75.0 (17.3) 0.529 
Functional 
1
 Physical 88.9 (17.8) 89.1 (9.8) 89.1 (13.2) 0.817 
 Role 85.8 (21.5) 83.3 (19.3) 88.9 (19.6) 0.538 
 Emotional 79.6 (19.0) 79.5 (24.5) 81.8 (20.2) 0.650 
 Cognitive 87.0 (14.9) 82.7 (15.4) 82.7 (19.9) 0.230 





Fatigue 25.9 (15.1) 27.8 (18.5) 21.4 (19.7) 0.223 
Nausea and 
vomiting 
1.2 (6.4) 3.0 (9.1) 0.0 (0.0) 0.174 
 Pain 14.8 (18.1) 8.3 (14.0) 11.1 (17.9) 0.327 
Single items 
2
 Dyspnoea 7.4 (16.9) 11.9 (18.6) 8.6 (14.9) 0.433 
Insomnia 22.2 (33.3) 22.6 (27.3) 24.7 (28.6) 0.472 
 Appetite 9.9 (18.1) 4.8 (11.9) 3.7 (10.7) 0.150 
 Constipation 12.4 (21.0) 11.9 (22.6) 11.1 (20.7) 1.000 
 Diarrhoea 2.5 (8.9) 2.4 (8.7) 4.9 (15.2) 0.646 
 Financial 14.8 (25.0) 10.7 (18.3) 11.1 (18.5) 0.723 
Brief Fatigue Inventory     
 Total
3 1.5 (1.5) 1.3 (1.5) 1.5 (1.5) 0.097 
Beck Anxiety Inventory     
 Total4 5.9 (6.6) 6.0 (7.1) 4.6 (4.6) 0.870 
1A higher score is indicative of better functioning/health status. Maximum score for all EORTC-QLQ-C30 subscales is 100. 
2A higher score is indicative of more or worse symptoms. Maximum score for all EORTC-QLQ-C30 subscales is 100. 
3A higher score is indicative of more severe fatigue. Maximum total score for BFI is 10. 












6.3 Prevalence and severity of post-chemotherapy cognitive changes by 
objective measures 
Overall, as compared to baseline T1, memory (31.5%) and attention (30.7%) 
impairments were prevalent after the completion of chemotherapy (Table 6.6). 
Overall impairment in the domains of processing speed (6.8%) and response 
speed (19.1%) was less significant.  
Notably, the declines in response speed and memory were the most 
apparent from T2 to T3 (27.6% and 26.7%, respectively). Overall from T1 to T3, 
there were approximately one-tenth of the patients who suffered from severe 
impairment in the memory domain.  
The proportion of patients with their corresponding number of impaired 
domains is presented in Figure 6.3. A total of 38 patients (36.2%) did not have 
significant changes in their cognitive function on the Headminder™. However, 
majority of the patients suffered from impairment in one or two of the cognitive 
domains (43.8% and 17.1%, respectively).   
Figure 6.3: Proportion of patients with objective impairments in cognitive 






Table 6.6: Prevalence and severity of post-chemotherapy objective cognitive 
changes as detected by Headminder™ in the CT group (N=105) 
 





 From T1 to T2* From T2 to T3* Overall 





3 (2.9) 7 (6.7) 4 (3.9) 
Severe 
impairment 2 
2 (1.9) 2 (1.9) 3 (2.9) 
Total 
3
 5 (4.8) 9 (8.6) 7 (6.8) 
 
Response speed Mild 
impairment 1 
9 (8.6) 21 (20.0) 17 (16.2) 
Severe 
impairment 2 
1 (1.0) 8 (7.6) 3 (2.9) 
Total 
3




14 (13.3) 21 (20.0) 22 (21.0) 
Severe 
impairment 2 
10 (9.5) 7 (6.7) 11 (10.5) 
Total 
3




19 (18.1) 19 (18.1) 26 (24.8) 
Severe 
impairment 2 
3 (2.9) 1 (1.0) 6 (5.9) 
Total 
3
 22 (21.0) 20 (19.1) 32 (30.7) 
 
* The mean (SD) duration between T1 and T2 was 46.7 (7.1) days. 
  The mean (SD) duration between T2 and T3 was 47.1 (9.8) days. 
  The mean (SD) duration between T1 and T3 was 93.8 (13.1) days. 
1 Defined as a reliable change index of -1.5 to -2.5  
2 Defined as a reliable change index of lower than -2.5  







6.4 Prevalence and severity of post-chemotherapy perceived cognitive 
changes by subjective measures 
Across all time-points, there was a statistically significant difference in the 
perceived cognitive functioning (p=0.005) (Table 6.7). Over time, CT patients 
reported gradually decreasing scores from T1 to T3, with the lowest mean score at 
125.6±18.9 points. Post-hoc analysis showed that overall from T1 to T3, there was 
a statistically significant reduction of FACT-Cog score by 6.0 points (p=0.006). 
In particular, overall changes in perceived mental acuity (p<0.0001), memory 
(p=0.013) and concentration (p=0.002) were also evident. 
Based on the MCID of FACT-Cog, a total of 43 patients (41.0%) were 
classified as having an overall clinically-significant perceived cognitive 
impairment. Self-reported lapses in memory (29.5%), mental acuity (30.5%) and 






Table 6.7: Prevalence and severity of post-chemotherapy subjective cognitive 



























14.2 (2.3) 13.7 (2.7) 13.1 (2.9) <0.0001 32 (30.5) 
 Concentration 
(0-16) 
14.1 (2.4) 13.7 (2.6) 13.2 (2.6) 0.002 18 (17.1) 
 Memory      
(0-28) 
24.7 (3.6) 24.4 (3.4) 23.4 (3.9) 0.013 31 (29.5) 
 Verbal ability 
(0-24) 




14.1 (2.1) 14.0 (2.1) 13.8 (2.1) 0.494 11 (10.5) 
 Multi-task   
(0-16) 
13.7 (2.5) 13.5 (2.8) 13.0 (2.9) 0.305 35 (33.3) 
Subscales Noticeability 
(0-16) 
15.4 (1.5) 15.4 (1.2) 15.2 (1.6) 0.404  
 Quality of life 
(0-16) 
13.7 (4.0) 13.3 (4.1) 13.0 (3.7) 0.020  
1. Based on the minimal clinically important difference of FACT-Cog, a drop of 10.6 points in the total FACT-Cog score 
was considered as a significant perceived cognitive impairment. 
2. Based on the minimal clinically important difference of FACT-Cog domain, a drop of 10.0% in the FACT-Cog domain 







6.5 Comparison of prevalence of cognitive changes in chemotherapy-
receiving patients and non-chemotherapy receiving controls 
This section aims to compare the prevalence of both objective and 
subjective cognitive impairment in CT patients and non-CT controls.  
Table 6.8 presents the proportion of patients with objective cognitive 
impairment on Headminder™ in both groups. Surprisingly, the proportion of 
patients who suffered from objective cognitive impairment was comparable 
between both groups. Similar to the CT patients, impairments in the controls’ 
memory (31.2%) and attention (46.4%) were more prevalent than in the domains 
of processing speed (3.6%) and response speed (17.9%). To note, overall 
impairment in the attention domain was higher in the non-CT group (46.4%), as 
compared to the CT group (30.7%).  
A change in perceived cognitive functioning was not observed in non-CT 
patients. However, it is interesting that the CT patients reported consistently 
higher FACT-Cog scores than non-CT patients across all three time-points, 
indicating that the non-CT controls experienced more cognitive disturbances than 
CT patients (Figure 6.4). In particular, at T2, the median FACT-Cog score 








Table 6.8: Comparison of prevalence and severity of objective cognitive 
impairment in CT and non-CT patients (N=133) 
 














4 (3.9) 1 (3.6) 
Severe 
impairment 2 
3 (2.9) 0 
Total 
3
 7 (6.8) 1 (3.6) 
Response speed Mild 
impairment 1 
17 (16.2) 4 (14.3) 
Severe 
impairment 2 
3 (2.9) 1 (3.6) 
Total 
3
 20 (19.1) 5 (17.9) 
Memory Mild 
impairment 1 
22 (21.0) 5 (17.9) 
Severe 
impairment 2 
11 (10.5) 4 (14.3) 
Total 
3
 33 (31.5) 9 (31.2) 
Attention Mild 
impairment 1 
26 (24.8) 10 (35.7) 
Severe 
impairment 2 
6 (5.9) 3 (10.7) 
Total 
3
 32 (30.7) 13 (46.4) 
* The mean (SD) duration between T1 and T3 was 93.8 (13.1) days for the chemotherapy group, and 107.6 (81.3) days for 
the non-chemotherapy group. 
1 Defined as a reliable change index of -1.5 to -2.5  
2 Defined as a reliable change index of lower than -2.5  








Figure 6.4: Comparison of subjective cognitive changes in CT and non-CT 






































     FACT-Cog total score at Time-point T1 
     FACT-Cog total score at Time-point T2 
     FACT-Cog total score at Time-point T3 
     Refers to within-group comparison of FACT-Cog total score across the 3 different time-points 
     (Wilcoxon signed-rank test, Bonferroni corrected p-values presented in blue) 
 
     Refers to between-group comparison of FACT-Cog total score at the 3 different time 






6.6 Determinants of objective cognitive changes 
6.6.1 Univariate analysis on the association between demographic/clinical 
/pharmacological/psychosocial factors and Headminder™ domain 
scores  
Univariate analysis revealed that age was significantly associated with both 
processing speed (rs=-0.149; p=0.092) and attention (rs=-0.266; p=0.002) scores. 
Years of education correlated moderately with all four cognitive domains 
(rs=0.185 to 0.417; all p<0.05), suggesting higher education level may be 
associated with better cognitive functioning on objective measures. Interestingly, 
baseline BMI was also negatively associated with processing speed (rs=-0.250; 
p=0.004), response speed (rs=-0.141; p=0.100) and attention (rs=-0.175; p=0.047) 
scores. Patients who were post-menopausal performed worse on attention test 
than pre-menopausal patients (p=0.042). Comparing with patients who had Stages 
I and II breast cancers, patients with Stage III cancer had the lowest memory 
(p=0.076) and response speed (p=0.093) scores. Lastly, patients with concurrent 
comorbidities had poorer processing speed (p=0.049) and attention (p=0.091) 
performances. Univariate analysis did not identify any significant relationship 
between objective cognitive functioning and other demographic or clinical factors 
such as ECOG performance status, race and haemoglobin level. 
 As for pharmacological factors, there was overall no difference in objective 
cognitive scores between CT patients and non-CT controls (p=0.199 to 0.809, 
across all four cognitive domains). However, within the CT patients, patients 





processing speed (p=0.082) and attention (p=0.065), as compared to patients 
receiving taxane-based regimens.  
 In terms of psychosocial variables, fatigue correlated weakly with memory 
scores (rs=-0.158; p=0.077). Univariate analysis also suggested that more severe 
anxiety was associated with worse processing speed (rs=-0.152; p=0.090).   
Therefore, for the subsequent identification of determinants of objective 
cognitive impairment, the covariates: age, BMI, years of education, cancer staging, 
and types of chemotherapy regimens, fatigue and anxiety, were adjusted in all 
analyses.   
 
6.6.2 Linear mixed model results on the determinants of objective cognitive 
functioning 
 Demographic, clinical, psychosocial and pharmacological characteristics, 
that were pre-identified as factors associated with objective cognitive functioning 
in the univariate analysis, were included in the linear mixed model. Four linear 
mixed models were built for the cognitive domains of processing speed, response 
speed, memory and attention.  
Analyses suggested that performance on the majority of domains of 
cognitive functioning was the worst at T3, upon the completion of chemotherapy 
(Table 6.9). For processing speed, response speed and memory domains, the 
effect of the interaction between time of assessment and receipt of chemotherapy 





significantly worse at T2, as compared to the non-CT patients. However, the 
overall effect of time on cognitive performances was not statistically significant 
for all 4 domains. This might be so as the sample size might not be adequately 
powered to detect the effect of these interacting terms.  
Educational level was a strong predictor of all four cognitive domains of 
processing speed, response speed, memory and attention. Older age was 
associated with worse response speed and attention performance. Interestingly, 
baseline BMI was a determinant for attention performance but not in the other 
cognitive domains. The mixed model results for each cognitive domain are briefly 
discussed in the following section: 
 
Processing speed  
A higher education status (Estimate 1.254; 95% CI: 0.890 to 1.612; 
p<0.0001) was found to be a statistically significant predictor of better process 
speed performance. At T2, the interaction between time and receipt of 
chemotherapy was associated with 0.567 reduction in processing speed scores 
(p=0.013). Poorest processing speed was found in CT patients at T3 (Estimate: -
3.021; 95% CI -9.223 to 3.181; p=0.328). However, this was not statistically 
significant. 
As for psychosocial factors, both anxiety and fatigue are predictive of 













Table 6.9: Estimates and standard errors as a function of clinical, pharmacological and psychosocial determinants, time of 
assessment, and interaction between CT/non-CT group and time of assessment (N=133) 
 
Parameter Estimate of parameter (standard error) 
 Processing speed Response speed Memory Attention 
Time of assessment 
 
 p=0.585  p=0.046  p=0.344  p=0.267 
Time-point 1 0  0  0  0  
Time-point 2 -0.658 (1.120) -4.267* (2.128) -2.443 (2.371) -0.514 (1.887) 
Time-point 3 -3.220 (1.260) -2.529 (1.931) -2.548 (2.401) -1.008 (1.921) 
         
Interaction between time of 
assessment and receipt of 
chemotherapy 
 
 p=0.180  p=0.757  p=0.555  p=0.208 
Time-point 1 and control 0  0  0  0  
Time-point 2 and control 0.242 (1.839) -2.247 (2.975) 0.544 (3.790) 4.567 (3.153) 
Time-point 3 and control -0.145 (1.386) -0.381 (0.861) -1.116 (3.240) 1.891 (3.266) 
Time-point 1 and chemo -1.574 (1.386) -0.390 (1.391) 2.420 (1.772) 0.094 (0.540) 
Time-point 2 and chemo -0.567* (0.215) -3.848* (1.524) -3.645* (4.290) -1.259 (1.465) 













Parameter Estimate of parameter (standard error) 
 Processing speed Response speed Memory Attention 
Intercept 94.218** (5.856) 80.850** (10.666) 79.774** (11.894) 112.609** (10.278) 
Clinical determinants: 
 
        
Age -0.042 (0.066) -0.376** (0.121) 0.159 (0.135) -0.322* (0.116) 
Years of education 1.254** (0.183) 0.663* (0.329) 1.276** (0.366) 1.331** (0.318) 
Baseline body mass index -0.057 (0.139) -0.108 (0.254) -0.017 (0.283) -0.564* (0.244) 
Pharmacological determinants: 
 
        
Non-chemotherapy receiving 1.028 (1.880) 0.109 (3.364) 0.953 (4.137) 9.568* (3.273) 
Anthracycline-based 
chemotherapy 
-1.338 (1.301) -1.793 (2.365) -4.078* (2.631) -0.299* (2.279) 
Psychosocial determinants: 
 
        
Anxiety -0.443** (0.112) -0.082 (0.203) -0.037 (0.226) -0.150 (0.195) 
Fatigue -2.211** (0.443) 0.547 (0.807) 0.271 (0.900) 1.168 (0.779) 
* denotes statistical significance at p<0.05 






Response speed  
Age (Estimate -0.376; 95% CI: -0.615 to -0.137; p=0.002) and education 
level (Estimate 0.663.; 95% CI: 0.012 to 1.314; p=0.046) were demographic 
factors that predicted cognitive impairment in response speed. However, 
education level was not a statistically significant factor. At T2, CT patients were 
expected to have a 3.848 reduction in response speed scores (p=0.013). However, 




For memory, years of education was the only demographic factor that might 
have a protective effect against cognitive impairment; patients who were more 
highly educated were associated with better objective memory performance 
(Estimate 1.276; 95% CI: 0.554 to 1.998; p=0.001). However, age and BMI were 
not statistically significant factors. The interaction between time and receipt of 
chemotherapy were significant predictors for memory performance. At T2, CT 
patients was associated with the lowest memory score (Estimate -3.645; 95% CI: -
12.207 to -1.917; p=0.045). Patients who received anthracycline-based 
chemotherapy were expected to have lower score than taxane-based 
chemotherapy recipients (Estimate -4.078; 95% CI: -6.300 to -1.111; p=0.037). 
Anxiety and fatigue were not statistically significant associated factors for 







For attention, years of education, baseline BMI and age were found to be 
predictors for objective attention performance (p=0.001, 0.034 and 0.013, 
respectively). Overall, non-CT patients performed better than CT patients; the 
former scored 9.568 points higher on the Headminder™ attention test (p=0.008). 
However, after taking into account the effect of time of assessment, CT patients 
were expected to have a 2.412 reduction in attention scores at T3 (p=0.027); the 
interaction between time and receipt of chemotherapy was statistically significant. 
Among CT patients, anthracycline-based chemotherapy recipients had marginally 
worse attention impairment than taxane-based chemotherapy regimen (p=0.048). 
Anxiety and fatigue were not predictors of attention performance (Table 6.9).  
 
In summary, the interaction between time and receipt of chemotherapy was 
found to be predictors for all four domains. In particular, CT patients had 
statistically poorer performances on processing speed, response speed and 
memory at T2, which referred to the mid-chemotherapy time-point. At T3, 
attention performance was worst in CT patients. We acknowledge that these 
findings must be interpreted with caution as the main effect of time alone was not 
found to be statistically significant.  
Among patients who received chemotherapy, lower memory and attention 
scores were found in anthracycline-based chemotherapy recipients, as compared 
to patients who underwent taxane-based chemotherapy regimens. As for clinical 





cognitive domains of processing speed, response speed, memory and attention. 
Older age was associated with worse response speed and attention performance. 
Interestingly, baseline BMI was a determinant for attention performance but not 
the other cognitive domains. 
Lastly, psychosocial factors of anxiety and fatigue predicted processing speed 
impairment but not the other cognitive domains of response speed, memory and 





6.7 Determinants of subjective cognitive changes 
6.7.1 Univariate analysis on the association between 
demographic/clinical/pharmacological/psychosocial factors and 
subjective cognitive functioning 
Interestingly, univariate analysis did not identify any significant relationship 
between subjective cognitive functioning and other demographic factors such as 
age, years of education, ECOG performance status, race, menopausal status and 
haemoglobin level (all p>0.100). 
 As for pharmacological factors, there was a marginal difference in total 
FACT-Cog scores between chemotherapy-receiving patients and controls that did 
not receive chemotherapy (p=0.094). There was no statistical difference between 
patients who received anthracycline-based chemotherapy regimens and those who 
received taxane-based regimens.  
 It is worthwhile to note that total FACT-Cog score were moderately 
associated with all the psychosocial variables. Both fatigue (rs=-0.396; p<0.0001) 
and anxiety (rs=-0.553; p<0.0001) correlated well with FACT-Cog score. There 
was also a strong relationship between FACT-Cog score and emotional 
functioning (rs=-0.552; p<0.0001). Univariate analysis also suggested that 
superior subjective cognitive functioning was associated with better self-
perceived health status, as depicted by higher EORTC-physical functioning 
(rs=0.270; p=0.002), EORTC-role functioning (rs=0.235; p=0.007), EORTC-
social functioning (rs=0.174; p=0.049) and global health status (rs=0.383; 





Therefore, for the subsequent identification of determinants of subjective 
cognitive changes, the covariates: receipt of chemotherapy, fatigue, anxiety, 
global health status, social, role, physical and emotional functioning were 
adjusted in all analyses.   
 
6.7.2 Linear mixed model results on the determinants of subjective cognitive 
functioning 
 Psychosocial and pharmacological characteristics that were pre-identified 
as factors associated with subjective cognitive functioning in the previous 
univariate analysis were included in the linear mixed model (Table 6.10).  
 Interestingly, results from the model revealed that breast cancer patients 
who did not receive chemotherapy scored 9.292 points lower on FACT-Cog total 
score, as compared to CT patients (p=0.014). However, at T3 of assessment, the 
interaction between the receipt of chemotherapy and time was significant; CT 
patients had a 1.944 reduction in total FACT-Cog score at T3, which was the 
lowest across the three time-points and between the two groups (p=0.046). 
Among the patients who received chemotherapy, the receipt of anthracycline-
based chemotherapy is associated with worse perceived cognitive functioning 
than taxane-based chemotherapy regimen (Estimate -2.428; 95% CI -6.346 to -
1.490; p=0.042).  
 A number of psychosocial determinants of perceived cognitive functioning 





reported HRQoL parameters such as physical functioning (p=0.009), emotional 
functioning (p<0.0001), role functioning (p=0.001) and global health status 
(p=0.013) were associated with higher total FACT-Cog scores. It is worthwhile to 
note that while anxiety and fatigue were both individual predictors for perceived 
cognitive functioning, the interaction between these two factors were a stronger 
predictor. Results showed that the interaction between anxiety and fatigue was 
expected to cause a 6.987 reduction in the total FACT-Cog score, which crossed 








Table 6.10: Estimates and standard errors for clinical, pharmacological and 
psychosocial determinants of subjective cognitive impairment (N=133) 
 
Parameter Estimate Standard 
error 
95% CI of estimate p-value 





Intercept 94.748 9.260 76.539 112.956 <0.0001 
Pharmacological determinants: 
 
    
Non-chemotherapy receiving -9.292 3.757 -16.714 -1.870 0.014 
Anthracycline-based 
chemotherapy 
-2.428 1.993 -6.346 -1.490 0.042 
Interaction between time of 
assessment and receipt of 
chemotherapy 
     
Time-point 1 and control 0     
Time-point 2 and control 0.127 4.947 -9.618 9.872 0.980 
Time-point 3 and control 0.0687 4.074 0.062 0.415 0.772 
Time-point 1 and chemo 4.952 4.863 -4.626 14.531 0.310 
Time-point 2 and chemo 4.074 5.101 -6.035 14.183 0.426 
Time-point 3 and chemo -1.944 4.396 -10.726 -0.837 0.046 
Psychosocial determinants: 
 
    
Anxiety -1.011 0.259 -1.521 -0.501 <0.0001 
Fatigue -2.044 0.863 -3.741 -0.348 0.018 
Global health status 0.161 0.064 0.035 0.287 0.013 
Role functioning 0.182 0.055 0.074 0.290 0.001 
Physical functioning 0.218 0.083 0.055 0.381 0.009 
Emotional functioning 0.248 0.070 0.110 0.387 <0.0001 
Social functioning 0.022 0.056 -0.088 0.132 0.690 
Interaction between anxiety 
and fatigue 
-6.987 1.077 -9.494 -0.350 0.001 








6.8 Correlation between objective and subjective measures410 
At post-chemotherapy T3, objective memory performance is associated with 
both self-reported memory (rs=0.315; p=0.001) and mental acuity (rs=0.261; 
p=0.007). From baseline to post-chemotherapy T3, the change in self-reported 
memory score has a weak association with change in objective memory 
performance (rs=0.288; p=0.003) (Table 6.11). Change in objective processing 
speed is also correlated with change in self-reported functional interference 
(rs=0.205; p=0.044). An increase in self-reported mental acuity score is associated 
with a corresponding increase in objective response speed performance (rs=0.203; 
p=0.032). 
 
Table 6.11: Strength of correlation (rsp) between changes in objective 
Headminder™ domain scores and FACT-Cog domain scores (N=133) 
 
  Change of Headminder™ domain scores  
(N=133) 





 Total 0.171 0.062 0.191 0.011 
Mental acuity 0.152 0.203* 0.100 0.074 
Concentration 0.115 0.030 0.280** 0.012 
Memory 0.128 0.056 0.288** 0.028 




 0.106 0.160 0.019 
Multi-tasking 0.060 0.026 0.156 0.011 
** Correlation coefficient (rsp) is significant at p<0.01 
























 The results from this study showed that, after the completion of 12 weeks 
of chemotherapy, 31.5% and 30.7% of the patients experienced a mild to severe 
decline in their memory and attention, respectively. The prevalence of impaired 
processing speed and response speed were lower, at 6.8% and 19.1%, respectively. 
Approximately 40% of the chemotherapy patients reported a clinically significant 
deterioration in their perceived overall cognitive function on completion of the 
treatment. 
 
Objective cognitive functioning 
 This is one of the first Asian studies to evaluate objective cognitive 
changes among breast cancer patients. The results on prevalence were fairly 
consistent with other published studies that adopted a similar methodological 
design. Our study found that 36% of the patients at T3 did not suffer from 
impairment in any of the four cognitive domains; this result is similar to those of a 
Canadian study that observed that 37.0% of 31 breast cancer patients had intact 
cognitive function in Headminder™ at follow-up assessments, when the mean 
interval between assessments was 17 days (range: 7–90 days).255 The same study 
also demonstrated that 46.0% and 17.0% of the patients suffered from impairment 
in one and two cognitive domains of Headminder™, respectively, which 
corresponds to our findings of 44.0% and 17.0%. However, caution must be taken 
when comparing the results of these two studies, because they adopted different 





reduction in the RCI, the Canadian study adopted a less conservative definition of 
a 1.0 reduction in the RCI. Moreover, the interval between each assessment for 
the Canadian study varied from 7 to 90 days, and the prevalence of cognitive 
impairment in the individual domains was not presented.
255
 
In another study by Hedayati et al., which used the same computerised 
neuropsychological (Headminder™) assessment in 18 breast cancer patients, the 
memory scores were found to decline significantly (p<0.01) 1 month after the 
completion of chemotherapy compared with the baseline.
66
  This suggests that 
Headminder™ detected impairment in the memory domain in breast cancer 
patients over the course of chemotherapy. Interestingly, the same study also 
observed that attention performance seemed to improve in patients at the follow-
up time-point, which is similar to our findings that the proportion of patients who 
suffered from impairment in the attention domain from T2 to T3 (19.1%) was 
lower than that from T1 to T2 (21.0%).  The authors suggested that this might 
have been due to a practice effect associated with the test itself.
66
  
The prevalence of impairment in the domain of processing speed was less 
apparent, similar to the Hedayati et al. study that did not observe a decline in 
processing speed in Headminder™ from baseline to the completion of 
chemotherapy.
66
 This is in contrast to another study that demonstrated that post-
chemotherapy processing speed was significantly lower in 60 breast cancer 
patients when traditional neuropsychological tests were used.
97
 Notably, this 
study found that older patients who received chemotherapy had significantly 





increase in age) compared with both healthy controls and breast cancer patients 
who did not receive chemotherapy (z-score difference of 0.11 per 10 years).
97
 
Hence, it is postulated that this discrepancy may be due to the younger age of the 
breast cancer patients who participated in our cohort study and in the Hedayati et 
al. study (mean ages of 51 and 52 years, respectively).  Another explanation for 
this anomaly might be a lack of sensitivity of Headminder™ to detect subtle 
changes in processing speed compared with traditional neuropsychological tools. 
An important research question that this thesis attempts to answer is 
whether treatment with chemotherapy is a determinant of cognitive changes in 
breast cancer patients. While impairment was detected among the patients 
receiving chemotherapy, interestingly the prevalence of objective cognitive 
impairment in Headminder™ was comparable between patients who received 
chemotherapy and the controls who did not. Some studies in the literature did not 
find any changes in neuropsychological performance among breast cancer 
patients who received standard adjuvant chemotherapy treatment.
60,67,120
 While 
the study design, types of neuropsychological tool and the intervals between each 
assessment might have contributed to the disparity in findings, several other 
reasons may explain the comparable prevalence of cognitive changes in CT and 
non-CT patients in our study: 
1. Approximately half of the non-CT patients in this study also received 
concurrent radiation therapy with or without anti-hormonal treatment (53.5%) 
at the time of recruitment and across the three time-points of assessment.  The 





had an impact on their cognitive function; evidence from the literature has 
suggested that radiation treatment can contribute to cognitive changes in 
breast cancer patients.
9,79
 One study that involved 62 Stage 0-II breast cancer 
patients treated with chemotherapy plus radiotherapy and 67 patients who 
received radiotherapy only observed no differences between the two groups of 
patients in objective neuropsychological assessments made 6 months after the 
completion of treatment and 36 months later.
81
 Another study attempted to 
evaluate the severity of fatigue and cognitive impairment in 161 breast cancer 
patients who received a combination of chemotherapy and radiation and 141 
patients who received radiation only during treatment and 1 year later.
9
 The 
results showed that initial mild cognitive impairments were reported by 34% 
of the patients and were persistent at 1 year in half of them.
9
 It was suggested 
that the destruction of tumour cells through radiation treatment can cause a 
consequent release of deleterious chemicals or an overactive response (e.g., 
anti-inflammatory or immunological) to the injury in the brain cells.
146
 Future 
research should investigate potential mechanisms such as residual symptoms 
related to radiation therapy, including fatigue and persistent cytokine 
dysregulation, that may occur in radiotherapy-treated breast cancer patients. 
2. A substantial number of non-CT patients in this study also received anti-
hormonal treatment with or without radiation treatment (64.3%) during the 
period of the study. Evidence in the literature has highlighted the potential 
neurocognitive toxicity of anti-hormonal treatment on the cognitive function 
of breast cancer patients.
76,80,98,248,249





the cognitive function of patients was discussed earlier (Chapter 5.4.1), and 
might explain the higher prevalence of impairments in attention and memory 
domains in the non-chemotherapy patients. It is proposed that long-term 
follow-up neuropsychological assessments should be conducted to evaluate 
whether cognitive function differs between patients who receive a 
combination of chemotherapy and anti-hormonal treatment and patients who 
receive either treatment only. It is hypothesised that, if both chemotherapy and 
anti-hormonal treatment have toxic effects on the cognitive function of breast 
cancer patients, the administration of a combination of both therapies may 
lead to a high risk of cognitive impairment among these patients. 
3. Operational and feasibility issues with the study procedure did not allow for a 
comparable interval between assessments for patients and non-CT patients. 
The intended duration between each time-point was 6 weeks, because CT 
patients were scheduled for standard chemotherapy treatment at the study site 
every 3 weeks, it was methodologically feasible for neuropsychological tests 
to be conducted at regular intervals. However, it was not feasible to perform 
standardised follow-up with the non-CT patients because their follow-up 
consultations with the oncologists varied greatly depending on the condition 
of their health. Therefore, the mean interval between each assessment for the 
non-CT controls was 56.3 days (T1-T2) and 75.3 days (T2-T3), which was 
longer and had a wider range than that of the CT group (46.7 (T1-T2) and 47.1 
(T2-T3) days). Although this study adopted a robust statistical approach 





classification of patients with objective cognitive impairment in 
Headminder™ that resulted from repeated measures within a shorter time 
period, it may be a potential reason why the CT patients seemed to perform 
better in the neuropsychological assessments than the non-CT patients.  
4. The sample size of non-CT patients was too small to draw meaningful 
conclusions. Based on a prior sample size determination, this study in its 
current state was not sufficient powered to detect differences in the trajectory 
of cognitive changes between the two groups. Moreover, the sample size was 
calculated based on the subjective neuropsychological assessment, FACT-Cog, 
instead of the Headminder™ estimates as the latter were not available during 
the inception of this study. The recruitment of non-CT patients into this study 
was challenging due to the stringent inclusion criteria, and it was uncommon 
for breast cancer patients not to receive any chemotherapy treatment if they 
had been diagnosed with Stages I–III breast cancer. Furthermore, at present, 
DCIS only constitutes 30% of all breast cancers detected in pre-menopausal 
women in Singapore.
1
 Hence, the prevalence of cognitive changes presented 
in this study might not be reflective of the true rates due to the small sample 
size of non-CT patients.    
5. The overall percentage of drop-out rate was approximately two-fold higher in 
the CT group (13.9%) than the non-CT group (6.7%). This might have 
resulted in a selection bias as patients who dropped out from the study might 
tend to be sicker while patients who completed the study might have better 





drop-out as “feeling too tired to continue the study”. Therefore, it was 
plausible that the comparatively better cognitive functioning of the CT 
patients might be attributed to this potential bias.  
 
The mixed model results showed that the interaction between time and the 
administration of chemotherapy was significant in the four domains. This 
interaction was not observed in the non-chemotherapy controls, suggesting that, 
over time, patients who received chemotherapy had poorer objective cognitive 
performances than the controls. More importantly, this interaction was most 
significant at T2 of the assessment, which corresponded to approximately 6 weeks 
after that the start of the chemotherapy; and indicated that, at the mid-point of the 
treatment, CT patients had a significantly poorer performance in the domains of 
processing speed, response speed and memory than the non-CT controls. Current 
studies have also attempted to delineate the onset and trajectory of cognitive 
impairment in cancer patients.
66,71
 Our study results suggest that the most 
apparent manifestation of objective cognitive changes occurs approximately 6 
weeks after the start of chemotherapy or after the administration of two cycles of 
chemotherapy. Nevertheless, this piece of finding must be interpreted with 
caution as we acknowledge the sample sizes of both groups might not be 
comparable.   
This chapter also seeks to delineate the demographical, clinical, 
pharmacological and psychosocial determinants of objective cognitive changes in 





cognitive decline, and researchers have speculated that older adults may be more 
vulnerable to the adverse cognitive effects of cancer treatments. High cognitive 
reserve, which represents innate and developed cognitive capacity (influenced by 
education, occupational attainment and lifestyle), has been shown to be a 
‘protective factor’ against cognitive decline.97 Evidence from the field of 
neuropsychology and age-related neurocognitive disorders has also revealed a 
strong relationship between changes in cognition and the interactions between age 
and cognitive reserve.
99,411
 Our findings are consistent with a previously 
mentioned study by Hedayati et al. that observed that younger and better educated 
patients had significantly better cognitive performances in Headminder™ than 
older patients.  
Among the patients who received chemotherapy, anthracycline-based 
regimens appeared to be associated with more severe impairment of memory and 
attention compared with taxane-based regimens. The candidate mechanism 
behind the potentially more neurocognitive toxicity of anthracycline-based 
regimens has not been elucidated to date. One explanation might be the stronger 
cytokine-inducing nature of anthracyclines.
139,146
 More specific evidence that 
doxorubicin directly contributes to an inflammatory response comes from an 
animal study, in which doxorubicin was given to non-tumour-bearing mice.
158
 
Peripheral and brain-inherent levels of the cytokine TNF-α, were increased even 
though doxorubicin was not found to cross the BBB.
158,160,161,412
 The peripheral 
increase in TNF-α was also associated with an increase in reactive oxygen species 





cognitive performance will be evaluated and discussed in the next chapter 
(Chapter 7). Although these findings are preliminary in nature due to the limited 
sample size of patients in each chemotherapy group, this observation is crucial 
because the continuation of taxane (paclitaxel and docetaxel) after the completion 
of an anthracycline-based regimen (commonly known as the ACT regimen) is 
now widely prescribed for the treatment of high-risk nodal-positive breast cancer, 
and suggests that patients who receive a cocktail of these cytotoxic drugs might 
be more susceptible to cognitive impairment. A longer duration of follow-up 
assessments must be carried out to evaluate this possibility.  
It is noteworthy that baseline BMI seemed to be associated with attention 
performance. Although our results suggested that a higher BMI may be associated 
with poorer attention performance, a definite conclusion cannot be drawn because 
BMI was not a determinant of other cognitive domains. Moreover, scientific 
evidence in the current literature that advocates a relationship between BMI and 
cognitive performance is lacking. However, several preliminary studies on 
neurological diseases in the elderly may shed some valuable information with 
regard to this research question. One study that elucidated the effect of BMI, 
waist circumference and waist:hip ratio on various parameters of cognitive 
function in 60 healthy women found a significant decrease (p<0.05) in all the 
cognitive parameters in the overweight/obese group compared with the control 
group of non-overweight/obese women
413
 The results of another study that 
examined the effects of both BMI and waist circumference on local grey matter 





associated with a decrease in prefrontal, hypothalamic, cerebellar and temporal 
regions of grey matter, which is indicative of diminished brain function.
414
 This 
hypothesis, however, warrants further investigation. Future studies could be 
conducted to ascertain the role of body weight, waist circumference and body-fat 
composition on post-chemotherapy cognitive changes in cancer patients.   
Although the EORTC-physical functioning was not associated with 
objective cognitive function and was excluded from the model in the univariate 
analysis, the effect of physical function on the perceived cognitive function of 
patients merits discussion. Numerous studies in the literature have demonstrated 
the benefits of physical activities on the cognitive health of elderly patients.
415-417
 
One recent large-scale study attempted to evaluate the effect of cognitive 
behavioural therapy (N=109), physical exercise (N=104) and these two 
interventions combined (N=106) on menopausal symptoms and HRQoL in 
patients with breast cancer
418
 Significant overall favourable effects in the 
intervention groups were found for the vitality, role-emotional and mental health 
subscales of the Short Form-36 HRQoL questionnaire. This result gives valuable 
research directions on how lifestyle factors can potentially affect the cognitive 
function of cancer patients. 
 
Subjective cognitive functioning 
With regard to subjective cognitive changes, it is interesting to note that the 
FACT-Cog scores of the CT patients were consistently higher than those of the 





reported better perceived cognitive function. This observation also paralleled 
those in the current literature that show that objective neuropsychological 
assessment scores do not reflect the subjective or self-reported cognitive changes 
that patients perceive. It is proposed that this anomaly might be explained by one 
of the observations recorded in a previous quantitative study conducted on local 
Asian breast cancer patients (Chapter 3.2); most participants in the focus group 
study claimed that they did not experience any cognitive changes while they were 
receiving chemotherapy. They suggested that their experience of physical side 
effects of the chemotherapy (such as numbness and vomiting) predominated their 
experience of cognitive side effects. Furthermore, many patients were absent from 
their jobs while they received chemotherapy, and therefore did not experience the 
actual impact of these cognitive changes. These changes surfaced only after 
treatment when they returned to their normal activities of daily living. With 
regard to the controls, most of them were fully employed and, hence, it is 
postulated that they might have been more sensitive to these cognitive changes 
when they performed their daily activities at home or at their workplace.
53,54
  
The patients who received chemotherapy reported better perceived 
cognitive function than the controls, as shown from the linear mixed model results 
that suggested that controls were expected to have a 9-point lower FACT-Cog 
score than chemotherapy recipients. As explained earlier, this observation might 
be due to the controls being more sensitive to the actual impact of cognitive 
changes when they performed their daily activities at home or at their workplace, 





were on medical leave from their jobs during their treatment. However, our 
findings are logical because a significant interaction was observed between the 
time-point of assessment and the administration of chemotherapy; they showed 
that CT patients had the lowest FACT-Cog scores at T3 after the completion of 12 
weeks of chemotherapy. This indicates that, as the chemotherapy treatment 
proceeded, patients might have experienced its cumulative adverse cytotoxic 
effects and hence reported poorer cognitive function. Notably, patients who 
received an anthracycline-based regimen had a statistically significant lower 
FACT-Cog score than those on a taxane-based regimen. This parallels the 
findings on objective cognitive function in which recipients of anthracycline-
based regimens had poorer memory and attention performances than recipients of 
taxane-based regimens.  
Nevertheless, the strongest determinants of subjective cognitive function 
were psychosocial determinants, such as anxiety, fatigue, global health status and 
emotional function. It is widely known from the literature that perceived cognitive 
changes are associated with psychological distress that patients experience during 
the course of their cancer treatment. In our local focus group study (Chapter 3.2), 
participants rationalised that they felt that “chemobrain” was a multifactorial 
phenomenon; while no consensus was reached on the main cause of their 
cognitive changes, many attributed this phenomenon to the physical adverse 
effects of chemotherapy, which led to mood changes, psychological disturbances 
and, consequently, cognitive changes. Hence, over time, the CT patients gradually 





interaction between anxiety and fatigue was shown to be a stronger predictor of 
subjective cognitive changes than anxiety or fatigue alone; the results showed that 
patients experienced a 7-point reduction in FACT-Cog score for every one unit 
increase in their anxiety and fatigue severities. This change of 7 points is similar 
to the MCID of FACT-Cog (6.9–10.6 points), indicating a clinically significant 
perceived change in cognitive functioning. Therefore, it is reasonable to suggest 
that screening for anxious and fatigued patients during the course of 
chemotherapy may potentially be helpful in identifying patients who experience 
cognitive distress.   
Lastly, existing evidence suggests that the results of objective 
neuropsychological assessments do not correlate with an overall/global subjective 
neuropsychological score.
102,104
 Hence, this study was designed to examine the 
relationship between specific domains of subjective cognitive complaints and 
objective neuropsychological tests. A weak association between specific objective 
and self-reported cognitive domains was observed. Our results suggest that a 
relationship exists between objective memory performance and self-reported 
memory score. From baseline to post-chemotherapy T3, the change in self-
reported memory score had a weak association with the change in objective 
memory performance, while the change in objective processing speed also 
demonstrated a weak relationship with self-reported functional interference. This 
finding is novel and important, as highlighted by a recent study that involved a 
large sample of 189 early-stage breast cancer patients who received adjuvant 





complaints that were statistically significantly associated with domain-specific 
neuropsychological test performances.
419
 Further studies that involve the 
refinement of precise subjective neuropsychological tools are needed to establish 
the criterion validity of self-reported cognitive complaints with objective 
measures of specific cognitive domains. These results further support the value of 





6.10 Limitations of study 
The choice of an appropriate control group remains a challenge for 
researchers. It is proposed that, for future studies, it might be more appropriate to 
include both non-CT breast cancer controls and healthy controls as references for 
a comparison. By having healthy controls, the effect of the cancer itself and the 
effect of ageing on cognitive changes can be taken into account.  However, it is 
important to note that healthy controls may fail to account for possible 
constitutional risk factors, psychological distress and disease-related cognitive 
changes. Hence, it is recommended by the International Cognition and Cancer 
Task Force that the most appropriate controls are those that closely resemble the 
target group, that is, disease-specific controls or controls who have experienced a 
major life event (for example, in studying the effects of chemotherapy, an optimal 
control group might consist of patients with a similar type of cancer who received 
only local treatment).
199





also be conducted to control for demographical factors that might affect cognitive 
performance, such as age and level of education. 
Other factors that could potentially affect cognition were not evaluated in 
detail due to the constraints of resources and time within a clinical setting. For 
example, depression was not investigated and a full assessment of the physical, 
mental and psychological aspects of fatigue was not conducted in this study. The 
emotional function subscale in the validated QLQ-C30 briefly examined the mood 
changes experienced by patients, but it is not comprehensive. The inclusion of 
depression and psychological distress in future studies could improve our 
understanding of the multifactorial nature of cognitive changes in cancer patients.  
Lifestyle-related factors such as nutrient intake, sleep patterns and physical 
activity were not captured in this study. Mediated by an inflammatory response, 
anthropometric changes, dietary patterns and physical exercise may also have an 
effect on cognitive changes.
420
 Evidence in the literature has suggested that an 
increase in moderate physical activity and a balanced diet that contains 
appropriate amounts of antioxidants, eicosapentaenoic acid and docosahexaenoic 
acid might protect against neurodegenerative disorders,
421-424
 and it is important 
that future studies evaluate the impact of these lifestyle-related factors on the 
cognitive status of patients.  
Finally, the sample size of the controls was small and conclusive findings 
cannot be drawn due to their under-representation. Therefore, the findings from 
the mixed model must be interpreted with caution as the study might not be 





point of view, we acknowledge that a number of tests of comparisons were 
conducted, especially in the univariate analyses (Sections 6.6.1 and 6.7.1); this 
could have contributed to a statistical pitfall, known as “multiple testing”. The 
current sample size might not be powered to conduct these tests, hence resulting 
in spurious findings or “false positives” (variables that were statistically 
significant by chance). However, given that the purpose of the univariate analyses 
was a preliminary stage to identify those variables that might have potential 
associations with cognitive functioning, we reason that it might be valid to 
conduct such exploratory analysis and interpret the results with caution.  
In addition, the interval between assessments differed for the CT patients 
and the non-CT controls. However, we adopted a rigorous statistical approach 
using a linear mixed model to account for the unbalanced arm and uneven spacing 
of the repeated measurements. Despite these limitations, the study methodology 
adopted in this thesis is congruent with the gold standard recommendations 
published by the International Cognition and Cancer Task Force and 
experts.
96,199,208
 An interval of 6 weeks between each assessment would facilitate 
the detection of transient cognitive changes while breast cancer patients undergo 
chemotherapy treatment and, at the same time, minimise the negative impact of a 







6.11 Summary of important findings 
The prevalence and severity of patients who suffered from objective and 
subjective post-chemotherapy cognitive impairments have been identified from 
this prospective, cohort study.  
Overall, as compared to baseline, this study suggested that an estimated 60% 
of the patients suffered impairment in at least one of the four cognitive domains. 
The most prevalent impairments were found in the domains of memory and 
attention; approximately one-third of Asian breast cancer patients suffered from 
mild to severe impairments in the memory and attention upon the completion of 
12 weeks of chemotherapy. Overall impairment in the domains of processing 
speed and response speed was less significant.  
CT patients reported gradually decreasing scores over the course of 
chemotherapy. Overall from T1 to T3, there was a statistically significant 
reduction of FACT-Cog score, with a total of 41.0% of patients being classified as 
having an overall clinically-significant perceived impairment. Self-reported lapses 
in memory (29.5%), mental acuity (30.5%) and multi-tasking ability (33.3%) 
were also apparent among the patients.  
In general, this study also suggested that age, level of education and 
baseline BMI contributed to objective cognitive changes in breast cancer patients. 
The interaction between time and administration of chemotherapy was significant 
in the four domains, indicating that, over time, the patients who received 
chemotherapy had worse objective cognitive performances. Among the patients 





detrimental to their cognitive function than taxane-based regimens. With regard to 
subjective cognitive function, psychosocial determinants, such as the anxiety and 









Thus far, we have established that the determinants of cognitive changes in 
cancer patients include clinical, psychosocial and pharmacological factors. 
Results from the literature review in Chapter 1 also suggested that pro-
inflammatory cytokines may be mediators of chemotherapy-associated cognitive 
changes. Cytokine induction in the central nervous system has been suggested to 
mediate "sickness behaviour" in patients with severe infection or cancer, together 
with the adverse neuropsychiatric effects of treatment with interferon and 
interleukins.
143,147,198
 Cytokines may play a dominant role in the 
neuroimmunoendocrine processes induced by cancer cells and cytotoxic 
chemotherapy.  
To gain a better understanding of the role that cytokines play in the 
“chemobrain” phenomenon, it is necessary to evaluate the sequence of events 
involving chemotherapy and the cytokine-based immune response that affects 
cognitive functioning in cancer patients. Thus far, there is a paucity of studies 
specifically evaluating the associations between chemotherapy, cytokine 
induction and cognitive changes. This chapter aims to answer the research 
question: 
- What are the biological determinants associated with objective cognitive 






- What are the biological determinants associated with subjective cognitive 




Study design and settings 
This was a prospective cohort study conducted at NCCS and KKH between 
December 2011 and October 2013. The study was approved by the CIRB and 
written informed consent was obtained from all participants.  
Patients 
Subjects that were analysed in this study were patients who completed the 
prospective cohort study between December 2011 and October 2013, and had 
provided a complete set of blood from the three time points (T1, T2 and T3) in 
Chapter 6. Specific details on the study procedure and study tools have been 
described in the previous chapter (Chapter 6.1). 
Cytokines analysis 
The study procedure and timing of blood draws are presented in Figure 6.1. 
At each time-point (T1, T2 and T2), a 10 ml of blood was drawn from patients 
prior to the administration of chemotherapy in ethylenediaminetetraacetic acid 
(EDTA) tubes and centrifuged at 1000rpm for 30 minutes within 30 to 40 minutes 
of collection. Plasma was aliquoted and stored aseptically at -80
o
C until analysis. 





GM-CSF, IFN-γ, was quantified using a high sensitivity multiplex immunoassay 
(Luminex ®) in triplicates. The above panel of plasma cytokines was selected as 
they include the pro-inflammatory cytokines of interest that may affect cognition 
based on the literature review conducted in Chapter 1. The pre-mixed customised 
Bio-Plex Pro™ human cytokine immunoassay kit was utilised for the analysis and 
it included coupled magnetic beads, detection antibodies, standards, assay buffer, 
detection antibody diluents and streptavidin-PE. All cytokine analysis was 
conducted at the Bio-Rad Laboratories (Singapore) Pte. Ltd. under the supervision 
of trained personnel.  
Statistical analysis 
As there was a total of nine cytokines tested in this study, caution had to be 
taken to adopt a statistical approach that can aid in the identification of the 
strongest predictors for objective and subjective cognitive changes.   
 
i. Step 1: Identification of factors associated with specific cytokine 
levels 
Firstly, univariate analysis was conducted to evaluate the association between 
baseline cytokine levels and baseline clinical or demographic factors. The 
objective of this exploratory step is to identify factors that may influence cytokine 
levels and serve as covariates in subsequent analyses. The factors tested are 






Table 7.1: List of independent variables that may be associated with cytokine 
levels (exploratory univariate analysis) 
 




Years of education 
Body mass index 
Race (Chinese vs. Malay vs. Indian vs. others) 




 Breast cancer stage (Stages 0 and 1 vs. 2 and 3) 
Haemoglobin level 
ECOG performance status (0 vs. 1) 
Presence of comorbidities (yes vs. no) 
Menopausal status (pre- vs. post-menopausal) 
Surgical treatment (mastectomy vs. lumpectomy) 
Pharmacological
76,80,98,248,249
 Receipt of chemotherapy (yes vs. no) 






EORTC-Global quality of life 
EORTC-Emotional functioning 
EORTC- Physical functioning 




Factors that were shown to have an association with cytokine levels at 
significance level of p-value<0.1 were identified as covariates, and were adjusted 
in subsequent analysis. A p-value of <0.1 instead of p-value <0.05 was chosen to 







ii. Step 2: Identification of specific cytokines associated with objective 
and subjective cognitive changes 
Differences in the levels of cytokines were conducted between patients who 
exhibited objective and subjective impairment from baseline T1 to T3, from those 
who did not. These differences were evaluated using Mann-Whitney U test 
(before adjusting for covariates identified in Step 1) and ANCOVA (after 
adjusting for covariates identified in Step 1). 
As an exploratory analysis, simple spearman’s correlation test was utilised 
to delineate the associations between the changes in cytokines levels and 
cognitive score changes across the three time-points. Partial correlation was 
conducted for the same purpose as above, after adjusting for covariates. Baseline 
cognitive functioning and cytokine levels at T1 were used as reference values for 
individual patients to avoid errors that may occur with multiple comparisons. 
Cytokines that were shown to have an association with objective or 
subjective cognitive performances at significance level of p-value<0.1, would be 
included into the linear mixed model in the next step (Step 3). 
 
iii. Step 3: Linear mixed model approach to identify biological 
determinants of objective and subjective cognitive changes 
Linear mixed models were used to determine the effect of cytokine levels 
on objective and subjective cognitive impairments. The analyses were conducted 





processing speed, response speed, memory and attention. For subjective cognitive 
changes, the dependent variables referred to the total FACT-Cog scores.  
Finally, a linear mixed modelling using an unstructured covariance structure 
was built. Aiming to minimise the number of cytokines in the final linear mixed 
model, only those cytokines that had shown an association with the dependent 
variables in the previous step (Step 2) were included. Clinical, pharmacological 
and psychosocial variables that were shown to be determinants for objective and 
subjective cognitive changes in the previous section (Chapter 6) were also 
included as covariates into the model.  
 
7.2 Baseline characteristics of patients  
Patients’ characteristics 
Eighty-two CT breast cancer patients had a complete set of blood samples 
across the three time-points and were included in this analysis (Table 7.2). The 
mean age of the patients was 50.2±8.4 years. Majority of patients were Chinese 
(79.3%), post-menopausal (50.0%), early-stage breast cancer patients. Majority of 





Table 7.2: Baseline demographics of patients in the cytokine determinants study 
(N=82) 
 
Demographic Information Frequency (%) 
Age (in years) Mean ±SD 
 
50.2±8.4  
Education (in years) Mean ±SD 9.5±3.0  
Education (in levels) Primary (Elementary) 12 (14.6) 
 Secondary (Junior high) 42 (51.2) 




Race Chinese 65 (79.3) 
 Indian 3 (3.7) 
 Malay 10  (12.2) 
 Others: Burmese, Filipino 
 
4 (4.9) 
Marital status Single 17 (20.7) 
 Married 60 (73.2) 




Employment status Employed 48 (59.3) 
 Unemployed/medical leave 
 
34 (41.7) 
Medical Information Frequency (%) 
Cancer staging I 13 (15.9 
















Menopausal status Post-menopausal 
 
41 (50.0) 











Haemoglobin level (g/dl) Mean ±SD 12.7±1.3  
Baseline BMI (kg/m
2
) Mean ±SD 24.9 ±4.4  




T1 and T2 Mean ±SD 48.2±5.7  
 T2 and T3 Mean ±SD 46.2±8.2  
ECOG: Eastern Cooperative Oncology Group; SD: standard deviation 
1Mean duration from time of diagnosis is refers to the difference (in number of weeks) between date of diagnosis of breast 
cancer or ductal carcinoma in situ and T1 date of assessment  
2 Chemotherapy regimens are defined in Table 6.1 
3 Mean duration between assessments refers to the difference (in number of days) between T1 date of assessment and T2 





Across all time-points, there was no statistically difference in the overall 
perceived cognitive functioning (129.8±17.7 vs. 129.9±17.6 vs. 126.0±18.1; 
p=0.039) (Table 7.3). Post-hoc analysis showed that from T2 to T3, there was a 
reduction of FACT-Cog score by 4.0 points (p=0.016). It is also worthwhile to 
highlight that perceived mental acuity (p=0.009) and memory (p=0.050) were 
statistically different from baseline to post-chemotherapy assessment too. 
Patients’ global HRQoL differed across the three time-points (p=0.004), of 
which patients reported the poorest health status upon the completion of 
chemotherapy at T3. Using QLQ-C30, a significant worsening in the perceived 
cognitive functioning was observed (p=0.001), when there was a significant 
reduction of 6.81 points from T1 to T3. A change on physical functioning and 
symptoms such as insomnia (p=0.012) and constipation (p=0.0001) were noted 
throughout the start and completion of chemotherapy (Table 7.3).  
The most severe degree of fatigue was observed at T3 upon the completion 
of chemotherapy, as compared to T1 and T2 on both the QLQ-C30 fatigue scale 
and BFI (p=0.003 and 0.0001, respectively).  
 Patients experienced mild anxiety throughout their chemotherapy treatment, 
with the most severe anxiety level at T3. However, anxiety severity was not 






Table 7.3: Changes in patients’ subjective cognitive functioning, HRQoL, fatigue 
and anxiety (N=82) 
 
 T1 T2 T3  
 Mean  (SD) Mean  (SD) Mean (SD) p-value 
*
 
FACT-Cog      
 Total
1 129.8 (17.4) 129.9 (17.6) 126.0 (18.1) 0.039 
Domain Mental acuity 13.9 (2.4) 13.8 (2.7) 13.1 (2.7) 0.009 
 Concentration 13.8 (2.5) 13.7 (2.4) 13.3 (2.6) 0.093 
 Memory 24.4 (3.8) 24.5 (3.3) 23.6 (3.8) 0.050 
 Verbal ability 21.6 (3.0) 21.5 (3.0) 21.2 (2.9) 0.330 
 Functional 
interference 
13.9 (2.3) 14.0 (2.2) 13.8 (2.2) 0.911 
 Multi-task 13.4 (2.5) 13.6 (2.7) 12.9 (3.0) 0.503 
Subscales Noticeability 15.3 (1.6) 15.4 (1.2) 15.2 (1.6) 0.822 
 Quality of life 13.4 (4.2) 13.4 (4.0) 13.0 (3.5) 0.103 
EORTC-QLQ-C30      
Global QoL
2
 Global health 
status 74.1 (17.1) 69.6 (19.0) 67.2 (18.3) 
0.004 
Functional 
2 Physical 87.4 (15.4) 86.8 (13.2) 83.2 (15.9) 0.022 
 Role 86.5 (21.2) 84.6 (19.7) 82.7 (21.2) 0.079 
 Emotional 81.7 (20.0) 84.7 (16.6) 83.0 (17.4) 0.191 
 Cognitive 91.8 (14.6) 87.0 (15.1) 85.0 (17.9) 0.001 





Fatigue 23.8 (16.0) 29.8 (21.3) 35.4 (21.8) 0.0001 
Nausea and 
vomiting 1.5 (4.8) 10.3 (18.2) 9.1 (17.4) 
0.0001 
 Pain 13.5 (18.7) 17.5 (19.9) 20.1 (23.1) 0.174 
Single items 
3
 Dyspnoea 8.0 (16.2) 12.4 (17.0) 13.4 (20.2) 0.030 
Insomnia 21.1 (26.3) 28.0 (28.1) 27.6 (27.1) 0.012 
 Appetite 8.0 (18.7) 16.9 (23.6) 18.7 (24.6) 0.002 
 Constipation 6.8 (13.5) 20.2 (27.2) 17.1 (24.7) 0.0001 
 Diarrhoea 1.7 (7.4) 3.7 (13.9) 6.9 (14.6) 0.015 
 Financial 33.3 (34.2) 25.1 (29.6) 23.2 (31.3) 0.021 
Brief Fatigue Inventory     
 Total 4 1.5 (1.5) 2.1 (2.0)  2.9 (11.0) 0.003 
Beck Anxiety Inventory      
 Total 
5 6.8 (6.2) 8.0 (7.1) 8.7 (7.9) 0.236 
1A higher score is indicative of better cognitive functioning. Maximum score for FACT-Cog is 148. 
2A higher score is indicative of better functioning/health status. Maximum score for all EORTC-QLQ-C30 subscales is 100. 
3A higher score is indicative of more or worse symptoms. Maximum score for all EORTC-QLQ-C30 subscales is 100. 
4A higher score is indicative of more severe fatigue. Maximum total score for BFI is 10. 





7.3 Univariate analysis on the association between cytokine levels and 
clinical/demographic factors 
Patients’ cytokine levels across all three time-points are presented in Table 
7.4. Notably, levels of IL-2, IL-10 and IFN-γ were below the detection limit 
throughout T1 to T3, and there were large inter- and intra- patient variations in 
GM-CSF and IL-2 levels.  
 
Table 7.4: Comparison of cytokine levels across the three time-points of 
assessments (adjusted and non-adjusted) (N=82) 
 
Cytokines 
Cytokine levels (pg/ml)  
Median (interquartile range) 
p-value 




 T1  T2  T3    
GM-CSF 0.30 
(0.00 – 4.10) 
0.58 
(0.00 – 7.90) 
0.55 
(0.00 – 12.03) 
0.122 0.769 
IFN-γ 0.00 
(0.00 – 0.00) 
0.00 
(0.00 – 0.00) 
0.00 
(0.00 – 0.00) 
0.882 0.586 
IL-1β 0.71 
(0.43 – 2.34) 
0.89 
(0.47 – 3.11) 
0.78 
(0.38 – 3.43) 
0.931 0.526 
IL-2 1.14 
(0.00 – 5.71) 
0.00 
(0.00 – 6.72) 
0.00 
(0.00 – 6.27) 
0.686 0.725 
IL-4 0.00 
(0.00 – 0.46) 
0.00 
(0.00 – 0.62) 
0.00 
(0.00 – 0.75) 
0.227 0.529 
IL-6 1.09 
(0.00 – 3.62) 
1.23 
(0.00 – 3.67) 
2.07 
(0.00 – 5.77) 
0.002 0.662 
IL-8 4.75 
(1.90 – 22.66) 
4.89 
(2.05 – 24.53) 
5.19 
(1.08 – 11.09) 
0.556 0.949 
IL-10 0.00 
(0.00 – 0.50) 
0.00 
(0.00 – 0.53) 
0.00 
(0.00 – 0.59) 
0.793 0.591 
TNF-α 1.63 
(1.63 – 3.29) 
1.64 
(0.56 – 2.88) 
2.05 
(0.80 – 3.40) 
0.198 0.041 
Bold: denotes statistical significance at p<0.05 





On univariate analysis, baseline cytokine levels were significantly 
correlated with age, body mass index, types of chemotherapy regimens 
(anthracycline-based vs. taxane-based) and cancer staging (Stages I vs. Stages II 
vs. Stage III). Higher levels of IL-4 (rs=0.251; p=0.024) and GM-CSF (rs=0.209; 
p=0.061) were associated with increased age. Patients possessing higher BMI 
also had elevated levels of GM-CSF (rs=0.258; p=0.02), IFN-γ (rs=0.281; 
p=0.011) and TNF-α (rs=0.269; p=0.015).   
As compared with patients who received taxane-based regimen, patients 
who received anthracycline-based chemotherapy regimens had higher post-
chemotherapy levels of IL-6 [1.218 (0.00 – 5.27) pg/ml vs. 2.275 (0.00 – 6.29) 
pg/ml; p=0.041] and GM-CSF [0.075 (0.00 – 2.06) pg/ml vs. 0.770 (0.00 – 17.59) 
pg/ml; p=0.072]. There were no statistically significant difference in baseline 
cytokines between patients of different cancer stages, except for TNF-α; patients 
who suffered from stage III breast cancer possessed higher baseline level of TNF-
α than patients who had earlier stages of cancer [Stage III: 2.138 (0.58 – 5.60) 
pg/ml vs. Stage II: 1.451 (0.38 – 3.24) pg/ml; Stage I: 0.950 (0.00 – 2.04) pg/ml; 
p=0.071].  
Although other demographic or clinical parameters such as presence of co-
morbidities, ECOG performance status and menopausal status were documented 
in the literature as factors that can cause dysregulation in cytokine levels, no 






Therefore, for the subsequent preliminary identification of specific 
cytokines that are associated with objective and subjective cognitive impairment, 
the covariates: age, BMI, cancer staging and types of chemotherapy regimens 
were adjusted in all analyses.   
 
7.4 Biological determinants of objective cognitive changes 
7.4.1 Preliminary identification of cytokines that are associated with 
objective cognitive impairment 
 This step involved the use of traditional inferential statistics to select 
specific cytokines that suggest a relationship with objective cognitive impairment. 
As compared to baseline, memory (28.1%), attention (34.1%) and response speed 
(21.9%) impairments were prevalent 12 weeks from the start of chemotherapy 
(Tables 7.5a to 7.5c). Analysis on the processing domain was not conducted as 
only 6 patients (6.1%) suffered from impairment and the sample size was too 
small to draw meaningful conclusion.  
 After adjusting for age, BMI, staging and chemotherapy regimen, patients 
experiencing memory impairment had higher levels of circulating TNF-α than 
patients with intact memory [2.05 (0.63-3.41) vs 1.94 (0.86-3.35) pg/ml, 
p=0.046], and patients suffering attention impairment had higher level of IL-6 
[2.43 (0.0-5.58) vs 1.99 (0.0-5.98) pg/ml, p=0.031]. As for response speed, there 
was a marginal elevation of IL-4 in patients who suffered from impairment 





patients with response speed impairment [5.28 (0.00-15.87) vs 1.69 (0.00-4.89) 
pg/ml, p=0.050]. 
 
Table 7.5a: Comparison of cytokine levels between patients who had impaired 
response speed performance and those who did not (N=80)  
Cytokine  Cytokine levels (pg/ml) 
Median (Interquartile range) 
p-value Adjusted 
p-value 
 No Change in  Response 
speed (N=62) 
Impairment in       
Response speed (N=18) 
  
GM-CSF 0.55 
(0.00 – 7.82) 
0.53 
(0.00 – 30.13) 
0.876 0.147 
IFN-γ 0.00 
(0.00 – 0.00) 
0.00 
(0.00 – 16.74) 
0.152 0.569 
IL-1β 0.79 
(0.38 – 3.41) 
0.68 
(0.12 – 3.74) 
0.977 0.147 
IL-2 0.00 
(0.00 – 6.09) 
2.43 
(0.00 – 6.62) 
0.537 0.361 
IL-4 0.00 
(0.00 – 0.62) 
0.67 
(0.00 – 1.62) 
0.026 0.067 
IL-6 1.69 
(0.00 – 4.89) 
5.28 
(0.00 – 15.87) 
0.122 0.050 
IL-8 4.61 
(0.45 – 9.79) 
7.31 
(4.08 - 21.76) 
0.166 0.473 
IL-10 0.00 
(0.00 – 0.54) 
0.06 
(0.00 – 0.73) 
0.407 0.223 
TNF-α 1.94 
(0.62 - 3.34) 
1.94 
(0.93 – 4.14) 
0.524 0.315 
Bold: denotes statistical significance at p<0.1 







Table 7.5b: Comparison of cytokine levels between patients who had impaired 
memory performance and those who did not (N=81)  
Cytokine  Cytokine levels (pg/ml) 
Median (Interquartile range) 
p-value Adjusted 
p-value 
 No Change in Memory 
(N=58) 




(0.00 – 3.14) 
0.83 
(0.00 – 29.02) 
0.154 0.831 
IFN-γ 0.00 
(0.00 – 0.00) 
0.00 
(0.00 – 0.00) 
0.407 0.843 
IL-1β 0.95 
(0.33 – 3.46) 
0.56 
(0.36 – 3.33) 
0.301 0.348 
IL-2 2.33 
(0.00 – 6.32) 
0.00 
(0.00 – 6.18) 
0.317 0.213 
IL-4 0.00 
(0.00 – 0.93) 
0.00 
(0.00 – 0.70) 
0.724 0.338 
IL-6 1.99 
(0.00 – 6.28) 
2.49 
(0.00 – 5.29) 
0.952 0.763 
IL-8 5.05 
(2.21 – 27.76) 
5.69 
(0.00 – 8.04) 
0.288 0.158 
IL-10 0.00 
(0.00 – 0.66) 
0.00 
(0.00 – 0.23) 
0.107 0.264 
TNF-α 1.94 
(0.86 – 3.35) 
2.05 
(0.63 – 3.41) 
0.124 0.046 
Bold: denotes statistical significance at p<0.1 
1 Adjusted for age, body mass index, breast cancer staging and type of chemotherapy treatment 
 
Table 7.5c: Comparison of cytokine levels between patients who had impaired 
attention performance and those who did not (N=80) 
Cytokine  Cytokine levels (pg/ml) 
Median (Interquartile range) 
p-value Adjusted  
p-value 
 No Change in Attention 
(N=52) 




(0.00 – 10.66) 
0.45 
(0.00 – 20.87) 
0.773 0.557 
IFN-γ 0.00 
(0.00 – 0.00) 
0.00 
(0.00 – 0.00) 
0.884 0.904 
IL-1β 1.04 
(0.26 – 3.62) 
0.58 
(0.46 – 2.80) 
0.475 0.279 
IL-2 1.68 
(0.00 – 6.54) 
0.00 
(0.00 – 5.78) 
0.317 0.325 
IL-4 0.00 
(0.00 – 0.70) 
0.36 
(0.00 – 1.43) 
0.814 0.704 
IL-6 1.99 
(0.00 – 5.98) 
2.43 
(0.00 – 5.58) 
0.029 0.031 
IL-8 4.61 
(0.00 – 9.80) 
5.30 
(2.94 – 17.16) 
0.578 0.883 
IL-10 0.00 
(0.00 – 0.57) 
0.00 
(0.00 – 0.59) 
0.648 0.843 
TNF-α 2.08 
(0.87 – 3.41) 
1.87 
(0.66 – 3.30) 
0.655 0.661 
Bold: denotes statistical significance at p<0.1 





 Exploratory partial correlation test was also conducted to delineate the 
associations between changes in cytokine levels and objective cognitive domain 
scores (Table 7.6). After adjusting for covariates, reduction of memory scores 
were associated with higher levels of IL-8 (r=-0.231, p=0.041). Correlation 
between changes of cognitive scores was not observed in other cytokines levels.  
Table 7.6: Strength of correlation (rsp) between changes in cytokine levels and 
Headminder™ cognitive domain scores (N=82) 
Cytokine 
Correlation coefficient of change in cytokine level and change in 
Headminder™ cognitive scores 1 
 Processing speed Response speed Memory Attention 
GM-CSF -0.065 -0.142 0.076 0.141 
IFN-γ 0.022 -0.029 -0.009 0.072 
IL-1β 0.105 0.090 -0.157 -0.064 
IL-2 -0.74 -0.039 0.119 0.071 
IL-4 0.091 0.096 -0.147 -0.069 
IL-6 0.048 -0.027 0.014 -0.098 
IL-8 -0.159 0.096 -0.231 -0.075 
IL-10 0.031 0.068 -0.108 -0.090 
TNF-α -0.066 0.052 0.133 -0.077 
Bold: denotes that correlation coefficient (rsp) is statistically significant at p<0.1 
1 Adjusted for age and body mass index 
  
 These preliminary findings suggest that an increase in the post-
chemotherapy levels of TNF-α, IL-1β, IL-4, IL-6 and IL-8 may have an 
association with the manifestations of objective cognitive impairment in Asian 
breast cancer patients. No statistically significant differences or meaningful trends 
were observed with cognitive functioning and the levels of IL-2, IL-10, GM-CSF 
and IFN-γ. These identified cytokines would be included in the linear mixed 
model at the next step (Section 7.4.2) to delineate the effect of these cytokines on 





7.4.2 Linear mixed model results on the biological determinants of objective 
cognitive changes 
 A linear mixed model was built with the potential determinants of objective 
cognitive functioning based on the previous preliminary analysis (IL-1β, IL-4, IL-
6, IL-8 and TNF-α), and the other pre-determined factors from Chapter 6 (age, 
BMI, years of education, type of chemotherapy treatment and time of assessment). 
Mixed models were built to determine the effect of biological markers on the 
cognitive domains of processing speed, response speed, memory and attention 
(Table 7.7). A one unit increase in plasma IL-1β was associated with a 5.458 
decrease in response speed performance (95% CI: -7.928 to -0.449; p=0.008). 
TNF-α might be a potential biological determinant of memory performance; A 
one unit increase in plasma TNF-α corresponded to a 3.158 (95% CI: -5.232 to -
1.084; p=0.050) reduction in memory score. For attention, a one unit increase in 
plasma levels of IL-4 and IL-8 were associated with a 3.862 (95% CI: -5.487 to -
0.165; p=0.025) and 4.112 (95% CI: -9.180 to -0.051; p=0.021) reduction in 
attention score, respectively. No biological predictor for change in processing 













Table 7.7: Estimates and standard errors for biological determinants of objective cognitive impairment (N=82) 
 
 
Parameter Estimate of parameter (standard error) 
 Processing speed Response speed Memory Attention 
Intercept 110.650** (7.393) 98.660** (13.140) 100.915** (14.242) 139.431** (11.587) 
IL-1β 0.304 (0.392) -5.458* (0.630) -0.379 (0.684) -0.287 (0.555) 
IL-4 -3.327 (0.343) -0.951 (0.601) 0.638 (0.653) -3.862* (0.529) 
IL-6 0.012 (0.014) 0.010 (0.025) -2.020 (0.027) -2.017 (0.384) 
IL-8 0.008 (0.021) -3.028 (0.036) 0.058 (0.039) -4.112* (0.932) 
TNF-α 0.038 (0.556) -0.656 (0.966) -3.158* (1.047) -1.593 (0.851) 
*: denotes statistical significance at p<0.05 





In summary, higher plasma levels of IL-1β and TNF-α were found to be 
associated with poorer respond speed and memory, respectively. A lower 
attention score were observed with higher levels of IL-4 and IL-8. No biological 
determinant was identified for the cognitive domain of processing speed.  
Other cytokines such as IL-2, IL-6, IL-10, GM-CSF and IFN-γ were not 
associated with cognitive impairment.  
 
7.5 Biological determinants of subjective cognitive changes 
7.5.1 Preliminary identification of cytokines that are associated with 
subjective cognitive impairment 
 This step involved the use of traditional inferential statistics to select 
specific cytokines that demonstrate a relationship with subjective cognitive 
impairment, as depicted by FACT-Cog total score. Based on the pre-determined 
MCID, thirty-one patients (38.2%) were classified as having a clinically 







Table 7.8: Comparison of cytokine levels between patients who reported 





Cytokine levels (pg/ml)  
Median (interquartile range) 
p-value 




 No Change on FACT-Cog 
(n=49) 
















































Bold: denotes statistical significance at p<0.1 
1 Adjusted for age, body mass index, breast cancer staging and type of chemotherapy treatment 
 
After adjusting for age, BMI, staging and chemotherapy regimen, only IFN-
γ was identified to be marginally increased in patients with poorer perceived 
cognitive functioning (p=0.074). There were no other cytokines that were 
associated with subjective cognitive impairment.  
 Exploratory correlation test suggested that after adjusting for covariates, 
reduction of FACT-Cog score was associated with higher levels of IL-1β (r=-
0.162, p=0.082) and IL-6 (r=-0.305, p=0.045) (Table 7.9). Correlation between 






Table 7.9: Strength of correlation (rsp) between changes in cytokine levels and 
changes in FACT-Cog total score changes (n=82) 
 
Cytokine  Correlation coefficient (rsp) between change in cytokine level 












Bold: denotes that correlation coefficient (rsp) is statistically significant at p<0.1 
1 Adjusted for age and body mass index 
 
 
These preliminary findings suggest that an increase in the post-
chemotherapy levels of IL-1β, IL-6 and IFN-γ may have an association with 
perceived cognitive disturbances in Asian breast cancer patients. No statistically 
significant differences or meaningful trends were observed with cognitive 
functioning and the levels of IL-2, IL-4, IL-8, IL-10, GM-CSF and TNF-α.  
These identified cytokines would be included in the linear mixed model at 
the next step (section 7.5.2) to delineate the effect of these cytokines on 








7.5.2 Linear mixed model results on the biological determinants of 
subjective cognitive changes 
 A linear mixed model (Table 7.10) was built with the potential 
determinants of subjective cognitive functioning based on the previous 
preliminary analysis (IL-1β, IL-6 and IFN-γ), and the other pre-determined factors 
in Chapter 6 (age, BMI, years of education, type of chemotherapy treatment, 
time of assessment, anxiety, fatigue, global health status, emotional functioning, 
role functioning, social functioning and the interaction between fatigue and 
anxiety). 
None of the biological determinants was identified for subjective cognitive 
impairment. Similar to the findings from the previous Chapter 6, results from the 
linear mixed model showed that the interaction between anxiety and fatigue, 
global health status, emotional functioning and physical functioning were 
psychosocial factors that were associated with perceived cognitive functioning. 
To note, the interaction between anxiety and fatigue must be interpreted with 
caution, given that the main effect of fatigue alone was not found to be 







Table 7.10: Estimates and standard errors for biological determinants of 
subjective cognitive impairment (N=82) 
 
Parameter Estimate Standard 
error 
95% CI of estimate p-value 





Intercept 123.657 17.953 88.087 159.227 <0.0001 
Time of assessment      
Time-point 1      
Time-point 2 3.514 2.084 -0.695 7.723 0.099 
Time-point 3 1.106 1.944 0.104 8.107 0.045 
Clinical determinants: 
 
    
Age 0.051 0.200 -0.346 0.448 0.799 
Baseline BMI 0.201 0.342 -0.478 0.880 0.558 
Pharmacological determinants: 
 
    
Anthracycline-based 
chemotherapy 
-0.298 3.469 -6.576 7.171 0.932 
Psychosocial determinants: 
 
    
Anxiety -1.097 0.419 -1.927 -0.268 0.010 
Fatigue -2.732 1.471 -5.646 0.181 0.066 
Interaction between 
anxiety and fatigue 
-4.960 0.094 -8.420 -0.205 0.041 
Global health status 0.140 0.111 0.234 2.206 0.045 
Emotional functioning 0.182 0.123 0.021 0.959 0.042 
Role functioning 0.969 0.091 -0.249 0.111 0.450 
Physical functioning 0.218 0.092 0.118 0.645 0.039 
Biological determinants: 
 
    
IL-1β 0.010 0.322 -0.628 0.648 0.975 
IL-6 -3.007 0.028 -3.048 0.063 0.052 
IFN-γ -0.030 0.035 -0.101 0.040 0.391 







Most studies in the literature reported dysregulation of cytokine levels with 
chemotherapy, but there is conflicting evidence with regards to the strength and 
direction of the association between changes in cytokine levels and 
cognition.
131,165,169,170
 Results from our study show that dysregulation in IL-1β, 
IL-4, IL-6 and TNF-α are determinants for objective impairment in the domains 
of response speed, memory and attention.  
Findings from this study are rather consistent with the limited evidence in 
the literature.
170
 Kesler et.al. evaluated the association among serum cytokine 
levels, left hippocampal volumes and objective memory performance in 20 
chemotherapy-receiving breast cancer patients and 23 healthy controls.
170
 The 
assessments were conducted 4.8±3.4 years post-chemotherapy. It was found that 
the breast cancer group had reduced left hippocampal volumes (p=0.01) and 
cognitive performance and evaluated levels of IL-6 (p=0.003) and TNF-α 
(p<0.0001), as compared to healthy controls. In the breast cancer group, lower 
left hippocampal volume was associated with higher levels of TNF-α (β=-1.56; 
p=0.04) and lower IL-6 (β=0.734, p=0.03). The interaction between TNF-α and 
IL-6 was also significant (β=1.23; p=0.04). These associations were not observed 
in the healthy control group. Authors concluded post-chemotherapy altered 
hippocampal volume and verbal memory difficulties may be mediated by TNF-α 
and IL-6 in breast cancer patients. 
This study did not identify any biological determinants for subjective 





(AC/FAC) chemotherapy and CMF on cytokine levels and perceived cognitive 
impairment.
131
 Significant increases in IL-6 (p=0.042) and IL-8 (p=0.060) levels 
were observed in the AC/FAC treatment group. Patients receiving AC/FAC 
experienced more severe self-reported symptoms of heavy-headedness, difficulty 
thinking, and problems with concentration. Janelsins et.al. concluded that IL-6 
may be associated with poorer self-reported cognitive outcomes in patients who 
are receiving anthracycline-based regimens.
131
 In our final linear mixed model, 
IL-6 was close to statistical significance (p=0.052) as a predictor for FACT-Cog 
total score. This suggests that IL-6 may be a predictor for subjective cognitive 
performance but further validation of this observation must be conducted. 
In another recently published prospective cohort study
169
, assessment on 
patients’ cognitive function was performed on 49 CT and 44 non-CT breast 
cancer patients using an objective neuropsychological battery and self-reported 
Squire Memory Questionnaire. The time-points of assessment were at baseline 
within 3 months of completing primary breast cancer treatment but before 
initiating breast cancer targeted endocrine therapy, 6 months later and 12 months 
later. Brain imaging with positron emission tomography scans was evaluated in a 
subset of patients. The authors observed an increase of sTNF-RII (a surrogate 
marker for TNF-α) among CT patients, as compared to non-chemotherapy 
receiving patients (p=0.0019). Higher baseline sTNF-RII in chemotherapy 
patients was significantly associated with increased self-reported memory 
complaints. In chemotherapy exposed patients, the longitudinal decline in sTNF-







 No signification association between objective 
neuropsychological tests and pro-inflammatory cytokines was reported.  
Lastly, this study consisted of breast cancer patients who received either 
standard anthracycline- or taxane-based chemotherapy. In the univariate analysis, 
it was found that patients who received anthracycline-based chemotherapy had 
higher cytokine levels than patients who received taxane-based regimens. It is 
proposed that upon the completion of this study, it is worthwhile to evaluate how 
the types of chemotherapy regimens contribute to different presentations of other 
inflammatory-mediated responses, such as fatigue, myalgia and psychological 
distresses. 
 
7.7 Limitations of study 
The key limitation in this study is the lack of concurrent non-CT cancer 
controls and thus, accounting for cytokine dysregulation and cognitive 
impairment as a result of the progression of cancer was not possible.
176
 
Nevertheless, the finding of an association between chemotherapy exposure, 
plasma TNF-α, IL-1β, IL-4 and IL-6 and cognitive performance at baseline and in 
longitudinal outcomes, provides support for continued examination of post-
chemotherapy inflammation as a causal factor in this phenomenon. It is also 
logical to assume that cancer progression is less likely to cause an increase of 
cytokine levels among these early-stage breast cancer patients who were receiving 





Finally, the sample size of the blood samples was small and may limit 
conclusive interpretations. As the study might not be adequately powered to 
detect the effects of the cytokines and interacting terms, results from the mixed 
model must be interpreted with caution. Some studies have proposed that the 
interpretation of biomarker data might be limited by the traditional statistical 
methods used; in the analysis of data of this sort, the multiple putative interactions 
between mediators need to be considered as well as the timing of production and 
high degree of statistical co-variance in levels of these mediators.
427
 The multi-
factorial characteristic of this type of study calls for a more robust analysis of the 
statistical data and an account of the various etiological agents involved. The use 
of Principal Component Analysis (PCA) is suggested to facilitate the 
reorganization of data and examine the causes of variance in the data. For 
example, one group successfully used this technique to identify the association 
between baseline cancer-related fatigue and IL-6, IL-6R and IL-17 (variance = 
78%).
428
 It is anticipated that a larger sample size of subjects and blood samples 
will allow for the use of PCA to delineate symptom clusters associated with a 
subgroup of cytokines.  
More importantly, these findings can only be suggestive of a potential 
association between the key cytokines and cognitive function; this association 
does not equate to causation. In addition to statistical methods, the results must be 
interpreted based on what is currently known from the literature. Hill provided a 
coherent set of criteria for determining causation; the proposed criteria included 







 As discussed earlier in the previous section (Section 7.6), 
similar studies have identified the role of IL-1β, TNF-α, IL-4 and IL-8, in 
neuropsychariatic conditions and chemotherapy-associated cognitive 
changes.
131,154,169,170,430,431
 Our finding also parallels the proposed mechanism 
behind the oxidative stress induced by cytotoxic chemotherapeutic drugs on brain 
cells that leads to the clinical presentation of cognitive impairment in animal 
models.
139,158,160
 Hence we propose that results from our study, though 
exploratory, preliminary and inconclusive in its current state, may provide 
directions for future research.  
 
7.8 Summary of important findings 
 
Higher plasma levels of IL-1β and TNF-α might be associated with poorer 
respond speed and memory, respectively. A lower attention score were observed 
with higher levels of IL-4 and IL-8. However, there was no biological determinant 
identified for subjective cognitive impairment. Our results are important because 
they suggest that cytokines would potentially be mechanistic mediators of 
chemotherapy-induced cognitive changes. 




Chapter 8 – Concluding remarks and recommendations for future work  
 
This thesis aimed to investigate the important supportive care problem of 
chemotherapy-associated cognitive changes in breast cancer patients. Through an 
evaluation of the prevalence and severity of chemotherapy-associated objective 
and perceived cognitive changes in an Asian breast cancer population, this thesis 
has demonstrated that chemotherapy-associated cognitive changes are prevalent 
and relevant in Asian breast cancer patients. More importantly, these cognitive 
changes have a significant impact on their family and working lives.  
At this point, it is worthwhile to reflect on what we currently know about 
this subject, and determine whether “chemobrain” or “chemofog” are appropriate 
terms to describe this phenomenon, as they may not accurately reflect the multiple 
potential aetiologies related to the occurrence of cognitive changes in breast 
cancer patients. In particular, this thesis has shown that the interplay between 
demographical, clinical, pharmacological, psychosocial and biological 
determinants contributes to the complexity of the problem. Cognitive impairment 
may represent a component of the cytokine- and inflammatory marker-mediated 
cluster of cancer- and treatment-related symptoms, such as fatigue, depression and 
anxiety. Figure 8.1 illustrates the possible relationship between chemotherapy-














Figure 8.1: Relationship between chemotherapy-associated cognitive changes and demographic, psychosocial, biological and 
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Information generated from this thesis can also contribute to the 
improvisation of symptom management algorithms in cancer institutions. 
Knowledge of the existence, prevalence and severity of this problem can be used 
by oncology practitioners to provide informed pre-chemotherapy counselling to 
patients, and patients can benefit from being more aware of this potential adverse 
effect of chemotherapy during the course of their anti-cancer treatment. Through 
the compilation of this thesis, the research team has had many valuable 
opportunities to share these important findings with other healthcare professionals. 
Over time, oncology practitioners have acknowledged the occurrence of these 
cognitive symptoms in their cancer patients and recognised their important 
implications. Although evidence-based knowledge on the timing and mode of 
neuropsychological monitoring is still in its infancy, it is proposed that the routine 
screening of cognitive function may be useful for patients who are at risk. Based 
on the study results, it is suggested that patients who are elderly, less well 
educated or recipients of anthracycline-based chemotherapy might potentially 
benefit from this screening initiative and more frequent monitoring during their 
chemotherapy treatment. 
Existing research in this area has found weak associations between 
objective cognitive function and subjective cognitive complaints. The value of 
subjective cognitive complaints for predicting the cognitive status of patients is 
still questionable. Nevertheless, patients’ perceived cognitive disturbances are 
reflective of their psychosocial distresses such as anxiety, fatigue, emotional 





were strong determinants of subjective cognitive function. In particular, patients 
who were both fatigued and anxious were more strongly predisposed to perceived 
cognitive disturbances. The finding that psychosocial distress can account for a 
significant amount of variability in symptom burden dimensions suggests that 
attenuation of the psychosocial distress of survivors should help to alleviate the 
symptom burden. Thus, for survivors who experience a high symptom burden, 
healthcare professionals should consider the other underlying psychosocial factors 
that may influence the frequency, severity and distress of these symptoms. The 
findings from this thesis highlight the importance of managing the psychological 
burden of breast cancer patients during the course of anti-cancer treatment, and 
pave the way for future intervention strategies that are targeted at managing their 
psychosocial distresses. 
To date, explorations into the biological mechanism behind this 
“chemobrain” phenomenon are in their infancy. The results from this thesis 
suggest that certain biological markers may potentially be mechanistic mediators 
of chemotherapy-associated cognitive changes. With the knowledge that 
biological determinants may plausibly play a mechanistic intermediary role in 
post-chemotherapy symptom clusters, it would be worthwhile to consider the use 
of biological markers as the mechanistic basis for intervention studies. In a 
number of studies that involved animal models of pain and affective disorders, 
several pharmacological agents were tested to antagonise sickness behaviour in 
animals.
317
 Donepezil was shown to reduce cognitive impairment induced by a 





proposed that one of the neuro-protective mechanisms of donepezil is its anti-
inflammatory property to reduce the levels of IL-1β, IL-6 and oncostatin M.433,434 
It is anticipated that neuro-protective agents will eventually be discovered to 
counteract the phenomenon of not just cognitive changes but the symptom 
clusters associated with sickness behaviour in cancer patients during their anti-
cancer treatment. 
Currently, in both Asian and local settings, the cognitive functions and 
psychosocial distresses of patients are monitored less routinely than physical 
symptoms. Recently, it has been widely recognised that psychosocial therapy is 
an important component of survivorship care.
197,239,301,302,435
 However, there is 
also conflicting evidence for the effectiveness of psychological treatment to 
reduce distress in cancer patients.
239
 The conduct of intervention studies involving 
non-pharmacological therapies poses major practical challenges, because blinding 
may not be feasible. It is proposed that future intervention studies could employ 
multi-modal assessments, such as subjective patient-reported cognitive deficits, 
objective neuropsychological tests, neuro-imaging and biological markers, to 
provide a comprehensive understanding of their clinical benefits. This proposed 
methodological approach would strengthen the study design and the scientific 
basis of the intervention. 
Although it has been established that breast cancer patients experience 
cognitive changes and psychosocial distress during the course of their 
chemotherapy treatment, limited evidence in the current literature shows the 





psychosocial burdens among breast cancer survivors, defined here as individuals 
with a diagnosis of breast cancer who have completed primary treatment for 
cancer, or the major aspects of  the anti-cancer treatment.
436
 It should be 
highlighted that studies that have explored the potential interactions and inter-
relationships between a physical symptom burden, psychological effects and 
neurocognitive function in breast cancer survivors are lacking in the literature. To 
shed light on the inter-relationships of these symptoms through clinical and 
laboratory data, it is proposed that a symptom cluster of cognitive dysfunction, 
mood disturbance, fatigue and anxiety may exist among breast cancer survivors. 
Future studies that involve breast cancer survivors may help to open new avenues 
for a novel symptom management approach to target their co-morbid cognitive, 
affective and somatic symptoms simultaneously. 
In addition to evaluating the neurodegenerative properties of cytotoxic 
chemotherapy, it would also be worthwhile to explore the neurocognitive toxic 
effects induced by newer targeted therapies, such as anti-angiogenic agents. The 
anti-angiogenesis process is currently used as a strategy for cancer treatment, and 
vascular endothelial growth factor (VEGF) inhibitors are now widely 
incorporated in clinical practice for the treatment of various malignancies, 
including colorectal cancer, renal cell carcinoma and sarcoma. In cancer patients, 
VEGF is a major stimulator of pathological angiogenesis, promoting the rapid 
growth of cancer cells and metastases. The angiogenic properties of VEGF 
inhibitors are achieved through the inhibition of VEGF, which leads to the arrest 







 However, VEGF also plays a prominent role in the central nervous 
system. Recently, emerging evidence suggested that VEGF could play a role in 
brain cognition, giving rise to concerns of whether VEGF inhibitors may induce 
neurotoxic effects on the cognitive function of cancer patients.
439
 VEGF is a 
hypoxia-inducible protein with well-known angiogenic and vascular 
permeability-enhancing properties.
440,441
 As VEGF inhibitors interfere with the 
normal functions of VEGF, it has been suggested that the use of these drugs may 
potentially interrupt the central nervous system functions of VEGF, leading to 
cognitive disturbances. This is supported by emerging clinical data that suggest 
that the use of VEGF inhibitors may cause cognitive disturbances in cancer 
patients.
442-445
 Therefore, it is proposed that VEGF may play a role in brain 
cognition, and that the inhibition of its function through the use of VEGF 
inhibitors may result in cancer treatment-related cognitive changes. 
Lastly, existing evidence in the literature suggests that shared genetic risk 
factors for the development of cancer and cognitive problems, coupled with the 
effect of chemotherapy on these systems, might contribute to cognitive decline in 
patients after chemotherapy.
93,446
 However, to date, studies in the literature that 
have investigated the role of genetic predisposition in chemotherapy-associated 
cognitive impairment in cancer patients are limited. Significant inter-individual 
variation in the pharmacokinetics and pharmacodynamics of anthracyclines and 
taxanes has contributed to significant inter-ethnic differences in docetaxel- and 
doxorubicin-induced systemic toxicity (myelosuppression) in three local ethnic 
groups (Chinese, Malays and Indians).
447





the apolipoprotein E (APOE) genotype with neuropsychological performance in 
long-term cancer survivors treated with standard-dose chemotherapy, and showed 
that survivors with at least one E4 allele had significantly lower scores in the 
visual memory and spatial ability domains, with a trend of lower scores in 
executive function compared with survivors who did not carry an E4 allele.
446
 
One study conducted in Singapore reported that the varying expression of the 
APOE allele genotype could possibly explain the observed ethnic differences in 
dementia. Reports have shown that Malays have the highest expression of the E4 
allele, whereas E2 is least common in Indians.
448
 From theoretical data based on 
these studies, differences in the expression of candidate genes may lead to 
variation in the severity and types of cognitive changes across ethnic groups. The 
results on prevalence from this study may pave the way for future genetic 
research work.  
In conclusion, breast cancer mortality rates have dropped significantly since 
the introduction and use of efficacious chemotherapy combinations. The 
challenge is now to reduce the morbidity associated with cancer further and 
improve the quality of life of breast cancer patients. The findings presented in this 
thesis on the multifactorial phenomenon of chemotherapy-associated cognitive 
changes have clinical implications for the early survivorship care of breast cancer 
patients. With these data, future clinical algorithms to alleviate these cognitive 
symptoms and psychosocial distress can be designed to help breast cancer patients 





of symptoms, and ultimately contribute to the development of quality 
survivorship care for breast cancer survivors. 
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 Legend and abbreviations: (listed according to alphabetical order within categories) 
Abbreviation for neuropsychological tools: 
BNT - Boston Naming Test; BSRT - Buschke Selective Reminding Task; BVRT - Benton Visual Retention Test; COWAT - Controlled Oral Word Association Test; CPT - Conner’s Continuous 
Performance Test; CVLT - California Verbal Learning Test; DAST - Dutch Aphasia Society Test; D-KEFS - Delis-Kaplan Executive Function System; FACT-Cog- Functional Assessment of 
Cancer Therapy- Cognitive Function; FT - Finger Tapping, GP - Grooved Pegboard; HSCS - High Sensitivity Cognitive Screen; HVLT - Hopkins Verbal Learning Test; MAE - Multilingual 
Aphasia Examination; MMSE - Mini-Mental State Examination; NART - National Adult Reading Test; PASAT - Paced Auditory Serial Addition Test; RAVLT/AVLT - (Rey) Auditory Verbal 
Learning Test; RBANS - Repeated Battery for the Assessment of Neuropsychological Status; ROCFT/RCFT - Rey-(Osterrieth) Complex Figure Test; SDMT - Symbol Digit Modalities Test; 
TEA - Test of Everyday Attention; TMT - Trail Making Test; VSRT - Verbal/Nonverbal Selective Reminding Test; WAIS-III - Wechsler Adult Intelligence Scale 3rd Edition; WAIS-R - 
Wechsler Adult Intelligence Scale Revised Edition; WASI - Wechsler Abbreviated Scale of Intelligence; WCST - Wisconsin Card Sorting Test; WMS-III - Wechsler Memory Scale 3rd Edition; 
WMS-R - Wechsler Memory Scale Revised Edition; WRAT-3 - Wide Range Achievement Test 3 
 
Other abbreviations:  
CMF- cyclophosphamide, methotrexate and 5-fluorouracil; CT- Chemotherapy receiving subjects; CTC- carboplatin, thiotepa and cyclophosphamide; CTRT- Chemotherapy and radiotherapy 
receiving subjects; CTET- Chemotherapy and endocrine (anti-hormonal) therapy receiving subjects; EOT- End of therapy; ET- Endocrine (anti-hormonal) therapy receiving subjects; ETRT- 
Endocrine (anti-hormonal) therapy and radiotherapy receiving subjects; FEC-  5-Fluorouracil, epirubicin and cyclophosphamide; NA: Not applicable; NR: Not reported; Non-CT- Non-
chemotherapy receiving subject
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ROCFT, Stroop Test, 
TMT, WAIS-R, WMS-R, 
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Appendix 2: Functional Assessment of Cancer Therapy – Cognitive Function (Version 3) 
(English) 
 
Below is a list of statements that other people with your condition have said are 
important. Please circle or mark one number per line to indicate your response as 




















CogA1 I have had trouble forming thoughts 0 1 2 3 4 
CogA3 My thinking has been slow 0 1 2 3 4 
CogC7 I have had trouble concentrating 0 1 2 3 4 
CogM9 I have had trouble finding my way to a 
familiar place 0 1 2 3 4 
CogM10 I have had trouble remembering where I 











CogM12 I have had trouble remembering new 
information, like phone numbers or simple 
instructions  
0 1 2 3 4 
CogV13 I have had trouble recalling the name of an 
object while talking to someone 0 1 2 3 4 
CogV15 I have had trouble finding the right 
word(s) to express myself 0 1 2 3 4 
CogV16 I have used the wrong word when I 
referred to an object 0 1 2 3 4 
CogV17b I have had trouble saying what I mean in 
conversations with others 0 1 2 3 4 
CogF19 I have walked into a room and forgotten 
what I meant to get or do there 0 1 2 3 4 
CogF23 I have had to work really hard to pay 
attention or I would make a mistake 0 1 2 3 4 
CogF24 I have forgotten names of people soon 
after being introduced 0 1 2 3 4 
CogF25 My reactions in everyday situations have 
been slow 0 1 2 3 4 
CogC31 I have had to work harder than usual to 
keep track of what I was doing 0 1 2 3 4 
CogC32 My thinking has been slower than usual 0 1 2 3 4 
CogC33a I have had to work harder than usual to 







Below is a list of statements that other people with your condition have said are 
important. Please circle or mark one number per line to indicate your response as 




















CogC33c I have had to use written lists more often 
than usual so I would not forget things 
0 1 2 3 4 
CogMT1 I have trouble keeping track of what I am 
doing if I am interrupted 
0 1 2 3 4 
CogMT2 I have trouble shifting back and forth 
between different activities that require 
thinking 
0 1 2 3 4 
 
 
Please circle or mark one number per line to indicate your response as it 


















CogO1 Other people have told me I seemed to have 
trouble remembering information 
0 1 2 3 4 
CogO2 Other people have told me I seemed to have 
trouble speaking clearly 
 
0 1 2 3 4 
CogO3 Other people have told me I seemed to have 
trouble thinking clearly 
 
0 1 2 3 4 














Please circle or mark one number per line to indicate your response as it  
applies to the past 7 days. 
 
Please circle or mark one number per line to indicate your response as it 
















CogPC1 I have been able to concentrate 
0 1 2 3 4 
CogPV1 I have been able to bring to mind words that 
I wanted to use while talking to someone 0 1 2 3 4 
CogPM1 I have been able to remember things, like 
where I left my keys or wallet 0 1 2 3 4 
CogPM2 I have been able to remember to do things, 
like take medicine or buy something I 
needed 
0 1 2 3 4 
CogPF1 I am able to pay attention and keep track of 
what I am doing without extra effort 0 1 2 3 4 
CogPCH1 My mind is as sharp as it has always been 
0 1 2 3 4 
CogPCH2 My memory is as good as it has always 
been 0 1 2 3 4 
CogPMT1 I am able to shift back and forth between 
two activities that require thinking 0 1 2 3 4 
CogPMT2 I am able to keep track of what I am doing, 
even if I am interrupted 0 1 2 3 4 










CogQ35 I have been upset about these problems 0 1 2 3 4 
CogQ37 These problems have interfered with my 
ability to work 
0 1 2 3 4 
CogQ38 These problems have interfered with my 
ability to do things I enjoy 
0 1 2 3 4 
CogQ41 These problems have interfered with the 
quality of my life 
 































CogA1 我曾在想东西时有困难 0 1 2 3 4 
CogA3 我在想东西时较慢 0 1 2 3 4 
CogC7 我曾在集中注意力方面有困难 0 1 2 3 4 
CogM9 我曾在对于寻找熟悉的地方有困
难 
0 1 2 3 4 
CogM10 我曾有困难记起我把东西（如我的
钥匙或皮夹）放在何处 
0 1 2 3 4 
CogM12 我曾在记住新信息（如电话号码或
简单的指示）时有困难 0 1 2 3 4 
CogV13 当我和别人交谈时，我曾有困难




0 1 2 3 4 
CogV16 我曾用过错误的词汇来指某个物
件 
0 1 2 3 4 
CogV17b 当我与别人交谈时，我会有困难
表达我想要说的话 
0 1 2 3 4 
CogF19 我曾走进房间时忘了自己在房间
里是要拿或做什么事 
0 1 2 3 4 
CogF23 我需要更加努力地集中注意力，
否则我会犯错 
0 1 2 3 4 
CogF24 我会很快忘记刚被介绍给我认识
的人的名字 



















CogF25 我在日常生活中的反应能力较慢 0 1 2 3 4 
CogC31 我需要比平常更加努力地专注我
所做的事 



































0 1 2 3 4 
CogC33a 我需要比平常更加努力来清楚地
表达自己 




0 1 2 3 4 
CogMT1 如果我受到干扰，我会有困难再
专注我正在做的事 
































0 1 2 3 4 
















有些 相当 非常 
CogQ35 
我曾为这些问题而感到苦恼 
0 1 2 3 4 
CogQ37 这些问题曾干涉到我的工作能力 0 1 2 3 4 
CogQ38 这些问题曾干涉到我所享受事情
的能力 
0 1 2 3 4 
CogQ41 这些问题曾干涉到我的生活质量 
 









有些 相当 非常 
 
CogPC1 我能够集中精神 0 1 2 3 4 
CogPV1 当我与别人交谈时，我能够记起
我想要用的词 
0 1 2 3 4 
CogPM1 我能够记起事情，如我把钥匙或
钱包放在何处 



























我的头脑如往常一样敏锐 0 1 2 3 4 
Cog 
PCH2 

















Appendix 4: Questionnaire on oncology practitioners’ perception of cognitive changes in 
cancer patients  
 
Post-chemotherapy neuro-cognitive toxicity, also termed as ‘chemobrain’ or ‘chemofog’, has been 
recognised as a potential adverse effect of chemotherapy. This is a survey on healthcare 
professionals’ views on its relevance in cancer patients. This survey is coordinated by the 
Department of Pharmacy, National University of Singapore. Your responses will not be disclosed 
with any information that can personally identify you.  
We would appreciate if you could take time to fill up this survey. This survey should take about 5 
minutes to complete. 
Ms. Cheung Yin Ting (Ph.D student)   A/P Alexandre Chan (Supervisor) 
Demographics of Respondent 
1. Age  
□ 20 – 29  □ 40 – 49 □ >=60 
□ 30 – 39 □ 50 – 59  
 
2. Gender  
□ Male □ Female 
 
3. Profession  
□ Basic scientist □ Medical social worker □ Pharmacist (oncology) 
□ Clinical trial coordinator □ Neurologist □ Radiation oncologist 
□ General physician □ Neuro-oncologist □ Student 
□ General surgeon □ Neuro-surgeon □ Surgical oncologist 
□ Gynaecologist □ Nurse □ Translational scientist 
□ Haematologist □ Paediatric oncologist □ Urologist 
□ Medical oncologist  □ Patient advocate □ Others: _____________ 
 
4. Location of practice 
□ Singapore □ Other countries (please specify):____________ 
 
5. Years of healthcare practice 
□ < 5 years □ 11 – 20 years □ > 30 years 
□ 5 – 10 years □ 21 – 30 years  
 
6. Institution  
□ Government restructured hospital/ specialty centre 
□ Private practice 







7. Specialisation in main tumour types (select ALL that apply) 
□ Breast □ Kidney □ Prostate 
□ Bladder □ Liver □ Soft Tissue Sarcoma 
□ Blood □ Lung □ Stomach 
□ Bone □ Melanoma and Skin □ Thyroid 
□ Brain □ Neuroendocrine □ All 
□ Colorectal □ Ocular □ Others (please specify): 
□ Cervix □ Ovarian ____________________ 
□ Head and Neck □ Pancreatic □ Not applicable 
___________________________________________________________________________ 
1. Cognitive impairment is a frequent complaint among cancer patients. (select ONE) 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
□  □  □  □  □  
 
2. Cognitive impairment can significantly depreciate quality of life of cancer patients. (select ONE) 
Strongly Agree Agree Neutral Disagree Strongly Disagree 
□  □  □  □  □  
 
3. Chemotherapy is a major causative factor of cognitive impairment in cancer patients. (select 
ONE) 
Strongly Agree Agree Neutral Disagree 
Strongly 
Disagree 
□  □  □  □  □  
 
4. Routine monitoring of cognitive function in cancer patients using neuropsychological assessment 
tools is necessary. (select ONE) 
Strongly Agree Agree Neutral Disagree 
Strongly 
Disagree 
□  □  □  □  □  
 
5. In the absence of brain metastases, what are other contributing factors to cognitive impairment in 
cancer patients?      (select ALL that apply) 
□ Ageing □ Lack of Mental Activity □ Concomitant Neuro-
Degenerative Medication □ Anti-Hormonal Therapy □ Lack of Physical 
Activity 
□ Anxiety □ Lack of Social Support □ Concomitant Radiation 
Therapy □ Cancer Condition □ Post-Menopausal Status 









6. What are the common complaints of cognitive impairment that you may have received from 
your cancer patients? (select ALL that apply) 
 
□ Loss of attention/concentration 
(e.g. easily distracted, having trouble keeping track on task if interrupted) 
□ Poor learning abilities 
(e.g. unable to grasp concepts of newly learned subjects) 
□ Memory loss 
(e.g. unable to remember where object is placed, or names of familiar people and places) 
□ Poor planning abilities 
(e.g. unable to organise tasks) 
□ Loss of verbal function 
(e.g. having trouble finding the right words to express) 
□ Others (please specify): ____________________ 
 
7. When is the onset of cognitive impairment in cancer patients? (select ALL that apply) 
 
□ Shortly after diagnosis of cancer  
□ Before starting chemotherapy  
□ During chemotherapy  
□ Upon completion of chemotherapy 
□ Other (please specify): ____________________ 
 
8. Are you aware of the following coping mechanisms to cognitive impairment in cancer 
patients? (select ALL that apply) 
 
□ Complementary and Alternative 
Medicines (CAM)            
(e.g. TCM, gingko biloba extracts) 
□ Mental Exercise  
      (e.g. Sudoku, chess) 
□ Neuro-protective Agents   
(e.g. acetylcholinesterase inhibitors, 
anti-oxidants) 
□ Psycho-Social Support  
(e.g. psychotherapy, counseling) 
□ Vitamins and Supplements  
(e.g. omega 3) 
□ Others (please specify):__________________ 
  
 
 
 
 
